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Abstract
Traumatic joint injuries initiate acute degenerative changes in articular cartilage that can lead to progressive
loss of load-bearing function. As a result, patients often develop post-traumatic osteoarthritis (PTOA), a
condition for which there currently exists no biologic interventions. To address this need, tissue engineering
aims to mimic the structure and function of healthy, native counterparts. These constructs can be used to not
only replace degenerated tissue, but also build in vitro, pre-clinical models of disease. Towards this latter goal,
this thesis focuses on the design of a high throughput system to screen new therapeutics in a micro-engineered
model of PTOA, and the development of a mechanically-responsive drug delivery system to augment tissue-
engineered approaches for cartilage repair.
High throughput screening is a powerful tool for drug discovery that can be adapted to include 3D tissue
constructs. To facilitate this process for cartilage repair, we built a high throughput mechanical injury platform
to create an engineered cartilage model of PTOA. Compressive injury of functionally mature constructs
increased cell death and proteoglycan loss, two hallmarks of injury observed in vivo. Comparison of this
response to that of native cartilage explants, and evaluation of putative therapeutics, validated this model for
subsequent use in small molecule screens. A primary screen of 118 compounds identified a number of ‘hits’
and relevant pathways that may modulate pathologic signaling post-injury.
To complement this process of therapeutic discovery, a stimuli-responsive delivery system was designed that
used mechanical inputs as the ‘trigger’ mechanism for controlled release. The failure thresholds of these
mechanically-activated microcapsules (MAMCs) were influenced by physical properties and composition, as
well as matrix mechanical properties in 3D environments. TGF-beta released from the system upon
mechano-activation stimulated stem cell chondrogenesis, demonstrating the potential of MAMCs to actively
deliver therapeutics within demanding mechanical environments.
Taken together, this work advances our capacity to identify and deliver new compounds of clinical relevance
to modulate disease progression following traumatic injury using state-of-the-art micro-engineered screening
tools and a novel mechanically-activated delivery system. These platforms advance strategies for cartilage
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I  am  so  glad  we  did  this  together.    
Love,  Chaos  Bhavana    
To  Robert,    
I  dedicate  this  to  you.  See  I  do  love  you  more  than  the  cat.  


























Nearly  6  years  ago,  I  joined  the  McKay  labs,  first  as  a  research  engineer  and  then  as  PhD  
student  advised  by  both  Rob  and  George.  To  this  day,  I  still  cannot  believe  how  lucky  I  
am  to  have  the  both  of  them  as  my  advisors.  They  have  been  patient  and  supportive  of  
my  scientific  pursuits,  giving  me  the  time  to  learn  how  to  be  a  scientist  and  the  ability  to  
freely  explore  new  ideas  and  interests.  Not  only  did  they  instill  in  me  (and  I  think  all  of  their  
students)   a   love   for   research   itself,   but   also   the   importance   of   a   close-­knit   research  
environment.   This   sentiment   was   also   echoed   in   the   larger   orthopaedic   research  
community  that  Rob  and  George  welcomed  me  into-­  one  that  is  full  of  decades  of  familial  
academic  history  and  friendship.  As  I  finish  my  time  at  Penn,  any  success  that  I  have  had  
here  is  due  in  no  small  part  to  having  Rob  and  George  as  my  advisors.  Their  dedication  
to  their  students  knows  no  bounds,  and  I  am  thankful  to  have  had  the  opportunity  to  work  
with  them  during  my  PhD.    
  
I  also  want  to  thank  my  committee  members,  Drs.  Jason  Burdick,  Carla  Scanzello,  and  
Alan  Grodzinksy   for   their  guidance.   It  was  on   the  scientific   foundation   laid  down   these  
individuals  and  their  work  (as  well  as  that  of  my  advisors)  that  enabled  me  to  push  forward  
with  my  research,  and  I  truly  appreciated  their  input  and  feedback  during  this  process.  I  
also  want  to  thank  Dr.  Daeyeon  Lee  and  his  students  for  collaborating  with  us  to  build  the  
microcapsule  project  from  the  ground  up.  Fellowships  and  grants  were  also  critical  for  our  
research   efforts,   and   included   support   from   the   National   Institutes   of   Health,   National  





Our   lab   is  a   little   like  a  wild  and  unruly   family-­   from  the  first  generations  of   ‘Mauck-­ers’  
(Mauck  1.0-­1.5)  who  taught  me  how  to  dissect  a  cow  leg  in  my  first  week  in  lab  (thank  you  
Lara!),  to  my  cohort  and  the  most  recent  generation  of  students  (Mauck  2.5),  I  was  lucky  
enough  to  work  with  a  group  of  people  who  are  passionate  about  science.    I  have  enjoyed  
nearly  every  minute  of   the  past  6  years  because  of   the   lasting   friendships  built   in  and  
outside  of  lab.  A  special  thanks  goes  to  Alexandra  Farran,  who  by  example  showed  me  
how   to   be   a   diligent   scientist,   as   well   as   Greg  Meloni   for   his   help   on  many   projects,  
including  the  HTMS  platform  (he  also  taught  me  a  few  other  things,  like  machining  is  fun  
and  red  is  fast).  Mieke  Sinneseal,  Emilie  Rabut,  and  Ryan  Smalley  were  also  important  
members  of  our  team  as  these  projects  developed.  I  was  also  fortunate  to  have  worked  
with  Mac  Sennett  and  Brendan  Stoeckl,  who  were  always  willing  to  jump  in  and  happily  
tackle  new  challenges  (including  a  venture   into   the  start-­up  world).  A  number  of  senior  
students-­  Matt  Fisher,  Megan  Farrell,  Tristan  Driscoll,  Lara  Ionescu,  John  Martin,  Sylvia  
Qu,   Sarah  Gullbrand,   Spence   Szczesny,   Sun   Peck,   Sujin   Heo,   DongHwa   Kim,   Eddie  
Bonnevie,  and  Minwook  Kim-­  shaped  the  way  I  think  about  science  and  how  important  it  
is  to  think  critically  about  the  bigger  picture,  as  well  as  the  way  in  which  we  communicate  
our   ideas   to   the   world.   I   was   thankful   to   have   worked   with   Claire   McLeod   and   Brian  
Cosgrove   (both   helped   complete   Rob’s   circle   of   grief   this   year),   as   well   as   with   John  
Martin,  who  were  often  my  scientific  sounding  board.  They  were  always  willing  to  discuss  
exciting   research   developments,   or   alternatively   commiserate   and   troubleshoot  
experiments  on  bad  science  days.  A  huge  shout  out  must  go  to  Liz  Henning,  who  has  kept  
our  lab  running  smoothly  (through  two  moves,  no  less).  I  think  without  her  we  would  all  be  
lost.  Most   recently,   I   was   excited   to  welcome   the   new   additions-­   Sonia  Bansal,   Tonia  
Tsinman,  and  Eric  Dai-­  who  have  taught  me  many  new  words  and  been  patient  with  my  
complete  inability  to  use  them  correctly.  I  am  excited  to  see  where  your  science  takes  you  
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and  know  that  you  three  will  faithfully  carry  forward  the  many  traditions  of  our  lab  for  the  
next  generations.    
  
I  also  want  to  take  this  moment  to  thank  Brian  and  Jill  Cosgrove.  When  I  first  arrived  at  
Penn,   little  did  I  know  that   they  would  become  two  of  my  best   friends.  What  started  as  
happy  hours  and  dinners  over  a  shared  love  of  food  and  drink  has  evolved  over  the  past  
6   years   to   include  baking  experiments,   camping   in   extreme  weathers,   annual   birthday  
traditions,  feats  of  athleticism  and  daring  (sky  diving!),  and  most  recently,  embarking  on  
our  first  international  trip!  You  both  have  always  been  there  for  Rob  and  me,  to  celebrate  
the  highs  and  encourage  us  when  we  were  low.  We  are  so  thankful  to  have  you  as  our  
friends  and  can’t  wait  to  go  on  our  next  adventure  together.  
  
While  I  have  been  lucky  to  have  so  much  support  here  at  Penn  and  made  life-­long  friends  
along  the  way,  I  also  would  not  have  been  able  to  make  it  this  far  without  my  friends  who  
have  been  there  for  me  from  afar.  To  Joe  and  Casey,  you  both  have  always  been  so  good  
at  helping  me  keep  my  head  on  straight.  When  we  are  all  together,  either  just  because  or  
for  celebrations  of  life’s  big  moments,  it  is  always  easy  to  pick  up  where  we  left  off.  We  
joke  that  we  are  already  ‘old’  couples,  and  I  expect  that  when  we  actually  are  of  old  age,  
that  Casey  I  will  be  knitting  away  making  giant  blankets,  while  Joe  and  Rob  play  video  
games-­  a   future   that   I   really   look  forward  to.  To  Parimala,  Dhatri,  and  Jhumur-­  my  RPI  
girls  and  forever  dancing  partners-­  no  matter  how  scattered  we  are,  I  love  that  we  always  
find   time  to  come  together  at   least  once  a  year.  Your  collective  strength  and  optimistic  
outlook   on   life   inspires   me   to   find   the   silver   lining   in   any   situation   and   gives   me   the  
confidence  to  face  challenges  head  on,  as  I  have  watched  you  all  do  time  and  again.  To  
Akhila  and  Neal,  the  most  adventurous  and  hard-­working  couple  I  know,  you  both  have  
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shown  me  over  the  years  how  to  set  goals  and  go  for  them  full  out  until  you  achieve  them-­  
and   in  between  take  the  time  to  enjoy   life   in   food,   travel,   family,  and  friends.  You  have  
always  encouraged  and  believed   in  me  (even  when  my  enthusiasm  was  waning)  and  I  
appreciate  it  more  than  I  can  say  in  words.  I  look  forward  to  all  of  the  food-­centric  trips  we  
will   take   together   in  post-­school   life,  and  (hopefully)  one  day  we  will  make   it  out   to   the  
better  coast.  To  my  girls  from  Arizona-­  Rohini,  Kavya,  Neha,  Tara,  and  Neeraja-­  I  couldn’t  
imagine  a  better  group  to  grow  up  with.  Even  as  we  are  now  spread  across  the  globe,  
each  with  our  own  lives,  you  motivate  me  to  be  courageous,  be  different,  and  to  pursue  
my  dreams.  I  think  the  phrase  is  ‘home  is  where  the  heart  is’-­  and  I  know  whenever  I  am  
with  you  I  always  feel  at  home.    
  
To  my  family  who  made  all  and  any  of  this  possible  with  their  unwavering  support.  To  my  
parents,  who  for  so  many  years  (and  to  this  day)  worked  hard  to  make  sure  Hari,  Divya,  
and  I  had  the  opportunity  to  do  whatever  we  wanted.  You  volunteered  and  were  engaged  
in  the  activities  we  were  a  part  of,  encouraged  us  to  try  new  things,  and  found  time  to  take  
us  to  see  the  world,  all  the  while  keeping  us  connected  and  together.  I  appreciate  all  that  
you  have  done  for  me  and  Rob,  and  hope  that  you  are  proud  of  the  person  I  have  become.  
To  Hari,  the  older  of  my  two  wiser  and  smarter  younger  siblings-­  you  showed  me  how  to  
be  brave  and  not  be  afraid  of  making  big  changes  in  order  to  be  happy.  While  I  may  make  
fun  of  you  at  times  for  talking  like  a  robot  or  walking  like  a  cowboy,  I  couldn’t  have  asked  
for  a  better  brother  and  friend.  To  Divya-­  you  are  an  amalgamation  of  Hari  and  me  in  many  
ways  due  to  our  total  lack  of  filter  as  you  were  growing  up,  but  over  the  years  I  have  seen  
you  grown  into  your  own  person  and  I  am  so  very  excited  and  thankful  to  have  you  as  my  
sister.  To  my  extended  family,  from  Australia  to  India  to  England-­  many  of  the  decisions  I  
have  made  over  the  past  several  years  to  get  to  this  point  were  inspired  by  your  dedication  
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to  knowledge  and  education.  I  love  that  we  all  behave  like  a  group  of  lunatics  when  we  
are  all  together  (as  a  family  should),  and  I  hope  that  we  can  all  find  ourselves  in  one  place  
again   sometime   soon.   And   finally,   to   the   Middletons-­   Curtis,   Hiromi,   Grandpa   Bob,  
Grandma  Faith,  Aunt  Karen,  and  Mariko-­  who  warmly  welcomed  this   ‘city’  girl   into  their  
family  and  home.  You  have  always  taken  the  time  to  show  your  support  of  my  educational  
pursuits  and  even  made   the  effort   to  create   jokes  about  chondrocytes  when  we   talked  
about  my  projects.   I   have   truly   admired  how  generously   and   fully   the  entire  Middleton  
family  lives  their  lives,  and  this  motivates  me  to  do  the  same  in  the  coming  years.    
  
Finally,  to  (my)  Rob-­  since  we  first  met,  you  have  always  been  willing  to  try  new  things,  
and  over  the  years  you  inspired  me  to  do  the  same-­  which  I  think  is  why  I  was  so  excited  
about  going  to  graduate  school.  When  we  started  at  Penn,  I  knew  it  would  be  a  journey,  
but  what  I  didn’t  expect  was  just  how  much  fun  we  would  have  together  throughout  the  
process.  While  there  were  points  of  high  stress,  you  always  told  me  “you  can  do  it”,  and  
your   patience   and   encouragement   was   often   the   push   I   needed   to   keep   going.   After  
classes,  late  nights  in  lab,  writing,  conferences,  and  all  of  the  chaos,  coming  home  to  be  
with  you  (and  eventually  Turtle  cat!)  was  always  the  best  part  of  my  day.  Of  course,   to  
Turtle-­  thank  you  for  tolerating  me  when  I  loved  you  aggressively  and  for  being  my  late  
night  sidekick  as  I  finished  writing  my  thesis.  Although  this  adventure  is  coming  to  an  end,  










HIGH  THROUGHPUT  AND  MECHANO-­ACTIVE  PLATFORMS  TO  PROMOTE  CARTILAGE  
REGENERATION  AND  REPAIR  
  
Bhavana  Mohanraj  
Robert  L.  Mauck    
George  R.  Dodge  
  
Traumatic  joint  injuries  initiate  acute  degenerative  changes  in  articular  cartilage  that  can  
lead  to  progressive  loss  of  load-­bearing  function.  As  a  result,  patients  often  develop  post-­
traumatic  osteoarthritis   (PTOA),  a  condition   for  which   there  currently  exists  no  biologic  
interventions.  To  address  this  need,  tissue  engineering  aims  to  mimic  the  structure  and  
function  of  healthy,  native  counterparts.  These  constructs  can  be  used  to  not  only  replace  
degenerated   tissue,  but  also  build   in  vitro,  pre-­clinical  models  of  disease.  Towards   this  
latter  goal,  this  thesis  focuses  on  the  design  of  a  high  throughput  system  to  screen  new  
therapeutics   in   a   micro-­engineered   model   of   PTOA,   and   the   development   of   a  
mechanically-­responsive  drug  delivery  system  to  augment  tissue-­engineered  approaches  
for  cartilage  repair.      
  
High  throughput  screening   is  a  powerful   tool   for  drug  discovery   that  can  be  adapted  to  
include  3D  tissue  constructs.  To  facilitate  this  process  for  cartilage  repair,  we  built  a  high  
throughput  mechanical  injury  platform  to  create  an  engineered  cartilage  model  of  PTOA.  
Compressive   injury   of   functionally   mature   constructs   increased   cell   death   and  
proteoglycan  loss,  two  hallmarks  of  injury  observed  in  vivo.  Comparison  of  this  response  
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to  that  of  native  cartilage  explants,  and  evaluation  of  putative  therapeutics,  validated  this  
model  for  subsequent  use  in  small  molecule  screens.  A  primary  screen  of  118  compounds  
identified  a  number  of  ‘hits’  and  relevant  pathways  that  may  modulate  pathologic  signaling  
post-­injury.    
  
To  complement  this  process  of  therapeutic  discovery,  a  stimuli-­responsive  delivery  system  
was   designed   that   used   mechanical   inputs   as   the   ‘trigger’   mechanism   for   controlled  
release.  The  failure  thresholds  of  these  mechanically-­activated  microcapsules  (MAMCs)  
were   influenced  by   physical   properties   and   composition,   as  well   as  matrix  mechanical  
properties  in  3D  environments.  TGF-­β  released  from  the  system  upon  mechano-­activation  
stimulated  stem  cell  chondrogenesis,  demonstrating  the  potential  of  MAMCs  to  actively  
deliver  therapeutics  within  demanding  mechanical  environments.  
  
Taken  together,  this  work  advances  our  capacity  to  identify  and  deliver  new  compounds  
of   clinical   relevance   to   modulate   disease   progression   following   traumatic   injury   using  
state-­of-­the-­art   micro-­engineered   screening   tools   and   a   novel   mechanically-­activated  
delivery  system.  These  platforms  advance  strategies  for  cartilage  repair  and  regeneration  
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Chapter  1.  Introduction  	    
	  
The   discovery   and   development   of   therapeutic   strategies   for   early   intervention   in  
osteoarthritis  (OA)  remains  a  challenge  and  represents  an  unmet  clinical  need  for  patients  
who   require   joint   replacements   due   to   the   lack   of   therapeutics   and   biological   options.  
Articular   cartilage   functions   as   a   load-­bearing   structure   within   the   joint   that   uses  
mechanical  feedback  to  maintain  tissue  homeostasis.  While  normal,  physiologic  loading  
is  beneficial,  injury  or  supra-­physiologic  loading  can  initiate  acute  degenerative  processes  
that  lead  to  progressive  failure  of  the  articular  surface.    This  subset  of  joint  disease,  termed  
post-­traumatic  osteoarthritis  (PTOA),  is  often  the  direct  consequence  of  a  traumatic  event  
such  as  an  ACL  or  meniscus  tear.  Although  end-­stage  OA  is  well  characterized  clinically  
and  experimentally,  the  initial  signaling  cascades  post-­injury  that  eventually  culminate  in  
cartilage   degeneration,   inflammation,   and   overall   joint   destruction   are   still   poorly  
understood.  This  gap  in  knowledge  presents  an  opportunity  to  discover  therapeutic  targets  
and  advance  treatment  strategies  for  patients  at  different  stages  of  disease.    
  
Cartilage  tissue  engineering  is  one  platform  that  can  be  used  to  tackle  this  problem.  Over  
the   past   thirty   years,   tissue   engineering   has   generally   focused   on   the   fabrication   of  
constructs  in  vitro  that  can  repair  or  replace  the  structure  and  function  of  diseased  tissues  
in  vivo.  The  progress  made  in  this  field  has  also  enabled  the  development  of  pre-­clinical  
models   that   can  mimic   physiologic   features   of   disease   to   screen  drug   candidates   and  
delivery  systems  for  safety  and  efficacy.  This  dissertation  focuses  on  the  design  of  a  high  
throughput   platform   for   small  molecule   screening   in   an   engineered   cartilage  model   of  
PTOA  and  a  mechanically-­responsive  drug  delivery  system  to  advance  new  strategies  for  




To  provide  a  framework  for  the  work  described  herein,  Chapter  2  reviews  existing  tissue-­
engineered  models  of  musculoskeletal  disease.  Mechanical  systems  are  described  that  
both  initiate  measure  degenerative  responses  in  these  micro-­engineered  constructs  under  
disease   conditions.   In   vitro   observations   are   also   compared   to   in   vivo   hallmarks   of  
disease,  and  the  effect  of  compounds  known  to  modulate  pathology  in  vivo  are  discussed  
relative  to  against  clinical  observations  in  these  micro-­engineered  systems.    
  
Towards   the   development   of   an   in   vitro   model   of   PTOA,   Chapter   3   describes   the  
fabrication  and  maturation  of  cartilage   tissue  analogs  (CTAs).  Mechanical  properties  of  
CTAs  are  measured  as  a  function  of  culture  duration  and  benchmarked  against  those  of  
native  cartilage  explants.  Biochemical  and  histological  assays  are  also  used  to  evaluate  
structure-­function  relationships  with  regard  to  proteoglycan  and  collagen  content  in  CTAs.    
  
Chapter  4  reports  on  the  scale-­up  of  a  mechanical  testing  platform  as  a  step  towards  high  
throughput  mechanical  perturbation  of  engineered  cartilage.  The  compressive  mechanical  
properties  of  acellular  biomaterials  and  engineered  constructs  are  rapidly  assessed  in  a  
48-­well   format   and   validated   against   conventional   single-­sample   testing  methods.   The  
system  is  able  to  measure  constructs  with  equilibrium  moduli  between  25  and  300  kPa  
and  identify  changes  in  engineered  cartilage  properties  to  due  exogenous  stimuli.    
  
This  high  throughput  mechanical  testing  system  is  subsequently  adapted  for  mechanical  
injury  of  functionally  mature  CTAs  as  described  in  Chapter  5.  The  ability  of  the  CTA  injury  
response  to  mimic  the  acute  hallmarks  of  PTOA  in  native  cartilage  is  first  assessed  as  a  
function  of  strain  and  strain-­rate.     CTAs  exhibited   increased  proteoglycan   loss  and  cell  
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death  in  response  to  high  strains  (50  and  75%)  within  48  hours  of  injury.  High  throughput  
application  of   compressive   injury  was   consistent  with   single-­sample   results,   and  direct  
comparison  to  cartilage  explants  showed  similar  patterns  of  GAG  loss  and  LDH  release  
(an  indirect  soluble  measure  of  cell  death).  To  demonstrate  the  screening  potential  of  this  
in  vitro  model,  putative  therapeutic  compounds  known  to  modulate  the  injury  response  in  
explants  and  in  vivo  are  also  evaluated.  These  molecules  show  similar  levels  of  efficacy  
in  attenuating  matrix  damage  and/or  loss  of  viability  in  our  high  throughput  system  as  has  
previously  been  reported  in  the  literature,  validating  the  system.    
  
Chapter   6   continues   to   build   on   the   concept   of   a   high   throughput   mechanical   injury  
platform   as   an   in   vitro,   pre-­clinical   model   for   screening   and   identifying   potential   drug  
candidates.   The   commercial   small   molecule   libraries   chosen   for   these   screens   target  
pathways  relevant  to  cell  apoptosis  and  necrosis,  as  well  as  chondrocyte  signaling  and  
cartilage  development.  Out  of  the  118  compounds  evaluated,  7  ‘high-­performing  hits’  were  
found  that  strongly  reduced  either  cell  death  alone,  or  reduced  both  cell  death  and  matrix  
loss.  These  ‘high-­performing  hits’  were  subsequently  the  focus  of  secondary  screens  to  
evaluate  donor-­specific  variability  in  small  molecule  efficacy.    
  
While  mechanical  injury  initiates  specific,  acute  changes  in  cartilage,  long-­term  cartilage  
degradation  is  likely  mediated  by  the  the  inflammatory  environment  within  an  osteoarthritic  
joint.  Chondrocytes  and  MSCs  have  previously  been  explored  as  potential  cell  sources  for  
cartilage   repair;;   however,   the   relative   sensitivity   of   each   cell   type   to   pro-­inflammatory  
stimuli  is  unknown.  Understanding  these  differences  in  cellular  behavior  supports  not  only  
clinical   translation   of   tissue   engineered   cartilage   repair   approaches,   but   also   the  
development  of  in  vitro  models  to  study  agents  that  can  inhibit  cytokine-­mediated  catabolic  
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processes.  Therefore,  the  focus  of  Chapter  7  is  to  evaluate  the  response  chondrocyte-­  or  
MSC-­derived   engineered   cartilage   to   IL-­1β   or   TNF-­α,   two   of   the   primary   inflammatory  
cytokines   found   in  OA.  MSC-­derived  constructs  exhibit  a  greater  sensitivity   to  cytokine  
challenge   as   measured   by   a   dose-­dependent   decrease   in   mechanical   properties   and  
matrix  content.  Differential  regulation  of  nitric  oxide  production  and  MMP  activity,  catabolic  
mediators   induced  by  IL-­1β  and  TNF-­α,  was  also  observed  between  cell   types.     These  
results  suggest  that  chondrocytes  may  have  an  inherent  advantage  in  surviving  within  an  
inflammatory  environment.  In  addition,  screens  to  identify  compounds  of  interest   in  vitro  
and  in  vivo  should  consider  the  role  of  cell  source  in  interpreting  results.  
  
To  complement  this  process  of  therapeutic  discovery  using  a  tissue-­engineered  model  of  
PTOA,  Chapter  8  reports  on  the  design  of  a  mechanically  regulated  drug  delivery  system.  
Mechanically-­activated   microcapsules   (MAMCs)   are   hollow   spheres   containing   an  
aqueous   drug   core   and   can   be   tuned   to   rupture   and   release   under   defined   loading  
patterns.  This   chapter   defines  how  physical   properties,   such  as   the   shell   thickness-­to-­
diameter   ratio,   influence   failure   thresholds   under   direction   compression   in   2D.   It   also  
shows   that   when   MAMCs   are   embedded   in   3D   hydrogels   analogous   to   engineered  
tissues,  matrix  mechanical  properties  affected  rupture  under  dynamic  loading.  The  power  
of   this   system   as   a   delivery   vehicle   was   shown   in   the   encapsulation   and   release   of  
bioactive   compounds   (the   chondrogenic   growth   factor   TGF-­β3)   with   mechanical  
activation.  TGF-­β3  released  from  MAMCs  induced  MSC  chondrogenesis  in  an  engineered  




Finally,   Chapter   9   summarizes   the   work   presented   here   and   discusses   the   potential  
limitations   and   implications   of   these   approaches   for   treating   the   progressive   stages   of  
cartilage  degeneration  in  OA.  Future  studies  and  strategies  are  also  outlined  that  could  
improve  our  in  vitro,  high  throughput  model  of  PTOA  for  screening  applications  and  further  
demonstrate  the  potential  of  MAMCs  to  be  used  for  cartilage  repair.  
  













Chapter  2.  Micro-­scale  Tissue  Engineered  Models  of  Musculoskeletal  Disease  for  
High  Throughput  Screening  	  	  
  
2.1  Introduction    
The  musculoskeletal  system  integrates  several  types  of  tissues  (e.g.  muscles,  tendons,  
cartilage,   bone)   to   support   structural   and   load-­bearing   functions   that   are   required   for  
human  motion.  Injury,  aging,  and  disease  can  cause  degeneration  of  components  of  this  
system,  resulting  in  debilitating  pain  and  disability.  As  of  2012,  126.6  million  adults  within  
the  US  (1   in  2  adults)  was  diagnosed  with  a  musculoskeletal  condition;;   this   is   twice  as  
many  as  any  other  condition  (Watkins  et  al.  2016).  Although  this  currently  primarily  affects  
working  age  adults,  this  population  will  continue  to  age,  and  by  2040,  1  in  5  adults  over  
the   age   of   65  will   be   impacted.   In   addition,   children   and   adolescents  who   experience  
trauma  or   sports   injuries  may  have   to   contend  with   life-­long  chronic  pain  or   instability.  
Musculoskeletal   disorders   correspondingly   represent   a   growing   percentage   of   national  
health  expenditures.  In  2011,  treatment  for  musculoskeletal  disorders  (direct)  and  indirect  
costs  (e.g.  lost  wages)  represented  1.4%  of  US  GDP  or  213  billion  dollars;;  however,  as  of  
2015,  this  number  had  grown  to  5.7%  of  US  GDP  or  $874  billion  dollars.    While  current  
clinical   strategies  use  artificial  materials   (e.g.  plastics,  metals)   in  an  attempt   to   restore  
function,   and   reduce   pain   and   disability   for   patients   with   late   stage   disease   (e.g.   fully  
degenerated   discs,   osteoarthritis),   these   approaches   have   significant   limitations   (e.g.  
revision  surgeries).  Therefore,  there  has  been  a  concentrated  effort   to  develop  disease  
modifying   treatments   for  early   intervention  to  offset  degeneration   in  order   to  repair  and  




Tissue   engineering   is   one   such   strategy   that   utilizes   a   combination   of   cell   sources,  
biomaterials,  chemical,  and  mechanical  cues  to  fabricate  constructs  that  mimic  the  cellular  
phenotype,   as   well   as   structure   and   function   of   native   tissues.   The   first   techniques  
developed   in   the  early  1980’s   focused  on  engineering  skin  substitutes   to  cover  severe  
burn  wounds   (Green  et  al.  1979;;  Yannas  et  al.  1982),  but  quickly  expanded   to   include  
musculoskeletal  tissues  including  cartilage,  bone,  meniscus,  tendon,  and  muscle.  To  date,  
however,   few   strategies   have   reached   commercial   success,   including   autologous  
chondrocyte  implantation  for  cartilage  repair  (ACI,  Carticel  by  Genzyme)  and  biomaterial-­
based  delivery  of  BMPs  to  stimulate  bone  formation  (Infuse  by  Medtronic,  OP-­1  implant  
by  Stryker)  (Mao  et  al.  2015).  Although  a  number  of  engineered  tissues  are  able  to  achieve  
native   tissue   properties   in   vitro,   challenges   remain   in   translating   these   strategies   into  
clinically  successful  solutions  due  to  the  complexity  of   the   in  vivo  environment.  Despite  
these  difficulties,  advances  in  tissue  engineering  have  supported  the  development  of  non-­
therapeutic  applications,  including  micro-­scale  disease  models.    
  
Over  a  decade  ago,  Griffith  and  Naughton  speculated  that  one  of  the  greatest  impacts  of  
tissue  engineering  would  be  “the  design  of  in  vitro  physiological  models  for  the  study  of  
disease   pathogenesis   and   the   development   of   therapeutics”   (Griffith   et   al.   2002).   The  
ability  to  specifically  control  the  design  parameters  and  culture  microenvironment  of  a  3D  
tissue  in  vitro  make  mimicking  the  cellular  and  tissue  pathology  of  a  given  disease  feasible.  
Preclinical  models  for  drug  discovery  conventionally  proceed  from  2D  cellular  assays  to  in  
vivo  animal  models  to  evaluate  the  safety  and  efficacy  of  lead  candidates  (Breslin  et  al.  
2013).  However,  2D  models  often  fail  to  recapitulate  key  aspects  of  3D  tissue  features,  
including   appropriate   cell   morphology,   cell-­cell   and   cell-­ECM   interactions,   biophysical  
cues  (e.g.  matrix  stiffness),  and  external  stimuli  (e.g.  mechanical  loading),  which  may  also  
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play  a  role  in  cellular  response  to  potential  therapeutics  (Astashkina  et  al.  2012;;  Breslin  et  
al.  2013).  In  addition,  while  in  vivo  models  confer  the  benefit  of  studying  a  whole  system  
response   to  particular  drug,  screening  hundreds  or   thousands  of  compounds   in  animal  
models  is  neither  economically  efficient  nor  ethically  responsible  (Mobasheri  et  al.  2013).    
  
High  throughput  assays  and  reliable  engineered  disease  models  are  required  to  conduct  
combinatorial  screens  of  drug  libraries  and  accurately  predict   in  vivo  responses  in  an   in  
vitro  system.  Combinatorial  studies  often  become  increasingly  complex  as  the  number  of  
factors  (e.g.  cell  source,  environmental  cues,  therapeutic  compounds)  increases,  resulting  
in   large   sample   sets   that   need   to   be   rapidly   evaluated   (Figure   2-­1).   A   micro-­scaled  
approach   would   represent   a   novel   and   versatile   tool   for   not   only   understanding  
mechanisms  of  disease  at  the  cellular  level,  but  also  for  identifying  new  biological  targets  
and  therapeutic  compounds.  In  addition,  as  a  high  throughput  format  requires  micro-­scale  
tissues,  cells  could  be  isolated  from  patient  biopsies  to  fabricate  constructs  and  screen  for  
drug   combinations   that   have   the   greatest   efficacy,   realizing   our   goal   of   personalized  
medicine.  The  development  of  viability  and  functional  assays  to  rapidly  assess  biomarkers  
relevant  to  the  disease  state  (Kimlin  et  al.  2013)  would  further  support  this  platform.  This  
overview  Chapter  surveys  the  current  state  of  the  art  for  musculoskeletal  disease  models,  
with  a  specific  focus  on  mechanical  systems  used  to  create  or  evaluate  disease  states  in  






Figure  2-­1.  An  example  of  an  experimental  tree  for  combinatorial  screens  that  are  
possible  using  high  throughput,  in  vitro  micro-­engineered  disease  models.  In  this  
scenario  screening  only  two  compounds  to  combat  inflammation,  a  number  of  variables  
can  be  modulated,  including  dosage,  timing  of  administration,  and  outcome  measures  to  
assess  relevant  disease  biomarkers.  
  
2.2.  Skeletal  Muscle  Models  
Clinical  disorders  of  skeletal  muscles  generally   fall   into  two  main  categories,   those  that  
are   inherited   (e.g.   genetic   abnormalities)   or   are   acquired   (e.g.   due   to   inflammatory  
diseases,   exposure   to   toxins,   infection)   (Muthusamy   et   al.   2010).   These   myopathies  
clinically  present  as  various  patterns  of  weakness  and  dysfunction,  and  are  the  result  of  
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disruptions   in   structural   integrity   and   abnormal   cell   metabolic   activity.   Experimentally,  
skeletal  muscle   is   frequently   characterized  by  phenotypic  or  morphological   changes   in  
myotubes   or  myofibrils,   including   expression   of   differentiation   or   hypertrophic  markers  
(e.g.  insulin-­like  growth  factor  I  (IGF-­1),  myogenin  (Sharples  et  al.  2012)  and  alterations  
in  cell  and  histological  features  (e.g.  myofiber  size  and  fusion  (Sharples  et  al.  2012;;  Lee  
et  al.  2013)).  Although  these  measures  provide   insight   into   the  signaling  pathways  that  
regulate   skeletal   muscle   remodeling,   they   are   not   necessarily   reflective   of   muscle  
functional  properties.  Active  and  passive  force  generation  represent  the  overall  integration  
of  these  structural  and  signaling  events  and  may  better  predict  the   in  vivo  physiological  
response  to  a  potential  therapeutic,  as  compared  to  characterization  of  cellular  behavior  
(Vandenburgh   2010).   In   this   section,   bioengineered   skeletal   muscle   models   will   be  
described   wherein   force   generation   serves   as   the   primary   outcome   measure   for  
determining  how  degenerative  muscle  diseases  affect  muscle  function.    
	  
2.2.1.  Micro-­bioartificial  Muscles    
The   MyoForce   Analysis   System   developed   by   Vandenburgh   et.   al.,   is   a   high-­content  
screening   system   capable   of   measuring   active   forces   generated   by   micro-­bioartificial  
muscles  (mBAMs)  in  response  to  electrical  stimulation  (Vandenburgh  et  al.  2008)  (Figure  
2-­2A).  Proliferating  primary  mouse  myoblasts  were  mixed  with  naturally-­derived  matrix  
products   (fibrin   (Vandenburgh   et   al.   2008;;   Vandenburgh   et   al.   2009),   type   I   collagen  
(Vandenburgh   et   al.   2009),   or   collagen-­Matrigel   (Vandenburgh   et   al.   2008;;   Lee   et   al.  
2013))   and   seeded   in  wells   containing  elastomeric  PDMS  posts.   The   cell-­seeded  gels  
were  observed  to  contract  around  the  posts,  facilitating  alignment  of  the  myoblasts.  The  
addition  of  differentiation  medium  (low-­serum  conditions)  following  this  initial  contraction  
induced   myoblast   fusion   to   form   aligned   and   striated   muscle   fibers.   Under   electrical  
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stimulation,   fibers   were   able   to   rapidly   generate   isotonic   tetanic   forces,   resulting   in  
deflection  of  the  PDMS  posts.  Post  deflection  was  tracked  using  motion  detection  imaging;;  
the   magnitude   of   the   active   force   generated   by   an   mBAM   (on   the   order   of   µN)   was  
calculated  based  on  the  material  properties  and  geometry  of  the  posts.    
  
Scale-­up   to   a   96-­well   format,   compatible   with   a   robotic   liquid   handling   system,  
demonstrated  the  feasibility  of  high  throughput  fabrication  and  culture  of  mBAMs,  as  well  
as  the  potential  for  conducting  drug  screens  in  a  model  of  Duchenne  muscular  dystrophy  
(DMD)  (Vandenburgh  et  al.  2009).  DMD  is  a  lethal  disease  caused  by  the  absence  of  the  
functional  dystrophin  gene,  which  leads  to  progressive  muscle  breakdown  and  weakening  
(Matsumura  et  al.  1994).    This  genetic  mutation  occurs  1  in  3500  male  births  and  onset  of  
the  disease  is  observed  before  the  age  of  13  (Muthusamy  et  al.  2010).  Mechanical  stress  
applied  to  muscle  fibers  lacking  this  cytoskeletal  and  structural  support  protein  results  in  
cell  membrane  damage  and  reduced  force  generation.    In  this  in  vitro  model,  myoblasts  
from   a   genetic   murine   homolog   of   DMD   (mdx)   were   used   to   fabricate   miniature   mdx  
mBAMs   to   carry   out   combinatorial   screens   of   therapeutic   compounds   that   might  
strengthen  muscles   (Vandenburgh  et  al.  2009).  Of   the  31  compounds  screened,   those  
that   markedly   increased   mdx   mBAM   force   generation   (by   >30%)   included   anti-­
inflammatory  glucocorticoids   (e.g.  prednisone  and  deflazacort  which  are  currently  used  
clinically),  as  well  as  IGF-­1,  creatine,  and  Trichostatin  A.  To  determine  if  in  vitro  outcome  
measures   were   consistent   with   synergistic   activity   observed   in   vivo,   several   drug  
interactions  were  also  evaluated.  Treatment  with  creatine  and  glucocorticoids  for  3  to  4  
days   doubled   mdx   mBAM   maximum   tetanic   forces,   consistent   with   improvements   in  
muscle   strength   in   the  mdx  mouse  model   (Figure   2-­2B).   Clinically   observed   negative  
interactions  (i.e.  lack  of  improvement  in  DMD  patients)  were  also  mimicked  in  the  mdx  in  
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vitro  model,  where  the  addition  of  pentoxifylline  (an  antifibrotic  drug)  reduced  the  tetanic  
forces   generated   by   glucocorticoid   or   creatine   treatment   alone.   Taken   together,   these  
results   demonstrated   that   the   functional   properties   of   engineered   skeletal   muscle   are  
consistent  with  and  reflective  of  gross  muscle  changes  observed  in  animal  models,  as  well  
as  patients,  validating  this  system  as  a  micro-­scale  musculoskeletal  disease  model.    
  
	  
Figure  2-­2.  Engineered  muscle  models  can  be  used  to  induce  and  monitor  disease  
conditions   in   vitro.   (A)   Micro-­bioartificial   muscle   schematic   of   post   deflection   under  
electrical   stimulation   for   measurements   of   active   force   generation;;   the   96-­well   mBAM  
format  for  high  content  screening  is  shown  on  the  right  (Adapted  from  Vandenburgh  et  al.  
2008;;   Vandenburgh   et   al.   2009).   (B)   Treatment   of   mdx   mBAMs   with   combined   drug  
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treatment  (Arginine  and  Deflazacor)  improved  tetanic  force  generation  compared  to  either  
drug  alone  (Adapted  from  Vandenburgh  et  al.  2009).  (C)  Gross  picture  of  constructs  in  the  
Culture   Force   System   and   fluorescence   image   of   multi-­nucleated  myotubes   that   form  
during  construct  maturation  (Adapted  from  Player  et  al.  2014).  (D)  A  reduction  in  myotube  
area   (atrophic   response,  MPD)  was  observed   in  a  model   of   skeletal  muscle  aging,   as  
compared  to  healthy,  hypertrophic  controls  (CON)  (Adapted  from  Sharples  et  al.  2012).  
(E)  A  model  of  static  over-­loading  induced  expression  of  hypertrophic  markers,  IGF-­1  and  
MMP-­9  (Adapted  from  Player  et  al.  2014).  
  
Recently,  mBAMs  have  also  been  utilized   to   investigate   the  molecular  mechanisms  by  
which  tension  reduction  contributes  to  the  development  of  disuse  skeletal  muscle  atrophy  
(Lee  et  al.  2013).  Mature  mBAMs  (able  to  generate  a  stable  maximum  isometric  tetanic  
force)  were  subjected  to  a  length  reduction  by  shortening  the  post-­to-­post  distance  (25-­
50%),  thereby  reducing  tension  within  the  construct.  Within  6  days,  hallmarks  of  muscle  
atrophy  were   induced,   including  a   reduction   in  active   force  generation,  myofiber  cross-­
sectional   area,   total   protein   synthesis   rate,   and   non-­collagenous   protein   content.  
However,  these  changes  were  considered  modest  compared  to  literature  observations  of  
atrophy  in  an  in  vivo  rodent  hindlimb  unloading  model.  This  difference  in  the  magnitude  of  
the   degenerative   response   may   be   due   to   the   absence   of   certain   native   muscle  
physiological  factors  (e.g.  motor  neuron  innervation,  endocrine  effects,  vascularity)  in  the  
mBAM  microenvironment  that  contribute  the  skeletal  muscle  maturation  (e.g.  differential  
expression  of  contractile  protein  isoforms,  higher  level  myofiber  organization).    Inclusion  
of   these   components   in   future   iterations   of   the   mBAM   system   will   likely   improve   the  
accuracy  of  the  pathological  model  in  predicting  in  vivo  responses,  as  well  as  support  the  
discovery   of   new   therapeutics   that   can   inhibit   or   attenuate   muscle   wasting   due  
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musculoskeletal  disorders  (Vandenburgh  et  al.  2008;;  Vandenburgh  et  al.  2009;;  Lee  et  al.  
2013).    
  
2.2.2.  Culture  Force  System    
The  Culture  Force  System  (CFS)  was  designed  as  a  dual  purpose  system:  (1)  to  measure  
passive   force   generation   (Culture   Force   Monitor)   and   (2)   to   apply   acute   mechanical  
overload  (Tensioning  Culture  Monitor)  to  engineered  muscle  (Sharples  et  al.  2012;;  Player  
et  al.  2014)  (Figure  2-­2C).  In  an  adaptation  of  the  method  described  by  Vandenburgh  et.  
al.,   C2C12  murine   skeletal   muscle  myoblasts   were   suspended   in   type   I   collagen   and  
polymerized  between  polyethylene  mesh  flotation  bars  attached  to  stainless  steel  frames.  
Strain  gauges  attached  to  these  frames  measured  the  contraction  of  muscle  constructs  
during   differentiation   and   maturation   of   the   tissue.   In   the   first   application   of   CFS  
(specifically  as  a  Culture  Force  Monitor),  an  in  vitro  model  was  developed  to  investigate  
how  aging  contributes  to  skeletal  muscle  degeneration  (sarcopenia)  (Sharples  et  al.  2012).  
Expansion  of  myoblasts   in  monolayer  culture  to  >50  population  doubles  has  previously  
been  shown  to  induce  an  ‘aged’  phenotype  by  mimicking  the  process  of  cellular  expansion  
and  self-­renewal  that  occurs  during  a  lifetime  of  endogenous  muscle  repair  (Sharples  et  
al.  2011).  These  expanded  cells  were  subsequently  seeded  in  collagen  gels  to  form  ‘MPD’  
engineered  muscle  constructs.  Within   the   first  24  hours  of   culture,  a  decrease   in  peak  
force   generation   was   observed   in   MPD   constructs   as   compared   to   non-­expanded,  
parental  control  tissues.  By  day  14,  MPD  constructs  were  smaller  and  thinner  (reduced  
myotube  diameter  and  area)  indicating  an  atrophied  morphology  as  compared  to  control  
constructs  (exhibited  hypertrophic  growth)  (Figure  2-­2D).  These  changes  were  taken  as  
an   indication   of   altered   cell-­matrix   and   cell-­cell   interactions,   which   regulate   myoblast  
differentiation  and  fusion  into  myotubes.  At  early  time  points,  gene  expression  showed  a  
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reduction   in  MMP-­9,  myogenin,  and   IGF-­1,  as  well  as  an   increase   in   IGFBP-­2   in  MPD  
constructs  compared  to  parental  controls.  This  expression  pattern  supported  the  lack  of  
differentiation   capacity   in   engineered   MPD   muscles   and   mimicked   the   impaired  
regenerative  capacity  of  aged  muscles  in  vivo.    
  
Building  on  this  platform,  the  Tensioning  Culture  Monitor  was  developed  to  apply  acute  
mechanical  overload  to  engineered  muscle  and  the  transcriptional  signature  associated  
with  acute  hypertrophy  was  evaluated  as  a  function  of  loading  parameters  (Player  et  al.  
2014).  A  ‘rapid  static’  (immediate  application  of  10%  strain  held  for  60  minutes)  and  ‘slow  
ramp’  (continuous  stretch  to  reach  10%  strain  over  60  minutes)  loading  induced  lactate  
release,   indicating   increased   metabolic   activity   under   overloading   conditions.  
Measurement  of  gene  expression  focused  on  IGF-­1  regulation,  specifically   IGF  binding  
proteins   and  MMP-­9.  Together   these   factors   control   the   bioavailability   of   IGF-­1,  which  
plays   a   role   in   potentiating   the   acute   hypertrophic   response.   MMP-­9   expression   was  
significantly   up-­regulated   and   IGFBP-­5   markedly   down-­regulated   for   both   loading  
protocols,   matching   reported   in   vivo   observations   (Figure   2-­2E).   However,   IGF-­1  
expression   was   only   up-­regulated   following   static   stretch,   suggesting   that   the   cellular  
response   to   the   rate   of   stretch   may   be   differentially   regulated   and   impact   the   acute  
adaptive  response  of  skeletal  muscle  (Figure  2-­2E).    Genes  related  to  inhibition  of  protein  
synthesis  (myostatin)  and  activation  of  proteolytic  pathways  (MuRF-­1  and  MAFBx)  were  
also   considered   as   they   play   a   role   in   regulating  muscle  mass.  While   in   vivo  models  
describe  suppression  of  these  genes,  in  engineered  muscle,  minimal  down-­regulation  of  
myostatin  was  observed  and  no   change  was   seen   for  MuRF-­1  or  MAFBx   in   the   short  
duration  of  these  experiments.  Although  challenges  remain  in  recapitulating  physiologic  
signaling   events,   a   number   of   mechanisms   involved   in   skeletal   muscle   atrophy   and  
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hypertrophy  were  conserved  in  the  CFS  platform,  supporting  the  continued  development  
of  engineered  muscle  as  a  preclinical  model  system.	  	  
	  
2.3.  Tendon  Models  
Repetitive  or  cyclic  loading  plays  an  important  role  in  the  development  of  tendinopathy,  a  
common   overuse   injury   in   tendon,   for   which   the   etiology   is   not   well   understood.  
Tendinopathy  is  a  blanket  term  for  tendinitis  (pain  and  inflammation  in  tendon),  tendinosis  
(tendon  degeneration),  and  tenosynovitis  (inflammation  of  the  synovial  sheath);;  however,  
all  conditions  are  clinically  characterized  by  chronic  tendon  degeneration  leading  to  pain  
and  rupture  (Hopkins  et  al.  2016).  Athletes  and  workers  represent  the  most  at  risk  groups.  
Lower  extremity  tendinopathies  are  most  common  in  athletes  (e.g.  patellar  or  Achilles’),  
due  to  the  high  intensity  and  frequency  of  physical  activity.  For  workers  who  perform  highly  
repetitive  tasks,  upper  extremity  tendinopathies  are  the  most  common,  with  the  affected  
anatomical   site   dependent   on   the   occupation   (Hopkins   et   al.   2016).   Experimental  
hallmarks   of   tendinopathy   include   expression   catabolic  mediators,   as  well   as   aberrant  
tenocyte  differentiation  and  matrix  remodeling.  In  particular,  tendinotic  tissues  exhibit  an  
increase   in   type   III   collagen   and   glycosaminoglycan   (GAG)   content   as   compared   to  
healthy  tendons  which  are  primarily  composed  of  type  I  collagen  (Magnusson  et  al.  2010).  
Previous  work  has  described  the  development  of  2D   in  vitro  and  3D  ex  vivo  models   to  
mimic   specific   pathologic   features   of   tendon   disease.   In   a   scratch   wound   model   of  
tenocytes   isolated   from   normal,   tendinopathic,   or   ruptured   tendons,   tenocytes   from  
degenerated  tissues  expressed  a  higher  collagen  type  III  to  type  I  ratio  than  healthy  cells  
(Maffuli  et  al.  2000).  An  ex  vivo  explant  model  tested  the  hypothesis  that  increased  GAG  
content   was   likely   due   to   chondrogenic   differentiation   of   tendon   cells   towards   a  
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fibrocartilaginous  phenotype  (de  Mos  et  al.  2009).  Culture  of  explants  under  chondrogenic  
conditions  (TGF-­β)  induced  marked  up-­regulation  of  chondrogenic  (SOX9,  aggrecan,  and  
collagen  type  II)  and  hypertrophic  markers  (RUNX2  and  collagen  type  X),  similar  to  human  
tendinotic  tissues.  These  shifts  in  matrix  composition  may  significantly  affect  the  tensile  
load-­bearing  capacity  of  tendons  (e.g.  through  a  weakened  collagen  network  structure),  
thus  increasing  the  risk  of  rupture.  To  improve  in  vitro  investigations  of  signaling  pathways  
and  molecules  that  regulate  tendon  injury  and  disease,  this  section  will  describe  micro-­
scale  models  of  mechanical  stretch  using  tendon-­derived  cells  in  3D  environments.    
	  
2.3.1.  Mechanical  Stretch  on  Silicone  Membranes    
In  vitro  models  of  tendinopathy  have  frequently  utilized  isolated  tenocytes  or  fibroblasts  
seeded  on   flexible   silicone  membranes  or   in  microgrooves   (as   shown   in  Figure  2-­3A)  
coated  with  adhesive  proteins  (Archambault  et  al.  2002;;  Yang  et  al.  2005;;  Zhang  et  al.  
2009).   These   membranes   were   subjected   to   cyclic   stretch   at   low   (4%)   strains   to  
mechanically  stimulate  tissue  growth  and  suppress  inflammation,  or  at  high  (8%)  strains  
to  induce  catabolic  processes  leading  to  injury  (Agarwal  et  al.  2001;;  Agarwal  et  al.  2003).  
In  particular,  repetitive  application  of  injurious  strains  was  associated  with  arachidonic  acid  
signaling  and  matrix  metalloproteinase  (MMP)  activity.  Mechanical  stretch  up-­regulated  
gene   expression   of   COX-­2   (Archambault   JOR   2002)   in   a   strain-­dependent   manner,  
resulting   in   a   down-­stream   increase   in   PGE-­2   protein   expression   under   injurious  
conditions   (Yang   et   al.   2005)   (Figure   2-­3B).   MMP-­1   and   -­3   expression   was   also   up-­
regulated  with   increasing   strain  magnitude   (Figure   2-­3B).   Low   strains,  which   have   an  
anabolic  effect,  require  matrix  turnover  as  part  of  the  process  for  tissue  growth;;  however,  
an  imbalance  between  protein  synthesis  and  degradation  rates  at  high  strains  can  lead  to  
overall   protein   loss   and   tissue   atrophy.      The   effect   of   IL-­1β,   an   inflammatory   cytokine  
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associated  with  tendon  injury,  was  also  evaluated  in  the  context  of  mechanical  stretch  of  
silicone   membranes   (Yang   et   al.   2005).   While   low   strains   were   able   to   suppress  
expression  (MMP-­1,  COX-­2)  and  release  (PGE2)  of  catabolic  mediators,  high  strains  acted  
synergistically  with  IL-­1β  to  further  up-­regulate  these  factors.    
  
	  
Figure  2-­3.  Tendon  degeneration  and  de-­differentiation  in  vitro  is  a  function  of  the  
magnitude  of  applied  strain.   (A)  Tendon  stem  cells   seeded   in  microgrooved  silicone  
surfaces  exhibited  an  aligned  morphology  with  uniaxial  stretch  (Adapted  from  Zhang  et  al.  
2009).   (B)   MMP-­1   and   PGE2   levels   increased   following   cyclic   stretch   at   high   strain  
magnitudes  (8%)  in  human  patellar  tendon  cells  (Adapted  from  Yang  et  al.  2005).  (C-­D)  
Application   of   high   strain   (injurious)   regimens   induced   expression   of   abnormal   non-­
tenocyte  markers  (e.g.  LPL,  SOX9,  RUNX2)  that  were  also  up-­regulated  in  an  in  vivo  injury  





To  further  explore  tendon  differentiation  potential  in  response  to  mechanical  forces,  Zhang  
et  al.  cultured  primary  tendon  stem  cells  (TSCs)  in  silicone  microgrooves  and  subjected  
them  to  cyclic  tensile  stretch  at  4  or  8%  strain  for  12  hours  (Zhang  et  al.  2009;;  Zhang  et  
al.   2013).   At   both   strain   levels,   TSC   expression   of   collagen   type   I   was   significantly  
increased,   indicating   differentiation   towards   a   tenocyte   phenotype.   However,   aberrant  
differentiation  of  TSCs  was  observed  under  8%  strain,  as  evidenced  by  up-­regulation  of  
markers   for   chondrogenesis   (SOX9,   collagen   type   II),   osteogenesis   (RUNX2),   and  
adipogenesis  (PPARγ),  compared  to  unloaded  controls  (Zhang  et  al.  2009)  (Figure  2-­3C).  
These  phenotypic  changes  suggest  that  the  GAGs,  lipids,  and  calcified  regions  found  in  
tendinopathic   tissues  may  be   the  direct   result  of  mechanical  overload   initiating  several  
simultaneous   cell   differentiation   programs.     A   follow-­up   study   evaluating   differentiation  
markers  in  an  in  vivo  murine  model  of  tendinopathy  showed  similar  fold-­increases  in  the  
expression  of  non-­tenocyte  genes  following  intense  treadmill  running  (Zhang  et  al.  2013),  
as   compared   to   TSCs   in   vitro   (Figure   2-­3D).   One   difference   of   note   was   the   higher  
expression  (~3-­fold)  of  collagen  type  I  and  II  under  high  strain  conditions  in  vitro;;  however,  
overall,   key   hallmarks   of   altered   progenitor   cell   fate   due   to   an   injurious   mechanical  
environment  were  able  to  be  captured  in  an  engineered  tissue  system.    
	  
2.3.2.  Microfabricated  Tissue  Gauges  
While  phenotypic  changes  are  often  characterized  to  identify  mechanotransduction  events  
associated  with  tendinopathy,  tissue  functional  properties  also  play  an  important  role   in  
disease   progression.   Legant   et   al.   recently   developed   a   high   throughput   system   to  
fabricate   and   evaluate   the   contractile   properties   of   micro-­tissues   (Legant   et   al.   2009;;  
Ramade   et   al.   2014).   The   µTUG   array   (micro-­fabricated   tissue   gauges)   passively  
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measures  the  interactions  between  cell  contractile  forces  and  matrix  remodeling  on  micro-­
tissue  force  generation  (on  a  nN  scale,  Figure  2-­4  A-­B).  Similar   to   the  mBAM  system,  
cells   (e.g.   fibroblasts)   are   seeded   in   collagen  matrix   in   PDMS  wells   containing   raised  
cantilevers;;  cell  compaction  of  the  matrix  around  the  posts  causes  cantilever  deflection.  
Micro-­tissue   force   generation   increased   with   cell   number,   cantilever   stiffness,   and  
collagen  concentration  (Figure  2-­4C).  Changes  in  functional  behavior  also  matched  the  
observed  increase  in  matrix  production  (measured  by  immunofluorescence  of  Tenascin  C  
and   fibronection).   This   system   has   since   been   used   to   create   arrays   of   cardiac  
microtissues  to  study  the  effects  of  electrical  stimulation  and  drug  compounds  (Boudou  et  
al.  2012).  Since  tendons  undergo  pathological  matrix  remodeling  during  degeneration,  it  
may  be  possible  to  utilize  this  µTUG  system  to  fabricate  3D  micro-­tendon-­like  tissues  and  
create   a   disease   model   of   tendinopathy   with   measurable   force   output.   Micro-­tendons  
could  be  treated  with  growth  factors  to  induce  differentiation  (e.g.  TGF-­β),  fabricated  using  
combinations  of  collagen  types  and  concentrations,  or  seeded  with  tenocytes  and/or  TSCs  
from  healthy  or  diseased  tendons.  Control  over  cell  source,  matrix,  and  exogenous  stimuli  
in  this  system  would  enable  the  development  of  a  versatile,  in  vitro  model  of  tendinopathy  
with   the  potential   to   track   functional  outcomes,   in  a  high   throughput  manner,   that  have  





Figure  2-­4.  Micro-­fabricated  tissue  gauges  (µTUGs)  measure  cell  contractile  forces  
and  matrix  remodeling  in  micro-­patterned  arrays  of  3D  constructs.  (A)  Large  arrays  
of   micro-­tissues   were   fabricated   simultaneously   on   a   single   substrate.   (B)   Tension  
generated  within  the  construct  reaches  a  plateau  after  cell  contraction  of  the  matrix  (inset:  
fluorescence   image   of   cytoskeletal   and   matrix   components-­   actin,   fibronectin,   and  
tenascin  C).  (C)  µTUGs  fabricated  on  stiffer  MEM  cantilevers  and  seeded  with  a  greater  
number  of  cells,  exhibited  greater  tension  generation  within  the  construct.  (Adapted  from  
Legant  et  al.  2009).	  
  
2.4.  Cartilage  Models  
Arthritis   is   the   most   common   cause   of   disability   among   adults   within   the   US   and   is  
projected  to  affect  67  million  individuals  (~25%  of  the  adult  population)  by  the  year  2030  
(Watkins  et  al.  2016).  In  2011,  the  estimated  annual  cost  of  medical  care  for  arthritis  and  
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joint  pain  was  580  billion  dollars;;  the  total  estimated  cost  of  joint  replacements  alone  was  
66  billion  dollars.  In  particular,  osteoarthritis  (OA)  is  the  most  common  of  all  joint  diseases,  
with  the  majority  of  affected  individuals  aged  between  15  and  64  years  (Economics  2007;;  
Pereira  et  al.  2011).  For  a  subset  of  this  population,  an  acute  instance  of  supraphysiologic  
loading   (i.e.   traumatic   injury)   was   the   initiating   event   that   led   to   the   development   of  
cartilage   lesions  and   full  blown  OA   later   in   life.  This  sub-­category  of  OA,   termed  post-­
traumatic  osteoarthritis  (PTOA),  accounted  for  12%  of  all  OA  cases  (~6  million  people)  in  
the  US  as  of  2006  (Brown  et  al.  2006).  Traumatic  joint  injuries  increase  the  risk  of  OA  5-­
fold,  with  50  to  75%  of  patients  with  ACL  tears  or  meniscal  damage  developing  OA  10  to  
15  years  post-­injury  (Roos  et  al.  1995;;  Lohmander  et  al.  2004;;  Lohmander  et  al.  2007;;  
Neuman  et  al.  2008).  Clinically,  OA  is  characterized  by  joint  pain,  as  well  as  joint  space  
narrowing   and   cartilage   erosion   (observed   by   MRI,   (Kijowski   et   al.   2014)).   Additional  
biological  markers  of  PTOA  observed  experimentally  (in  vivo  and  in  vitro  explant  models)  
include  tissue  swelling,  cartilage  fibrillation  or  erosion,  cell  death  at  or  adjacent  to  the  site  
of   injury,   increased   expression   of   proteases   and   inflammatory   cytokines,   and   overall  
depletion  of  proteoglycans,  culminating  in  the  loss  of  cartilage  mechanical  function  (Kurz  
et  al.  2001;;  Quinn  et  al.  2001;;  Borrelli  et  al.  2003;;  Patwari  et  al.  2003;;  DiMicco  et  al.  2004;;  
Lee  et  al.  2005;;  Natoli  et  al.  2008;;  Hurtig  et  al.  2009;;  Boyce  et  al.  2013).  While  the  native  
microenvironment  plays  an  important  role  in  the  development  of  OA,  animal  and  explant  
model  systems  are  not  amenable  to  scale-­up  for  drug  development  due  to  considerations  
of  cost,  ethical  issues,  and  tissue  heterogeneity.  To  date,  no  pharmaceutical  solution  has  
been  approved  to  stop  the  structural  damage  caused  by  OA.  Yet  as  the  number  of  joint  
replacements   rise   (expected   ~10%   annually),   the   need   for   disease   modifying   OA  
therapies  for  early  intervention  becomes  apparent.  Micro-­scale  engineered  cartilage  may  
therefore  serve  as  an  appropriate   in  vitro  analog   to  study  how   inflammatory  milieu  and  
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mechanical   injury  contribute   to  progressive  cartilage  degeneration,  and   to  evaluate   the  
ability  of  putative  therapeutics  to  inhibit  this  process.  
  
2.4.1.  Role  of  Inflammation  in  OA  Pathogenesis  
Classic  inflammation  is  frequently  associated  with  OA  and  contributes  to  the  imbalance  of  
catabolic  and  anabolic  processes  that  lead  to  overall  cartilage  dysfunction.  Cytokines  (e.g.  
IL-­1,  TNF-­α,  IL-­6  (Goldring  2000))  produced  by  a  number  of  cell  types  within  the  joint  (e.g.  
macrophages,   synoviocytes,   and   chondrocytes   (Benito   2005;;   Bondeson   et   al.   2006))  
induce   the   production   of   catabolic   mediators   (e.g.   nitric   oxide,   MMP,   ADAMTS)   that  
progressively   change   the   quality   and   quantity   of   matrix   components,   including  
proteoglycans  and  type  II  collagen.  Recently,  engineered  cartilage  has  been  used  as  a  
platform  to   investigate  the  ability  of  specific  cytokines  to  stimulate  OA  hallmarks  and  to  
test  the  inhibitory  effects  of  candidate  drugs  (Willard  et  al.  2014).  Using  a  high  throughput  
platform,  cartilage  pellets  were  formed  from  mouse  iPSCs  and  cultured  for  three  weeks  in  
the  presence  of  chondrogenic   factors   (TGF-­β3  and  dexamethasone).  Treatment  of   this  
engineered  cartilage  with  IL-­1α  (1ng/mL)  increased  GAG,  nitric  oxide,  PGE2,  and  MMP  
release  to  the  medium,  comparable  to  the  response  observed  in  treated  native  cartilage  
explants   (Figure   2-­5A).      In   a   screen   of   candidate   therapeutic   agents   known   to   inhibit  
inflammation   (IL-­4),   COX-­2   (NS398)   and  NF-­kB   (SC-­514)   signaling,   and  MMP   activity  
(TIMP-­3   and  GM6001),   only   SC-­514  was   able   to   attenuate   production   of   all   catabolic  
mediators  in  response  to  IL-­1α  described  above.    
  
Although  the  above  study  demonstrated  the  scalability  of  an  OA  model  and  the  ability  of  
a   single   cytokine   to   mimic   several   features   of   cartilage   pathology   in   vitro,   the   in   vivo  
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environment  contains  several   factors   that  modulate  cell  signaling  all  at  once.  To  better  
recreate  signaling  events  that  occur  in  the  inflamed  joint  environment   in  vivo,  Sun  et  al.  
cultured  3D  silk-­fibroin  engineered  cartilage  with  macrophage-­conditioned  medium  (MCM)  
for  21  days  (Sun  et  al.  2011).  Chondrocyte  response  to  MCM  was  compared  to  medium  
with   exogenous   addition   of   TNF-­α   and   IL-­1β   at   the   same   concentration.   Exogenous  
cytokines  and  MCM   induced  expression  of  MMP-­1,   -­3,   -­13  and  ADAMTS4,  as  well   as  
suppression  of  GAG  accumulation  within  the  construct.  Although  the  magnitude  of  these  
changes  varied  between  the  two  conditions,  the  models  mimicked  many  early  hallmarks  
of   OA   observed   in   vivo.   However,   only   MCM   was   able   to   stimulate   chondrocyte  
hypertrophy  and  apoptosis,  suggesting  exogenous  cytokines  alone  may  not  be  sufficient  





Figure   2-­5.   Engineered   cartilage   models   of   OA   can   mimic   features   of   the  
inflammatory   and   mechanical   injury   response.   (A)   Induced   pluripotent   stem   cells  
(iPSCs)  were  used  to  fabricate  cartilage  pellets  in  a  high  throughput  model  of  inflammation  
in  OA.  Increased  GAG  release  and  MMP  activity  observed  in  the  engineered  system  was  
similar  to  the  native  cartilage  response  to  IL-­1α  (1ng/mL).  Evaluation  of  candidate  drugs  
showed   SC-­514   (an   inhibitor   of   NF-­κB   activity)   was  most   effective   at   restoring  matrix  
content  (Adapted  from  Willard  et  al.  2014).  (B)  The  ability  of  engineered  cartilage  to  repair  
the   surrounding   matrix   post-­injury   was   assessed   as   a   function   of   construct   maturity.  
Chondrocytes  in  Immature  (day  5)  constructs  were  able  to  restore  the  structural  integrity  
of   the   matrix   by   5   weeks   post-­injury,   while   permanent   loss   of   structural   integrity   was  




2.4.2.  Compressive  Injury  Models  using  Engineered  Cartilage  
Mechanical  injury,  as  it  relates  to  PTOA,  induces  acute  changes  in  cartilage  (primarily  cell  
death   and   proteoglycan   loss).   Over   time,   this   initial   traumatic   event   is   potentiated   by  
catabolic  signaling  that  eventually  leads  to  a  loss  in  load-­bearing  capacity.    To  date,  few  
in  vitro  models  have  been  developed  to  explore  the  mechanisms  that  cause  mechanical  
injury   to   progress   to   cartilage   degeneration.   In   recent   work,   Tan   et   al.   described   the  
intrinsic  ability  of  chondrocytes  to  repair  the  surrounding  matrix  as  a  function  of  engineered  
cartilage  maturity  (Tan  et  al.  2010).  Immature  (day  5)  or  mature  (day  35)  constructs  were  
subjected   to   compression-­induced   cracking   (ramp   to   failure   at   0.3%   strain/s),   and  
subsequently   cultured   for   up   to   3   months   (Figure   2-­5B).   Chondrocytes   in   immature  
constructs  were  able  to  infiltrate  and  repair  discontinuous  regions  by  4  weeks  post-­injury,  
resulting   in   equivalent   equilibrium   and   dynamic   moduli   as   compared   to   un-­injured  
constructs.  In  comparison,  mature  constructs  did  not  recover  with  time  in  culture.  A  large  
fraction   of   cells   remained   non-­viable   and   there   was   a   permanent   loss   in   mechanical  
integrity,   similar   to   observations   of   injured   explants   in   vitro.   This   disparity   in   the   injury  
response  with  construct  ‘age’  may  relate  to  the  density  of  the  surrounding  matrix  and  cell-­
ECM   interactions   that   influence   strain   transfer   to   embedded   chondrocytes.  A   separate  
study  also  evaluated   the  contribution  of  chondrocyte  phenotype   to   the   injury   response.  
Juvenile  or  adult  chondrocytes  were  embedded  in  a  poly(ethylene  glycol)  hydrogel  and  
subjected  to  impact  injury  (Farnsworth  et  al.  2012).  However,  age-­dependent  differences  
were  not  clearly  distinguishable,  indicating  that  mechanical  perturbation  may  be  context  
dependent.    
  
Although  these  systems  represent  a  first  step,  further  development  of  reliable,  engineered  
cartilage   injury   platforms   are   needed   to   aid   in   the   discovery   of   disease-­modifying  
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therapies.  Previously,  the  investigation  of  small  molecules  for  the  treatment  of  PTOA  has  
focused   on   factors   that   target   canonical   early   signaling   events.   These   agents   include  
those  that  block  pathways  related  to  cell  death  (e.g.  pan-­caspase  inhibitors  (D'Lima  et  al.  
2001;;  Martin  2009)),  repair  cell  membrane  damage  (e.g.  amphiphilic  surfactants  (Phillips  
et  al.  2004;;  Bajaj  2010)),  reduce  catabolic  mediators  (e.g.  free  radical  scavengers  (Martin  
2009)),  and  attenuate  or  reverse  proteoglycan  loss  (e.g.  growth  factors  (Hurtig  et  al.  2009)  
and  glucocorticoids  (Lu  et  al.  2011)).  However,  since  the  mechanisms  of  PTOA  have  not  
yet  been  fully  elucidated,  there  likely  exist  additional  agents  that  modulate  non-­canonical  
or   un-­explored   pathways  with   chondro-­protective   or   chondro-­regenerative   effects   (e.g.  
Kartogenin   (Johnson  et   al.   2012)).  A  high   throughput  mechanical   injury  platform  using  
engineered  cartilage  would  address  this  need  for  drug  discovery,  and  serve  as  a  valuable,  
unbiased  screening  tool  to  identify  new  therapeutics  for  early  intervention  in  PTOA.    
  
This   is   approach   is   the   major   focus   of   this   thesis.   Characterization   of   an   engineered  
cartilage  model,  design  of  a  high  throughput  mechanical  platform,  and  validation  of   the  
injury  response  in  vitro,  are  all  described  as  part  of  a  concentrated  effort  to  discover  and  
deliver   therapeutics   that   may   attenuate   the   progression   of   degeneration   initiated   by  
traumatic  mechanical  injuries.  
	   	  	  	    
2.5.  Conclusion  
Tissue  engineering   is  a  promising  strategy   for   the   repair  of  diseased  and  degenerated  
musculoskeletal   tissues,   but   difficulties   still   remain   in   translating   this   technology   into  
clinically  acceptable  solutions.  Despite   this  challenge,  advances  made   in   this   field  over  
the  past  thirty  years  have  supported  the  development  of  in  vitro  pre-­clinical  models  that  
more   closely  mimic   the   native   tissue   physiology.   The   current   state   of   the   art   in   tissue  
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engineered  musculoskeletal  disease  models  was  described  in  this  review,  with  a  particular  
focus  on  micro-­scaled  engineered  systems  that  can  incorporate  mechanical  perturbations  
to   reproduce   key   pathological   features   observed   in   vivo.   Improvements   in   throughput,  
recapitulation  of  native  tissue  properties  and  injury  responses  in  micro-­scaled  tissues,  and  
most  importantly,  incorporation  of  mechanical  stimuli  in  developing  platforms  will  pave  the  
























Chapter  3.  Time-­dependent  Functional  Maturation  of  Scaffold-­Free  Cartilage  
Tissue  Analogs	  	  
3.1  Introduction    
Articular  cartilage  is  a  dense  connective  tissue  lining  joint  surfaces  and  is  defined  by  the  
unique  zonal  architecture  of  extracellular  matrix  constituents  and  chondrocytes,  as  well  as  
by   its   load   bearing   capacity   during   physiological   activities.   As   a   consequence   of   the  
avascular   and   aneural   nature   of   this   specialized   tissue,   cartilage   has   limited   healing  
capacity   following   injury.  Surgical  methods   to   repair   chondral   defects   include  abrasion  
arthroplasty   (Johnson   1986),   subchondral   drilling   (Insall   1974),   and   osteochondral  
autografts  (Hangody  et  al.  2004).  Currently,  only  one  cell-­based  regenerative  approach  is  
FDA   approved;;   this   technology   is   termed   autologous   chondrocyte   implantation   (ACI)  
(Brittberg  et  al.  1994).    This  approach  utilizes  patient  cartilage  biopsies  that  are  digested  
to  isolate  chondrocytes.  These  cells  are  subsequently  expanded  and  re-­implanted  at  the  
site   of   cartilage   damage   to   induce   regeneration.      However,   these   techniques   have  
encountered  limited  success  due  to  issues  including  fibrocartilage  formation,  chondrocyte  
de-­differentiation,  and  lack  of  tissue  integration  and  mechanical  support  (Furukawa  1980;;  
Hunziker  2002).    To  address  these  limitations,  tissue  engineering  strategies  aim  to  repair  
cartilage  by  recapitulating   the  matrix  architecture,  cellular  composition,  and  mechanical  
properties   through   the   use   of   a   various   of   design   platforms.   These   systems   combine  
scaffolds,  cell  sources,  and  environmental  signaling  cues  to  guide  tissue  regeneration  and  
achieve  native  cartilage  properties.  
  
Research  in  this  field  is  active,  with  numerous  approaches  to  cartilage  tissue  engineering;;  
these  methods  can  be  generally  divided  into  two  groups:  scaffold-­based  vs.  scaffold-­free  
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constructs.    Scaffold-­based  methods  include  the  use  of  natural  and  synthetic  hydrogels  
(Mauck  et  al.  2002;;  Erickson  et  al.  2009;;  McCall  et  al.  2012;;  Ingavle  et  al.  2013;;  Rahman  
et  al.  2013)  and  fibrous  meshes  (Moutos  et  al.  2007;;  Kim  et  al.  2011),  with  or  without  cells  
(e.g.   chondrocytes   and   stem   cells)   and   other   cues   (e.g.   growth   factors),   to   grow  
engineered   cartilage.      Advantages   of   scaffold-­based   methods   include   the   ability   to  
temporarily  re-­differentiate  passaged  chondrocytes  (Capito  et  al.  2006),  to  achieve  near  
native  mechanical  properties   (Moutos  et  al.  2007;;  Erickson  et  al.  2009;;  Erickson  et  al.  
2012),  to  undergo  bioreactor  mechanical  stimulation  (Hu  et  al.  2006),  and  to  entrap  cells  
in  a  locally  controlled  environment.  However,  significant  disadvantages  of  material-­based  
approaches  include  phenotype  instability,  toxicity  of  degradation  products  and  crosslinking  
methods,  cell  adhesion,  and  inappropriate  biomaterial  remodeling;;  each  concern  depends  
on  the  materials  and  methods  utilized  (Hu  et  al.  2006).  Alternatively,  scaffold-­free  methods  
utilize  high  cell  density  cultures  in  combination  with  low  adhesion  surfaces  (Novotny  et  al.  
2006;;  Ofek  et  al.  2008;;  Revell  et  al.  2008;;  Kim  et  al.  2011),  bioreactors  (Furukawa  et  al.  
2003;;   Kelm   et   al.   2004),   or   centrifugation   methods   (Muraglia   et   al.   2003)   to   form  
aggregates   (Anderer  et  al.  2002;;  Furukawa  et  al.  2003;;  Revell  et  al.  2008;;  Huey  et  al.  
2011),  pellets   (Zhang  et  al.  2004;;  Bernstein  et  al.  2009)  and  micro-­tissues  (Kelm  et  al.  
2004).    These  techniques  can  retain  chondrocyte  phenotype,  facilitate  cell-­cell  interactions  
and   promote   the   elaboration   a   natural   ECM   (Anderer   et   al.   2002;;   Kelm   et   al.   2004;;  
Bernstein  et  al.  2009).  Enhancement  of  ECM  characteristics  (and  thus  improved  cartilage-­
like   characteristics)   has   also   been   achieved   with   the   addition   of   real-­time  mechanical  
loading  applied  to  these  constructs  (Elder  et  al.  2009;;  Kraft  et  al.  2011).  In  addition,  the  
uniformity   of   scaffold-­free   fabrication   enables   compatibility   with   high   throughput   assay  





We  have  previously  developed  a  scaffold-­free  approach   to  cartilage   tissue  engineering  
that  uses  primary  chondrocytes  seeded  in  hydrogel-­coated  culture  vessels  that  prevent  
cell  adhesion  and  promote  self-­aggregation  of   the  cell  suspension,  which  subsequently  
forms   into   a   cartilage-­like   biomass.      In   this   model,   chondrocytes   are   cultured   at   high  
density   in   tissue   culture   vessels   coated   with   poly   2-­hydroxyethyl   methacrylate  
(polyHEMA);;   this   hydrogel   coating   prevents   cell   attachment   to   the   plastic   substrate.    
Within   24   hours,   chondrocytes   coalesce   to   form   a   stable   construct   that   remains   in  
suspension  and  progressively  increases  in  mass  with  time.  We  refer  to  these  constructs  
as  cartilage  tissue  analogs  (CTA).  Chondrocytes  in  CTAs  possess  appropriate  phenotypic  
characteristics  and  deposit  ECM  that  is  similar  to  native  cartilage  (Estrada  et  al.  2001;;  Kim  
et  al.  2011)  and  can  be  produced  from  several  species,  including  neonatal  porcine,  bovine,  
equine,  and  human  chondrocytes  (Dodge  et  al.  1998;;  Richardson  et  al.  2000;;  Estrada  et  
al.  2001).  We  have  shown  that  CTAs  in  culture  continue  to  produce  collagen  type  II  and  
do   not   produce   collagen   type   I,   which   would   be   indicative   of   their   differentiation   to   a  
fibroblastic  phenotype  (Novotny  et  al.  2006).  However,  the  mechanical  properties  of  CTAs  
have  not  yet  been  evaluated  over  an  extended  time  course.  One  of  the  primary  limiting  
factors   in   the  clinical  application  of   cartilage   tissue  engineering   is   the   insufficient   load-­
bearing  capacity  of  the  repair  tissue  (Hunziker  2002;;  Khoshgoftar  et  al.  2013).    As  such,  
this   study   evaluated   the   temporal   development   of   CTA   mechanical   and   biochemical  
properties,  as  well  as  the  relationship  between  mechanics  and  matrix  content  in  order  to  





3.2.1.  CTA  Fabrication    
Articular   cartilage   was   harvested   from   juvenile   bovine   knees   (N=5,   age   2-­6   months,  
Research  87,  MA),  minced,  washed  with  PBS  with  2X  PSF  (2%  penicillin,  streptomysin,  
fungizone)  and  digested  in  Type  II  Collagenase  (298U/mg)  in  Basal  Medium  for  up  to  36  
hours  (1mg/mL  in  Dulbecco’s  Modified  Eagles  Medium  with  10%  v/v  Fetal  Bovine  Serum  
and  1%  v/v  PSF).    Digested  cartilage  was  filtered  through  70µm  strainers  to  separate  cells  
from  undigested  matrix,  diluted  with  2X  PBS-­PSF,  and  centrifuged  at  1750   rpm   for  20  
minutes   at   12oC.   The  wash  and   centrifugation   process  was   repeated   3X   to   pellet   and  
isolate  juvenile  bovine  chondrocytes.      
  
Chondrocytes   were   seeded   at   1x106   cells/well   (200   µL/well)   in   poly   2-­hydroxyethyl  
methacrylate   (polyHEMA)   hydrogel   coated   96  well   plates   (Ultra-­Low  Adhesion   96  well  
plates,   Corning)   to   form   cartilage   tissue   analogs   (CTA).   As   shown   in   Figure   3-­1,  
chondrocytes  initially  form  clusters  at  the  bottom  of  the  well  that  eventually  condense  into  
a  uniform  mass.    The  CTA  constructs  coalesce  within  24-­48  hours  and  continue  to  mature  
with  time  in  culture;;  the  chondrocytes  produce  cartilage  specific  extracellular  matrix  and  
increase  in  size  over  time.  CTAs  were  cultured  in  Complete  Medium  (DMEM  with  10%  v/v  
FBS,   100   U/mL   penicillin,   100μg/mL   streptomysin,   2.5μg/mL   fungizone,   1%   v/v   MEM  
Vitamin  Solution  (Gibco  #11120),  25mM  HEPES  buffer,  50  μg/mL  ascorbic  acid)  for  up  to  






Figure   3-­1.   Chondrocytes   aggregate   in   high   density   suspension   culture   to   form  
CTAs.  Chondrocytes  seeded  in  96  well  plates  begin  to  coalesce  within  12  hours  and  form  
stable   tissue   analogs   24-­48   hours   post-­seeding.   CTAs   4   hours   post-­seeding   show  
chondrocytes   beginning   to   coalesce,   form   a   mass   and   with   increasing   time,   contract  
(125,000  chondrocytes/CTA),  while  higher  seeding  densities  (1  million  chondrocytes/CTA)  
result  in  more  complete  contraction  and  formation  of  a  uniform  construct.    CTAs  4  and  42  
weeks  post  seeding  are  cylindrical  in  shape  and  relatively  uniform  in  size.  
  
3.2.2.  Adult  Bovine  Cartilage    
To   provide   a   suitable   benchmark   by   which   to   compare   CTAs,   native   cartilage   plugs  
(Ø4mm)   were   harvested   from   the   trochlear   groove   of   fetal   (second   or   third   trimester,  
Animal  Technologies,  TX),  juvenile  (2-­6  months,  Research  87,  MA),  and  adult  (2-­5  years)  
bovine   knees   (Animal   Technologies,   TX).      Explanted   cartilage   plugs   were   trimmed   to  
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remove  the  underlying  subchondral  bone,  but  retain  the  full  thickness  of  articular  cartilage.  
Adult  explants  were  utilized  for  mechanical  testing,  while  fetal,  juvenile,  and  adult  explants  
were  assessed  for  cell-­matrix  distribution  during  histological  analysis.    
  
3.2.3.  Mechanical  and  Biochemical  Evaluation    
CTAs  and  native  cartilage  explants  were  tested  using  a  custom  unconfined  compression  
testing   device   (Mauck   et   al.   2006)   to   determine   equilibrium   (10%   strain)   and   dynamic  
moduli  (1%  strain,  1Hz).    Only  CTAs  cultured  for  more  than  four  weeks  were  mechanically  
tested  due  to   lack  of  mechanical   integrity  prior   to  this  time  point.  After   testing,  samples  
were   lyophilized,   papain   digested   for   18   hours,   and   evaluated   for   glycosaminoglycan  
(DMMB)  (Farndale  et  al.  1986),  hydroxyproline  (OHP)  (Stegemann  et  al.  1967),  and  DNA  
(PicoGreen,  Invitrogen)  content.    
  
3.2.4.  Histology  and  Cell-­to-­Matrix  Analysis  
CTAs   (N=3-­5/age   category   with   combined   donors)   and   native   cartilage   explants  
(N=3/age/donor)  were  fixed  in  4%  paraformaldehyde,  dehydrated  in  ethanol,  and  paraffin  
embedded   for   histological   evaluation.      Sections   (8µm   thick)   were   stained   for  
proteoglycans  (Alcian  Blue  8GX,  Sigma)  and  nuclei  (Nuclear  Fast  Red,  Master*TechTM),  
and  a  series  of  20X  images  were  taken  of  each  CTA  or  cartilage  plug  (12  images/sample).    
The   cell-­matrix   ratio   for   each   image   was   quantified   using   ImageJ   (V1.46,  
rsbweb.nih.gov/ij/).  The   following   imaging  processing  steps  were   taken   to  calculate   the  
cell  area  fraction  of  the  total  matrix.    Each  image  was  split  into  RGB  channels,  and  the  red  
channel  selected  in  order  to  identify  nuclear  bodies  for  individual  cells  within  matrix.  Within  
the  image,  individual  cell  edges  were  found  and  contrast  enhanced  (0.4%);;  the  image  was  
then  converted  to  a  binary  image.  Cell  area  was  determined  by  analyzing  particles  that  fell  
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within  a  specified  size  range  (determined  by  measuring  the  long  axis  of  ~30  cells   in  an  
unprocessed  image  per  sample,  and  calculating  an  idealized  circular  cell  area).    The  sum  
of  the  area  of  all  particles,  or  “cells”,  was  divided  by  the  total  matrix  area  of  the  image  to  
generate   the  cell-­matrix   ratio.  Fidelity  of  area  measurements   to  unprocessed  cells  was  
manually  verified;;  images  which  poorly  represented  cell  area  due  to  background  noise  or  
poor  staining  were  excluded.  
  
3.2.5.  Statistical  Analysis  
Correlation  of  biochemical  content  and  equilibrium  modulus  was  calculated  using  linear  
regression  (Pearson’s  Coefficient)   to  determine   the  contribution  of  specific  extracellular  
matrix   components   to   the   temporal   development   of  mechanical   properties.      CTA   cell-­
matrix   ratios   were   grouped   into   multi-­week   categories   and   compared   to   that   of   fetal,  
juvenile,   and   adult   bovine   cartilage   (one-­way   ANOVA,   Tukey’s   post-­hoc;;   p<0.05).   All  
mechanics,  biochemical,  and  histological  outcome  measures  are  represented  by  mean  ±  
standard  deviation  values.  
  
3.3.  Results  
3.3.1.  CTA  Mechanical  Properties  
CTA  mechanical   properties   increased   in   a   uniform  manner   from   four   to   twelve  weeks  
across   all   donors.  While   the   average   equilibrium   (EY)   and   dynamic   (G*)  modulus   at   4  
weeks  was  8.7  ±  3.9  kPa  and  352.6  ±  176.0  kPa,  by  10  to  12  weeks  EY  increased  to  23.4  
±  7.0  kPa  and  G*  to  576.3  ±  211.3  kPa,  as  shown  in  Figure  3-­2.    After  12  weeks  of  culture,  
mechanical  properties  began  to  diverge  across  donors.    Equilibrium  and  dynamic  moduli  
either  continued  to  increase  with  culture  duration  or  reached  a  plateau;;  past  16  weeks  of  
culture,  EY  averaged  110.9  ±  85.0  kPa  and  G*  averaged  1215.9  ±  646.4  kPa;;  CTAs  tested  
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at  24  weeks  also  fell  within  this  range.  These  CTA  properties  approached  those  of  adult  




Figure  3-­2.  Mechanical  properties  of  CTAs  cultured  over  a  period  of  24  weeks.  (A)  
Equilibrium  modulus  and  (B)  Dynamic  modulus  of  CTAs  increased  with  culture  duration  
(N=4-­5  samples/donor;;  each  color  represents  a  different  bovine  donor),  and  approached  
native  adult  bovine  cartilage  (N=6  donors)  properties  by  16  weeks.    
	  
3.3.2.  CTA  Biochemical  Content  
Sulfated  glycosaminoglycans  (GAG)  and  collagen  content  of   individual  CTAs  harvested  
throughout   the   24-­week   culture   period   was   plotted   against   the   respective   equilibrium  
modulus  of  each  construct.    GAG  content  of  CTAs  at  early  time  points  (between  4  to  8  
weeks)   averaged   2.92   ±   0.7   GAG%WW,   and   increased   to   4.45   ±   1.0   GAG%WW   for  
constructs   16   weeks   or   older.   Collagen   content   also   increased   in   a   similar   manner,  
averaging   0.66   ±   0.19   COL%WW   at   early   time   points   and   increasing   to   1.65   ±   0.32  
COL%WW  by  16  weeks  or  older.  When  compared  to  native  adult  cartilage  matrix  content,  
GAG  content  was  similar   to   that  of  matured  CTAs,  averaging  5.27  ±  1.36  GAG%WW;;  
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however,  collagen  content   in  native  tissue  was  approximately  double,  averaging  10.2  ±  
1.61   COL%WW.   The   Pearson’s   correlation   coefficient   for   the   relationship   between  
biochemical   content   and   mechanical   properties   was   calculated   to   determine   the  
contribution   of   a   specific   matrix   element   to   mechanical   integrity.   GAG   (Correlation  
Coefficient:   0.63,   p<0.0001)   and   collagen   (Correlation   Coefficient:   0.64,   p<0.0001)  
strongly  correlated  to  the  temporal  increases  in  CTA  equilibrium  modulus  (Figure  3-­3A,C),  
while  DNA  content  did  not  show  any  correlation  (data  not  shown).  Similarly  strong,  positive  
correlations  were  seen  between  these  ECM  components  and  the  dynamic  modulus  (GAG-­
G*   Correlation   Coefficient:   0.51,   p<0.0001;;   Collagen-­G*   Correlation   Coefficient:   0.59,  
p<0.0001)  (Figure  3-­3B,D).      
  
	  
Figure  3-­3.	  Correlation  of  GAG  and  collagen  content  to  equilibrium  moduli  of  CTAs.	  
Correlation  of  GAG  with  (A)  EY  and  (D)  G*  showed  significant  contribution  of  proteoglycan  
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deposition  to  the  development  of  CTA  mechanical  properties.  Correlation  of  collagen  with  
(B)   EY   and   (D)   G*   similarly   showed   that   collagen   content   contributes   to   mechanical  
properties  over  24  weeks  of  culture.  Lightest  color:  youngest  constructs.  Darkest  color:  
oldest  constructs.    
  
3.3.3.  Cell-­to-­Matrix  Ratio  as  a  Function  of  Maturation    
Paraffin-­embedded  CTAs  and  native  cartilage  were  sectioned  and  stained  with  Alcian  Blue  
and  Nuclear  Fast  Red  in  order  to  analyze  the  ratio  of  cell  area  to  matrix  area.  One  week  
after   establishment   of   CTAs,   the   cell-­matrix   ratio   was   0.13   ±   0.03,   indicating   a   high  
cellularity  with  a  loosely  woven  matrix  (Figure  3-­4).    With  increasing  culture  duration,  the  
cell-­matrix   ratio   decreased   to   0.08   ±   0.01   between   4-­8   weeks,   as   matrix   deposition  
increased   (p<0.05).     Between  10-­24  weeks  of  culture,  CTA  cell-­matrix   ratio  decreased  
further   to  0.06  ±  0.02   (p<0.05).  The  majority  of  CTAs  within   this  group  had  cell-­matrix  
ratios  not   significantly  different   from  each  other.  The  cell-­matrix   ratio  of  CTAs  cultured  
longer   than   10   weeks   was   not   different   from   that   of   juvenile   cartilage   (0.05   ±   0.02).    
Juvenile  and  fetal  cartilage  (0.05  ±  0.01)  cell-­matrix  ratios  were  also  not  different  from  one  
another,  but  both  were  higher  than  adult  cartilage  values  (p<0.05),  which  had  a  cell-­matrix  





Figure  3-­4.  Quantification  of  cell-­to-­matrix  ratios  in  Alcian  blue  (GAG)  and  Nuclear  
Fast  Red  (nuclei)  stained  histological  sections  (20X  images).  (Top)  CTA  cell-­to-­matrix  
ratios  decrease  with  increasing  culture  duration  as  matrix  deposition  occurs.    After  long  
culture  durations,  CTA  values  approach  that  of  native  bovine  cartilage  (all  groups  p<0.05  





The   importance   of  matching   engineered   cartilage   properties   to   that   of   native   cartilage  
cannot   be   overstated.   While   physiological   mechanical   forces   are   thought   to   have   a  
positive   influence  on   tissue  repair,   these   forces  can  also   induce   long-­term  failure   if   the  
engineered   construct   does   not   closely  mimic   native   cartilage   characteristics   or   fails   to  
integrate  with  the  surrounding  tissue.    As  such  it  is  critical  to  bioengineer  tissue  equivalents  
that   can   survive   and   mature   within   the   joint   microenvironment.   Enabling   phenotypic  
correctness   of   the   resident   chondrocytes   within   constructs,   as   well   as   promoting   the  
deposition  of  appropriate  matrix  constituents   for   the  development  of   robust  mechanical  
properties,  will  be  necessary  for  creating  functional  engineered  cartilage.  To  assess  this  
functionality,  the  properties  of  engineered  cartilage  can  be  benchmarked  against  those  of  
native   cartilage.   Achieving   native   tissue   properties   indicates   the   potential   of   the  
engineered   tissue   for   application   in   model   systems   or   in   cartilage   defect   repair  
(Khoshgoftar  et  al.  2013).    Here,  we  show  that  as  CTAs  mature  over  a  period  of  24  weeks,  
the   constructs   take   on   cartilage-­like   characteristics   and  maintain   biochemical   integrity  
throughout.    As  shown  in  previous  studies  using  this  culture  model,  chondrocytes  undergo  
cell  division  over  the  first  3  weeks,  but  subsequently  increase  matrix  synthesis,  resulting  
in  an  increase  in  mass  by  as  much  as  a  6-­fold  over  the  following  7  weeks.  While  this  model  
is  scaffold-­free,  over   time,  a  natural  scaffold   is   formed  which  provides   the  confinement  
necessary  for  the  chondrocytes  to  elaborate  an  extracellular  matrix  (Estrada  et  al.  2001).    	  
  
In  the  current  study,  chondrocytes  within  the  CTA  produced  a  robust  extracellular  matrix  
which  correlated  with  increasing  mechanical  strength  and  decreasing  cell-­to-­matrix  ratios,  
leading   to   near   native   cartilage-­like   properties.      Although   scaffold-­based  methods   are  
capable   of   supporting   matrix   production   and   can   establish   near   native   mechanical  
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properties  more   quickly,   the   use   of   foreign  materials   for   cartilage   repair   is   a   clinically  
relevant   concern.      As   such,   scaffold-­free,   self-­aggregating   suspension   cultures   may  
present   a   viable   alternative   in   which   the   lack   of   a   foreign   material   might   enhance  
integration  potential  and  reduce  the  inflammatory  response.  Previous  work  has  shown  that  
scaffold-­free   constructs   can   form  a   functional   extracellular  matrix,  which   contributes   to  
improved  cartilage  mechanical  maturity  (Ofek  et  al.  2008;;  Revell  et  al.  2008;;  Brenner  et  
al.   2013).      Aggregates   of   chondrocytes   cultured   in   agarose   coated  wells   for   example,  
develop  mechanical  properties  which  increase  with  seeding  density,  with  the  aggregate  
modulus  of  these  constructs  ranging  from  ~70  kPa  (2  million  cells/construct)  to  ~300  kPa  
(55  million  cells/construct)   (Ofek  et  al.  2008;;  Revell  et  al.  2008).  Additional  methods  of  
scaffold-­free  culture  using  ceramic  carriers  have  reported  a  Young’s  modulus  of  ~30  kPa  
after  2  weeks  of  static  culture  (4  million  cells/carrier)  (Hoenig  et  al.  2011),  while  intermittent  
dynamic  stimulation  of  similarly  cultured  constructs  increased  the  equilibrium  modulus  to  
~80  kPa  (Waldman  et  al.  2004).  While  this  study  reports  that  CTA  mechanical  properties  
improve  with  increased  culture  duration  (and  fall  within  a  similar  range  to  other  scaffold-­
free   engineered   cartilage   constructs),   these   values   are   still   lower   than   that   of   native  
cartilage.  Therefore,   the  use  of   combined  strategies  may  be  necessary   to  achieve   the  
functional   properties   of   native   tissue.   For   example,   dynamic   loading   systems   (e.g.  
hydrostatic   pressure   (Kraft   et   al.   2011))   and/or   environmental   cues   (e.g.   growth   factor  
additives  (Waldman  et  al.  2004;;  Hoenig  et  al.  2011)),  can  enhance  matrix  production  and  
further  improve  mechanical  properties.    However,  if  CTA  mechanical  properties  exceed  a  
certain  threshold  (i.e.  the  matrix  composition  is  too  dense),  the  ability  of  the  engineered  
construct  to  integrate  with  native  cartilage  may  be  compromised  (Brenner  et  al.  2013).    As  
such,   there   may   be   a   balance   between   preconditioned   compositional   /   mechanical  




CTAs  were  observed  to  produce  abundant  matrix  within  the  construct  over  the  24  week  
culture   period.   When   compared   to   previous   reports   of   scaffold-­based   engineered  
constructs,  CTAs  produce  similar  amounts  of  matrix  as  agarose  constructs  at  eight  weeks  
(20  million  chondrocytes/mL,  ~3.2  GAG%WW,  ~2.1  COL%WW,  (Erickson  et  al.  2009)),  
MeHA  hydrogels  at  eight  weeks  (20  million  MSCs/mL,  ~3.5  GAG%WW,  ~1.8  COL%WW,  
(Erickson  et  al.  2012))  and  silk  hydrogels  at  four  weeks  (20  million  chondrocytes/mL,  ~3.25  
GAG%WW,   ~2.75   COL%WW,   (Chao   et   al.   2010)).      In   comparison,   self-­assembled  
aggregates  in  agarose  wells  cultured  for  four  weeks  show  similar  GAG  content  (2  million  
chondrocytes/construct,  ~4  GAG%WW),  although  collagen  content  exceeded  the  values  
reported  here  (~25  COL%WW)  (Revell  et  al.  2008).  Scaffold-­free  methods  using  ceramic  
substrates  have  also  produced  constructs  (2  million  chondrocytes/construct)  with  similar  
amounts   of   both   GAG   and   collagen   (~2-­3   GAG%WW   and   COL%WW)   following  
intermittent   dynamic   loading   during   eight   weeks   of   culture   (Waldman   et   al.   2004).    
Temporal  evaluation  of  CTAs  also  showed  that  both  proteoglycan  and  collagen  content  
strongly  and  positively  correlated  with  increasing  mechanical  properties.  This  data  meshes  
well   with   previous   studies   of   engineered   cartilage   which   have   shown   strong   positive  
correlations  between  GAG  density  and  compressive  modulus  in  type  II  collagen  scaffolds  
and  methacrylated  HA  scaffolds   (Pfeiffer   et   al.   2008;;  Erickson  et   al.   2009),   as  well   as  
temporally  matched   increases   in  GAG  content  and  aggregate  modulus  of   chondrocyte  
aggregates  over  8  weeks  of  culture  (Ofek  et  al.  2008).  Significant  correlations  of  both  GAG  
and  collagen  with  aggregate  modulus  and  hydraulic  permeability  have  also  been  found  for  
fetal,  juvenile,  and  adult  bovine  articular  cartilage  (Williamson  et  al.  2001).  Quantitation  of  
cell-­matrix  ratios  additionally  showed  a  decreasing  cell-­to-­matrix  ratio  as  CTAs  matured.  
Previous   work   by   Jadin   et   al.   has   shown   that   cellularity   of   cartilage   decreases   with  
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increasing  age,  matching  our  results  which  showed  that  beyond  10  weeks  of  culture,  CTA  
cell-­to-­matrix  ratios  decrease  to  approach  that  of  adult  native  cartilage  (Jadin  et  al.  2005).  
These   studies   support   the   idea   that   matrix   deposition   by   chondrocytes   in   both   tissue  
engineered  cartilage  and  native  cartilage  is  critical  for  the  development  and  maintenance  
of  mechanical  properties.  
  
3.5.  Conclusion    
In  this  study,  the  time-­dependent  functional  maturation  of  cartilage  tissue  analogs  (CTAs)  
was  characterized  and  benchmarked  against  native  tissue  properties.  Given  our  current  
understanding  of  the  development  of  mechanical,  biochemical,  and  phenotypic  properties  
of  CTAs,  we  have  begun   to  explore  applications  of   this  engineered  cartilage  model   for  
cartilage   defect   repair.      Experiments   are   currently   underway   to   explore   the   benefit   of  
intermittent  periods  of  hydrostatic   loading  (Novotny  et  al.  2006)  on  CTA  characteristics,  
and  whether  any  improvements  due  to  loading  would  be  reflective  of  in  vivo  maturation  in  
animal  models.    In  addition,  due  to  the  scalability  of  these  constructs,  we  have  started  to  
investigate   the  use  CTAs   in   high   throughput   screening   studies  of  mechanical   injury   to  
investigate  the  progression  of  cartilage  degeneration  in  the  development  of  post-­traumatic  
osteoarthritis   (Mohanraj   et   al.   2013).  With   further   development   of   the  CTA  model,   this  
tissue  engineered  construct  can  serve  both  clinical  and  experimental  applications  in  order  
to  better  understand  mechanisms  of  cartilage  repair  and  degeneration.    
  
Reprinted  from  Journal  of  Biomechanics,  Volume  47,  Issue  9,  Mohanraj  B,  Alexandra  FJ,  
Mauck  RL,  Dodge  GR.  Time-­dependent  Functional  Maturation  of  Scaffold-­free  Cartilage  
Tissue   Analogs,   Pages   2137-­2142,   Copyright   2014,   with   Permission   from   Elsevier.  
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Chapter  4.  A  High  Throughput  Mechanical  Screening  Device   for  Cartilage  Tissue  
Engineering	    
	  
4.1  Introduction    
Cartilage   tissue   engineering   has   made   marked   progress,   with   numerous   studies  
developing   methods   for   the   production   of   mechanically   functional   cartilage,   based   on  
either  native  chondrocytes  (Kelly  et  al.  2006;;  Novotny  et  al.  2006;;  Lima  et  al.  2007;;  Byers  
2008;;  Bian  et  al.  2010;;  Cheng  et  al.  2011;;  Ng  et  al.  2011)  or  mesenchymal  stem  cells  
(MSCs)  grown  as   three  dimensional   (3D)     constructs   (Mauck  et  al.  2006;;  Huang  et  al.  
2010;;  Moutos  et  al.  2010;;  Thorpe  et  al.  2010;;  Erickson  et  al.  2012).  However,  the  degrees  
of   freedom   present   in   any   experimental   design   can  make   even   the   simplest   of   tissue  
engineering  studies  difficult  to  execute,  where  an  investigator  can  vary  materials  (Mouw  
et  al.  2005;;  Chung  et  al.  2009;;  Chung  et  al.  2009;;  Hwang  et  al.  2011),  cell  number  (Mauck  
et  al.  2003;;  Weinand  et  al.  2009),  growth  factor  doses  and  combinations  (Blunk  et  al.  2002;;  
Gooch  et  al.  2002;;  Appel  et  al.  2009;;  Johnstone  et  al.  2013),  and  the  mechanical  loading  
environment  (Ng  et  al.  2009;;  Thorpe  et  al.  2010).    Moreover,  complexity  in  experimental  
design  leads  to  difficulties  in  capturing  outcome  parameters  in  a  cost-­  and  time-­efficient  
manner.  The  need  for  increased  throughput  in  assessing  outcomes  is  not  unique  to  tissue  
engineering.  Indeed,  high  throughput  screening  (HTS)  methods  emerged  very  early  in  the  
pharmaceutical  industry  (Drews  2000),  where  such  methods  were  essential  for  screening  
large   chemical   libraries   to   assess   compound   effects   on   biologic   activities   relevant   to  




The  underlying  premise  of  HTS   is   that   if   a   suitable  assay  can  be  developed   that   is  1)  
sufficiently  sensitive  to  measure  a  relevant  cellular  response,  2)  of  a  low  cost  per  sample,  
3)  easy  to  automate,  and  4)  reproducible,  then  one  can  expedite  drug  discovery.  While  
most   HTS   assays   are   performed   in   monolayer   culture,   recent   studies   have   begun   to  
implement  assays  in  3D  constructs  as  well.    For  example,  3D  multi-­cellular  spheroids  have  
been  used  to  screen  for  tumor  suppressive  agents  (Kunz-­Schughart  2004).    A  few  studies  
have   applied   HTS   principles   towards   applications   in   bone   and   cartilage   biology   and  
regeneration.      For   instance,   HTS-­based   assays   focused   on   MSC   osteogenesis   in  
monolayer  (Brey  et  al.  2011)  and  chondrogenesis  in  micro-­scaled  pellet  cultures  (Huang  
et  al.  2008)  have  been  used  to  screen  small  molecule  libraries  in  a  384-­well  format.    The  
potential   of   such  HTS  approaches   is  perhaps  best   illustrated  by  a   recent   study,  which  
employed   an   image-­based   HTS   method   that   identified   molecules   that   promoted   the  
formation   of   chondrogenic   MSC   nodules,   and   was   found   to   protect   cartilage   from  
degeneration  in  a  small  animal  model  of  joint  instability  (Johnson  et  al.  2012).    
  
While   most   HTS   assays   focus   on   molecular   events,   functional   outcomes   are   equally  
important  for  musculoskeletal  tissues  (Vandenburgh  2010).  This  is  particularly  relevant  for  
cartilage  as  the  properties  of  the  engineered  tissue  will  dictate  function  in  the  load-­bearing  
joint  environment  (Ateshian  et  al.  2005).  Thus,  it  would  be  ideal  if  HTS  approaches  could  
be   modified   to   include   mechanical   measures.   However,   traditional   one-­at-­a-­time  
assessments   of   mechanical   properties   can   be   prohibitively   time   consuming,   where   a  
typical  stress  relaxation  test  can  take  several  hours  per  sample  (Mauck  et  al.  2000;;  Soltz  
et   al.   2000).      In   even   relatively   simple   experimental   designs   (Erickson   et   al.   2012),  
involving   just   two   different   seeding   densities,   four   different   material   formulations,   one  
growth   factor  at  a  single  dose   (and  a  growth   factor-­free  control),  and   five  samples  per  
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group,   over   80   hours   of   testing   is   required   at   each   time   point.   Given   the   continued  
development   of   novel  materials   and   new   factors   influencing   cartilage   growth,   and   the  
requirement  that  each  of  these  inputs  be  carefully  evaluated  in  a  combinatorial  context,  
throughput  in  mechanical  analysis  has  become  a  significant  barrier  to  further  progress.  As  
such,  the  development  of  a  high  throughput  mechanical  screening  (HTMS)  system  would  
represent  a  valuable  tool  to  advance  cartilage  tissue  engineering.    
  
To   address   this   need,   several  mechanical   testing   systems   have   been   introduced   that  
enable   multi-­sample   evaluation.   For   instance,   the   Myoforce   Analysis   Device   was  
developed   to   monitor   bioartificial   muscles   to   identify   compounds   that   alter   contractile  
strength   (Vandenburgh   2010).      The  MATE  system   incorporated   real-­time  measures   of  
load   during   dynamic   stimulation   of   engineered   cartilage,   using   a   six-­sample   actuating  
system   (Lujan   et   al.   2011).   Still   more   recently,   a   12-­sample   tissue   stimulator   was  
developed   that   recorded   load   from  each  sample  via   individual   force  sensitive   resistors  
(Salvetti  et  al.  2012).  These  devices  illustrate  how  real-­time  and  multi-­sample  mechanical  
analysis  can  be   incorporated   into   tissue  systems.  While  promising,   throughput   in   these  
devices   is   restricted   to   a   relatively   small   sample   capacity,   and   expansion   to   higher  
throughput  formats  is  a  challenge  for  sensor  technology  (Lujan  et  al.  2011;;  Salvetti  et  al.  
2012).  Additional  development  is  needed  to  make  such  devices  compatible  with  HTS  of  
chemical  libraries.    
  
We  have  developed  a  novel  high  throughput  mechanical  screening  (HTMS)  device  that  
can  assess  mechanical  properties  of  biomaterials  and  engineered  cartilage  in  a  48-­well  
format.   Our   system   utilizes   a   custom   force   sensitive   resistor   (FSR)   array   to   measure  
instantaneous   and   time-­dependent   mechanical   response   of   up   to   48   samples  
47	  
	  
simultaneously.     The   increased  capacity  of   this  device  provides  a  platform   to  evaluate  
properties   in   complex,   combinatorial   studies   for   the   screening   and   optimization   of  
engineered  cartilage.  The  objective  of  this  study  was  to  design,  optimize,  and  validate  this  
system  for   the  screening  of  mechanical  properties  of  various  materials  and  engineered  
cartilage  models  in  several  experimental  configurations.  
  
4.2.  Methods  
4.2.1.  HTMS  Device  Components    
The  HTMS  device  was  designed  to  interface  with  mechanical  testing  systems  utilized  in  
most  orthopaedic  and  bioengineering  laboratories.    A  schematic  is  shown  in  Figure  4-­1.    
The  device  housing  consists  of  an  aluminum  base  plate  and  two  parallel  side  plates  onto  
which   linear   bearings   (Maintenance-­Free   Ball   Bearing   Carriages   and   Guide   Rails,  
McMaster-­Carr,  GA)  are  affixed  to  align  and  maintain  smooth  vertical  displacement  of  the  
platen.  The  sensor  platen  was  integrated  via  two  plates:  a  lower  plate  to  which  it  is  directly  
attached,  and  an  upper  plate  fixed  to  the  bottom  plate.    A  custom  force  sensitive  resistor  
(FSR)  array  was  mounted  via  adhesive  backing  to  this  bottom  plate  (Custom  48  Matrix  
FSR   Sensor   Array,   Sensitronics,  WA).   To   control   vertical   displacement   of   the   sensor  
platen,  an  Instron  (Model  5848,  Instron,  MA)  was  connected  via  an  adaptor  to  the  top  plate  
of  the  sensor  platen  (Figure  4-­1A,D).      
  
Opposing   the   sensor   surface,   a   well   plate   assembly   was   designed   to   accommodate  
standard  48-­well  plates  (BD  Falcon,  Multiwell  Cell  Culture  Plate,  #75875,  NJ),  as  well  as  
an  indenter  array  and  hole  plate  to  align  with  each  sensor  on  the  FSR  array  (Figure  4-­
1B).  The  hole  plate,  which  sits  on  top  of  the  48-­well  plate,  was  used  to  guide  vertical  and  
restrict  horizontal  movement  of  each  indenter  during  loading.  Indenters  were  composed  
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of   PTFE   (McMaster-­Carr,   GA)   rods  with   a   flat   bottom   surface   that   interacted  with   the  
sample  during  loading,  and  a  beveled  top  for  centered  activation  of  the  sensor  (Figure  4-­
1C).    Each  indenter  had  a  diameter  of  9.5mm  to  fit  within  the  10mm  diameter  well  of  the  
48-­well  plate  to  allow  fluid  displacement  during  unconfined  compression  testing.  A  small  
cotter  pin  (Dowel  Pins,  McMaster-­Carr,  GA)  inserted  at  the  top  of  the  indenter  allowed  for  
simultaneous  removal  of  all  indenters  after  testing,  without  interfering  with  the  motion  of  
adjacent  indenters  in  the  array  (Figure  4-­1D).    
  
	  
Figure  4-­1.  Schematic  of  HTMS  device.  (A)  The  system  includes  an  aluminum  housing  
frame,  sensor  platen  controlled  via  Instron  displacement,  and  (B-­C)  well  plate  assembly  
designed  for  a  standard  48-­well  culture  dish  with  indenter  platens.    (D)  Fully  assembled  





4.2.2.  HTMS  Device:  Sensor,  Components,  and  Software    
The  custom   force  sensor   includes   four   layers:  a   force  sensitive   resistor   (FSR)  shorting  
layer,  a  spacer  layer  (0.0005”),  a  trace  layer,  and  an  adhesive  layer  (3M)  (Figure  4-­2B).  
The  spacer  layer  between  the  FSR  layer  and  trace  layer  creates  a  gap  between  the  two  
conductive  layers.    Upon  compression,  the  conductive  layers  come  into  contact,  resulting  
in  a  decrease  in  resistance  in  the  circuit.    The  sensor  contains  48  “sensels”  (force-­sensitive  
locations)   that   match   the   well-­plate   layout   and   individually   capture   load   during  
compression  (Figure  4-­2B).    The  sensor  was  connected  via  a  voltage  supply  and  resistor  
(10kΩ)  to  create  a  voltage  divider  to  measure  change  in  resistance.  Each  sensor  on  the  
trace  layer  has  an  individual  conducting  pin  out,  and  all  sensors  have  a  common  power  
supply  pin  (connected  to  a  5V  source  in  the  NI  DAQ  board,  NI  USB-­6225  M  Series  DAQ,  
NI,  TX).  A  ribbon  (Nicomatic)  connected  the  sensor  to  a  custom  wiring  box  (Figure  4-­1D)  
with   the  circuit   illustrated   in  Figure  4-­2A.  Each  sensel  voltage  was  captured  as  analog  
input  to  DAQ  board  and  recorded  using  a  custom  LabVIEW  program  (LabVIEW  8.6,  NI,  
TX),  with  data  post-­processing  in  MATLAB  (MATLAB  R2010a,  Mathworks,  MA).  
  
4.2.3.  HTMS  Device:  Sensor  Calibration    
The   sensor   was   calibrated   by   inverting   the   sensor   platen   and   applying   displacement  
controlled  compression   to  each  sensel.  Sensors  were  compressed   to  ~5N  at  a   rate  of  
0.0004  mm/s  via  an  indenter  connected  to  the  Instron.    Force  and  voltage  was  recorded  
in  LabView,  and  the  resulting  force-­voltage  data  fit  to  an  exponential  curve  (Figure  4-­2C);;  
this  calibration  was  used  for  all  subsequent  testing.  An  example  3D  representation  of  force  
output   for  silicone  compression   is  shown   in  Figure  4-­2D.  The  most  sensitive   (greatest  
force  resolution)  and  nearly  linear  range  of  the  sensor  was  0-­1V,  corresponding  to  a  load  
of  ~1N.  This  sensitivity  is  determined  by  the  thickness  of  the  spacer  layer;;  increasing  the  
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thickness  of   the  spacer   layer  decreases   low-­load  sensitivity,  but  would  allow   for  higher  
forces  to  be  measured.    
  
	  
Figure  4-­2.  Sensor  calibration  and  testing  protocol.  (A)  Sensor  circuit  which  measures  
changes  in  voltage  due  to  compression  and  contact  of  sensor  layers  within  (B)  the  custom  
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matrix  array  sensor.   (C)  Example   force-­voltage  calibration  curve   for  one  position   in   the  
matrix  array  sensor.  (D)  3D  rendering  of  force  signal  from  one  step  of  HTMS  testing.    (E)  
Schematic   illustration   of   multi-­step   stress   relaxation   and   dynamic   testing   protocol.   (F)  
Example   time   dependent   response   with   three   applied   compression   steps   to   agarose  
hydrogel  (in  blue)  and  silicone  rubber  (in  black)  samples  in  the  HTMS  device.  Note  that  
the  sensor  can  capture  the  viscoelastic  stress  relaxation  behavior  of  hydrogel  sample.  
  
4.2.4.  HTMS  Device  Testing:  Protocols  and  Data  Analysis  
To  test   the  HTMS  device,  we   first  evaluated   the  properties  of  common  elastic   (silicone  
rubber)   and   viscoelastic   (agarose)  materials.      To   accommodate   differences   in   sample  
height,  we  devised  a  step-­wise  stress  relaxation  testing  profile  consisting  of  multiple  ramps  
of  10%  compressive  strain  (relative  to  original  average  sample  height)  applied  at  0.05%  
strain/sec  with  a  1000  second  hold  after  each  step.    At  each  step,  the  relaxation  phase  
was  followed  by  a  dynamic  deformation  phase  (1%  strain  applied  at  0.1  Hz),  followed  by  
a  further  60  second  hold  (Figure  4-­2E).    Before  starting  each  test,  the  device  displacement  
was  zeroed  to  the  height  of  the  tallest  sample.  The  number  of  steps  was  determined  by  
measuring   the   height   of   all   samples,   calculating   average  height   and   displacement   per  
step,   and   determining   how   many   steps   would   be   required   to   ensure   that   multiple  
compression  steps  were  applied  to  all  samples.  The  sensor  was  able  to  capture  the  elastic  
and  viscoelastic  (relaxation  behavior)  of  these  hydrogels  (Figure  4-­2,  D-­F).    
  
To   calculate   the   compressive   equilibrium  modulus   for   each   sample,   voltage   data  was  
imported  into  a  custom  MATLAB  program  to  extract  strain  and  equilibrium  load  for  each  
step.   All   sample   and   test   information,   including   sample   height,   width,   and   step  
displacement  magnitude  was  likewise  imported  into  the  program.  The  starting  actuation  
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point   for  each  sensor  was  determined  using  a  pre-­determined  voltage  threshold,  which  
was  then  used  to  calculate  applied  strain  for  the  sample  for  each  step.  A  “first  step”  was  
selected  for  calculation  of  the  compressive  modulus  based  on  an  8%  strain  threshold,  i.e.  
for  an  individual  sample  the  step  was  required  to  reach  at  least  8%  strain  for  it  to  count  as  
a  first  step.  Since  samples  differed  in  height,  this  ‘first  step’  was  in  some  cases  the  first  
actuation  of   the  sensor  (i.e.,   for  samples  making  good  contact   initially),  and  sometimes  
the  second  actuation  of  the  sensor  (i.e.,  for  shorter  samples  that  were  not  in  contact,  or  
not   compressed   by   at   least   8%,   during   the   first   actuation).   Following   capture   of   the  
transient  and  equilibrium  response  during  this  ‘first  step’,  all  data  (including  step  number,  
step   strain,   total   strain,   and   equilibrium   modulus)   were   exported   to   Excel   for   further  
analysis.  
  
4.2.5.  HTMS  Validation:  Multi-­sample  vs.  Sample-­by-­sample  Testing  
To  validate  the  HTMS  device,  we  measured  several  materials  with  a  range  of  compressive  
properties  and  compared  the  results  to  those  derived  from  single  sample-­by-­sample  tests.  
Two   types   of   hydrogels,   agarose   (Type   VII,   Sigma)   and   polyacrylamide   (National  
Diagnostics),   were   cast   between   glass   plates   to   create   gels   of   uniform   thickness   and  
punched  into  cylindrical  samples  (H:  2.25mm,  Ø  4mm).  Agarose  gels  were  cast  at  4  or  
10%   (w/v)   and   polyacrylamide   was   cast   at   15%   (w/v).      Construct   dimensions   were  
measured,   and   all   samples  were   arranged   in   a   48-­well   plate   for  HTMS   testing   (n=10-­
11/material).  HTMS  testing  consisted  of  a  five-­step  stress  relaxation,  and  for  comparison,  
single   sample-­by-­sample   testing   used   a   two-­step   stress   relaxation   test.   Since   HTMS  
results  provide  a  modulus  for  compression  ranging  between  10  and  20%  applied  strain  
(depending  on  when  the  sensor  actuated  for  a  given  sample),  the  equilibrium  modulus  at  
both   strain   levels  were   reported   for   the   sample-­by-­sample   testing.  Materials   screening  
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experiments  were  conducted  at   least  three  times,  with  one  representative  set  of  results  
shown  here.  
  
4.2.6.  Fabrication  and  Screening  of  Engineered  Cartilage    
To   evaluate   engineered   constructs   using   the   HTMS   device,   mesenchymal   stem   cells  
(MSCs)   were   isolated   from   bone  marrow   from   juvenile   bovine   femurs,   and   expanded  
(passage  2  or  3)  as  previously  described  (Huang  2010).    Methacrylated  hyaluronic  acid  
(MeHA)  was  prepared  as  previously  described  (Burdick  et  al.  2005;;  Erickson  et  al.  2009).    
To   generate   cell   seeded   constructs,   MSCs   were   trypsinized,   washed   and   centrifuged  
(300xg  for  5  minutes),  and  encapsulated  in  1%  (w/v)  MeHA  at  20  or  60  million  cells/mL  
(Erickson  et  al.  2012).  The  MeHA  solution  was  cast  between  two  glass  plates  and  exposed  
to  UV  light  for  10  minutes;;  gels  were  punched  to  form  cylindrical  constructs  (H:  2.25  mm,  
Ø  4mm).  Constructs  were  cultured  in  a  chemically  defined  chondrogenic  medium  (CM+)  
as  previously  described  (Mauck  et  al.  2006).  
  
Two  HTMS  evaluations  were  performed  with  MSC-­seeded  MeHA  constructs.    In  the  first,  
we  evaluated  the  concentration-­dependent  effect  of  a  pro-­inflammatory  cytokine  on  the  
mechanical   integrity  of  constructs.     For  this,  constructs  (20  million  cells/mL;;  1%  MeHA)  
were  cultured  in  CM+  for  12  weeks,  at  which  point,  constructs  were  cultured  for  a  further  
6  days   in  CM-­  medium  (lacking  TGF-­β3),  and  treated  with   increasing  concentrations  of  
TNF-­α  (0,  1,  5,  and  10ng/mL).  Media  was  changed  on  day  3  and  TNF-­α  replenished;;  all  
media  was  collected  for  further  analysis  of  GAG  loss  using  the  DMMB  assay  (Farndale  et  
al.   1986)   and   nitric   oxide   production   via   the   Griess   Assay   (Promega).   Mechanical  
properties  were  evaluated  6  days  after  exposure  to  TNF  using  the  HTMS  device  (n=10-­
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12/group).    To  validate  HTMS  results,  single  sample  unconfined  compression  (10%  step  
only)   was   performed   on   a   parallel   set   of   samples   (n=4/group)   (Mauck   et   al.   2006).    
Construct   GAG   (DMMB   assay)   and   DNA   (PicoGreen,   Invitrogen)   content   was   also  
evaluated  following  mechanical  testing.    
  
In  the  second  test,  we  evaluated  the  ability  of  the  HTMS  device  to  distinguish  differences  
in  properties  arising  from  constructs  seeded  with  MSCs  at  two  densities  (20  vs.  60  million  
cells/mL)  in  1%  w/v  MeHA  hydrogels.    Mechanical  properties  of  constructs  were  evaluated  
after  10  weeks  of  culture  using  the  HTMS  device  (n=8-­9/group)  and  compared  to  single  
sample-­by-­sample  testing  using  the  two-­step  protocol.    Biochemical  content  of  gels  was  
also  evaluated  as  described  above.  
  
4.2.6.  Statistical  Analysis    
Mechanical   properties   of   biomaterials   and   engineered   cartilage   constructs   evaluated  
using  the  HTMS  device  were  compared  to  single  sample  testing,  and  the  effect  of  TNF-­α  
on  construct  maturation  was  determined  using  one-­way  ANOVA  with  Tukey’s  post-­hoc  
test   (p<0.05).  To  perform  quality  control   (QC)  and  to  assess  validity  of   ‘hit’  criteria  with  
mechanical  screening,  the  strictly  standardized  mean  difference  (SSMD)  was  utilized  (see  
below),  with  positive  and  negative  controls   from  the   log-­transformed  (for  normalization)  





4.3.1.  HTMS  of  Materials  and  Engineered  Cartilage  
To   evaluate   the   HTMS   platform,   three   acellular   hydrogel   formulations,   4%   and   10%  
agarose,   and   15%   polyacrylamide   were   simultaneously   evaluated   for   compressive  
properties  using   the  HTMS  device,  with   results  compared   to  sample-­by-­sample   testing  
(Figure  4-­3A).  HTMS-­derived  equilibrium  moduli   for  all  materials  closely  approximated  
the  results  from  single  sample  first  and  second  step  equilibrium  moduli.    Indeed,  the  means  
from  HTMS  testing  were  not  different   from  sample-­by-­sample   testing  (HTMS  vs.  single  
samples:  4%  agarose:  31.1  ±  24.0  kPa  vs.  49.6  ±  18.7  kPa,  10%  agarose:  173.6  ±  74.8  
kPa  vs.  194.2  ±  46.8  kPa,  and  15%  polyacrylamide:  140.9  ±  61.6  kPa  vs.  109.9  ±  32.2  
kPa;;  p>0.05).  Engineered  cartilage  formed  at  20  or  60  million  cells/mL  (20M  or  60M)  were  
also  evaluated  for  mechanical  properties.  As  shown  in  Figure  4-­3B,  the  mean  values  from  
HTMS   testing   were   not   different   from   sample-­by-­sample   testing,   with   20M   constructs  
having  an  equilibrium  modulus  of  105.6  ±  99.1  kPa  vs.  128  ±  65.9  kPa  and  60M  constructs  
of  187.3  ±  65.7  kPa  vs.  179.2  ±  62.1  kPa  (p>0.05).  These  results  show  that  the  HTMS  
device  can  effectively  determine  and  distinguish  mechanical  properties  ranging  from  ~25  





Figure   4-­3.   HTMS   evaluation   of   biomaterials   and   engineered   constructs.   (A)  
Compressive  modulus  of  various  biomaterials  (single  sample,  N=4;;  HTMS,  N=10-­11)  and  
(B)   1%  MeHA   hydrogels   seeded  with  MSCs   at   two   densities   (20  million   or   60  million  
cells/mL,  single  sample  and  HTMS,  N=7-­9).    Comparison  between  single  sample  testing  
and  HTMS-­derived  moduli  show  no  significant  differences  in  mean  values  (p>0.05).  
	  
4.3.2.  HTMS  of  Engineered  Cartilage  Treated  with  Inflammatory  Cytokines  
Treatment  of  engineered  constructs  with  TNF-­α  resulted  in  a  dramatic  loss  of  properties  
in   a   concentration-­dependent   manner.   HTMS   measurement   of   properties   captured  
differences   between   treatment   groups   similar   to   that   of   the   sample-­by-­sample   testing  
(Figure  4-­4A).    Both  testing  methods  showed  that  exposure  to  higher  concentrations  (5  
and  10ng/mL)  of  TNF-­α  resulted  in  a  decline  in  mechanical  properties  compared  to  control  
or   1ng/mL   groups   (p<0.05).      Measurement   of   GAG   in   the   media   confirmed   matrix  
breakdown,  where  sustained  GAG  release  was  observed  during  six  days  of   treatment,  
with  the  higher  TNF  concentrations  resulting  in  ~3-­5  times  more  GAG  release  compared  
to  control  and  1ng/mL  groups  (Figure  4-­4B).  These  results  illustrate  that  the  HTMS  device  
can   capture   loss   of   properties   in   engineered   cartilage   as   a   consequence   of   graded  





Figure  4-­4.  HTMS  Screening  of  the  Effect  of  Inflammatory  Cytokines.  (A)  Treatment  
of  MSC-­seeded  constructs  with  TNF-­α  results  in  a  significant  loss  of  mechanical  properties  
in   a   concentration   dependent  manner   that   is   readily   captured   using   the  HTMS  device  
(single   sample,   N=4;;   HTMS,   N=10-­12).      (B)   Release   of   GAG   to   the  media   (SolGAG)  
correlates  with  the  loss  of  mechanical  integrity.  p<0.05:  *  vs  Control;;  #  vs  1ng/mL.  
  
4.3.3.  Quality  Control  and  ‘Hit’  Criteria  for  HTMS  Screening  
The  value  of   a  high   throughput   screening   system   lies  not   just   in   its   ability   to  measure  
multiple  samples  at  once,  but  specifically   in   its  ability   to  distinguish  between  groups   to  
identify  ‘hits’,  or  factors  that  produce  a  response  that  is  different  from  a  given  control.  To  
further  evaluate  our  HTMS  system  in  terms  of  quality  control  (QC)  and  hit  selection  criteria,  
we  used  a  statistical  parameter  developed  by  Zhang  termed  the  strictly  standardized  mean  
difference  (SSMD)  (Zhang  2007;;  Zhang  et  al.  2007;;  Zhang  2011).  SSMD  measures  the  
magnitude   of   difference   between   two   populations,   and   can   better   account   for   non-­
normality,   variability,   skewness,   and   outliers   within   a   population,   compared   to   other  
statistical   methods   (such   as   the   ‘z-­factor’)   (Zhang   et   al.   1999).   Non-­normality   and  
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skewness  are  common  features  of  HTS  data,  where  ‘hits’  are  few,  and  most  conditions  
produce  negative  results  (i.e.,  remain  at  the  baseline  level).  To  perform  a  quality  control  
(QC)  analysis,  one  first  selects  a  condition  that  provides  an  acceptable  baseline  (negative  
control)  level,  and  another  condition  that  constitutes  a  known  ‘hit’  (or  positive  control).  For  
our   biomaterial   screen,   we   chose   the   4%   and   10%   agarose   groups   as   negative   and  
positive  control  groups,  respectively.     For  the  TNF-­α   treatment  data  set,  we  chose  free  
swelling   controls   as   the   baseline,   and   10ng/mL   as   the   positive   control.      Using   log-­
transformed  data,  we  then  calculated  the  estimated  SSMD  from  the  ratio  of  median  and  
median  absolute  deviation  of  both  populations  (Zhang  2011).  From  this  analysis,  SSMD  
was   computed   to   be   -­2.16   for   the   biomaterial   screen   and   -­1.43   for   TNF-­α   treatment.  
Comparing   these   values   against   published   SSMD   QC   criteria   (Zhang   2011),   and  
assuming  that  our  controls  were  of  ‘moderate  strength’,  these  SSMD  values  indicate  that  
the  HTMS  screen  is  a  “good  to  excellent”  tool  for  identifying  ‘hits’.    Indeed,  by  randomly  
selecting  three  values  (a  reasonable  number  of  replicates  for  HTS)  from  each  group  in  the  
TNF-­α  study,  and  computing  the  SSMD  value  for  each,  the  1ng/mL  TNF-­α  condition  had  
an  SSMD  of   -­4.8,   indicating  a  strong  effect.   In  comparison,   the  values   for  5ng/mL  and  
10ng/mL  TNF-­α   treatments  were  -­23.5  and  -­8.4,   respectively,   indicating   that   these   two  
concentrations   had   extremely   strong   effects   (|SSMD|>5)   according   to  RNAi   hit   criteria  
(Zhang  2011).  Candidate  molecules  with  such  strong  effects  would  be  identified  as  ‘hits’  
based   on   empirically   determined   thresholds   in   a   high   throughput   screen,   and   the  






While   mechanical   properties   are   an   essential   outcome   in   any   study   of   engineered  
cartilage,  current  sample-­by-­sample   testing  methods   represent  a  significant  bottleneck,  
constraining   experimental   designs.      To   address   this   limitation,   we   developed   a   novel  
HTMS  device  to  enable  the  evaluation  of  up  to  48  samples  at  one  time.  Our  data  show  
that   this   device   can   successfully   determine   the   properties   of   various   biomaterials   and  
engineered  constructs,  in  a  rapid  manner,  while  producing  data  that  closely  matches  that  
of  sample-­by-­sample  testing.  The  current  device  was  designed  to  measure  mechanical  
properties   of   soft   biomaterials   and   engineered   cartilage   (in   the   range   of   25-­300   kPa).  
However,  given   the   flexibility  of   the  sensor   technology,  stiffer  materials  or   tissues   (e.g.  
bone)  could  be  evaluated  by  modifying  the  removable  sensor  to  shift  the  load-­sensitivity  
range   for   the   desired   application.   With   minor   modifications   (e.g.   inclusion   of   an  
independent  displacement  control  system),  the  device  could  likewise  be  adapted  to  apply  
long-­term   controlled   mechanical   stimulation   to   engineered   tissues   in   culture,   while  
measuring   real-­time   evolution   of   properties.  More   importantly,   this   device   reduces   the  
burden  of  time  spent  in  evaluation,  where  one  can  sequentially  test  several  48-­well  plates,  
thereby  enabling  a  single  user  to  derive  properties  from  ~400  samples  in  a  single  8-­hour  
day.  In  contrast,  single-­sample  testing  would  require  at  least  200  hours.  The  step  protocol  
implemented  here  also   takes   into  account  differences   in  sample  height,  and  allows  the  
user  to  select  a  “first  step”  after  completing  the  test,  which  is  then  used  to  calculate  the  
equilibrium  modulus.  In  contrast  to  previous  HTS  devices  that  used  individual  actuators  
(Lujan   et   al.   2011)   or   varying   height   plungers   (Salvetti   et   al.   2012)   to   account   for  
differences  in  sample  heights,  this  protocol  requires  no  additional  parts  and  is  easily  tuned  
to  apply  a  range  strain  magnitudes.  Additional  advantages  of  this  system  include  individual  
force  sensing  capability,  a  semi-­automated  MATLAB  program  for  data  analysis,  and  the  
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ability  to  fabricate  and  assemble  the  device  at  a  reasonable  cost  (~$6000  circa  2013).    
  
While  our  data  suggest  that  the  HTMS  device  is  a  useful  tool  for  the  rapid  evaluation  of  
multiple  materials  and  factors  for  cartilage  tissue  engineering,  it  is  not  without  its  limitations  
and   opportunities   for   refinement.   Namely,   while   the   mean   values   from   HTMS   testing  
matched  sample-­by-­sample   testing,   the  standard  deviations  were   larger.   In  developing  
screening  tools,  a  balance  must  be  achieved  between  accuracy,  throughput,  and  cost.    To  
address  this,  a  number  of  statistical  tests  exist  to  evaluate  whether  a  screening  tool  can  
ably  distinguish  ‘hits’  from  conditions  that  fail  to  generate  a  response.  One  such  test,  the  
SSMD  parameter,  has  been  validated   for  high   throughput  RNAi  assays,  and   its  use   is  
suggested   for   other   HTS   small-­molecule   screening   assays   (Zhang   2007).   Using   this  
method  and  data  from  HTMS  testing,  we  validated  the  HTMS  device  as  a  “good-­excellent”  
screening  tool.  One  caveat  to  this  statistical  method,  however,  is  the  consideration  of  the  
strength   of   the   controls,   as   this   factor   influences   QC   cutoff   criteria.   For   some   RNAi  
screens,  hits  by  definition  fall  between  an  extremely  strong  positive  control  and  negative  
reference,   which   defines   the   dynamic   range   (Zhang   et   al.   1999).      In   contrast,   when  
screening   properties   in   engineered   materials,   moderate   or   strong   controls   may   be  
sufficient,   as   the  effect   size   is  unknown   for  assayed  molecules,   and   their   action  might  
improve  or  reduce  properties  beyond  controls.  If  we  had  considered  our  QC  groups  to  be  
‘extremely   strong   controls’,   meaning   that   they   represented   a   maximum   possible  
compressive  modulus,  then  the  assay  would  only  fall  into  the  “inferior-­good”  range.  This  
highlights  the  importance  of  understanding  the  expected  differences  in  effect  size  in  order  
to   correctly   set   QC   criteria   as   well   as   hit   thresholds.   Despite   this   limitation,   using  
“moderate”  controls,  SSMD  analysis  identified  the  two  higher  doses  of  TNF-­α  as  having  
extremely  strong  effects  compared  to  controls,  validating  the  HTMS  device  as  a  screening  
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tool.  Moving  forward,  it  will  be  necessary  to  empirically  determine  SSMD  ‘hit’  thresholds  
based  on  the  desired  number  of  molecules  or  materials  to  be  evaluated  in  more  rigorous  
secondary  (in  vitro)  and  tertiary  screens  (in  vivo)  (Johnson  et  al.  2012).  
  
While  the  current  HTMS  device  is  sufficient  in  its  capacity  to  screen  differences  in  material  
properties,   it  will  be   important   in   future   iterations  to  not  only   increase  throughput  of   the  
system,   but   also   to   improve   the   sensitivity   and   range   of   force   detection   and   reduce  
measurement  variability.    To  increase  throughput  capacity,  we  are  currently  scaling  up  to  
a   96-­well   format.   This   modification   will   double   throughput,   making   screening   of   large  
chemical  libraries  more  practical  and  enabling  identification  of  compounds  that  promote  
cartilage  growth  and  repair.    To  further  adjust  the  range  of  load  sensitivity,  the  thickness  
of  the  spacer  layer  in  the  FSR  could  be  customized  for  a  desired  force  range.    Moreover,  
other  sensor  technologies  could  be  incorporated  into  the  design  that  may  provide  more  
stable   calibrations   and   force   readings   (for   example,   via   the   inclusion   of   an   integrated  
sensor   with   force   interpolation).   Additional   applications   of   the   HTMS   system   include  
controlled  mechanical  stimulation  via  the  addition  of  an  independent  displacement  control  
system  (LVDT,  stepper  motor,  and  feedback  control)  to  replace  the  Instron  displacement  
control.  This  possibility  opens  a  new  platform  whereby  testing  of  multiple  treatments  can  
be  carried  out  in  a  setting  of  real-­time  mechanical  loading.	  
  
4.4.  Conclusion  
This  HTMS  device  has  the  potential  to  dramatically  alter  the  landscape  of  what  is  possible  
in  the  experimental  design  of  studies  directed  towards  cartilage  tissue  engineering,  as  well  
as   injury   and   repair.      Most   sample-­by-­sample   studies   are   predicated   on   a   specific  
hypothesis,   and   as   such   use   a   defined   set   of   experimental   conditions   to   test   that  
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hypothesis.      Such   an   approach   inherently   limits   the   design   space,   and   biases   studies  
towards  evaluation  of  a  low  number  of  conditions  and  interrogation  of  already  well  known  
mechanisms.  In  contrast,  high  throughput  screening  methods  such  as  this  allow  discovery  
to  drive  hypothesis  formation.    A  multitude  of  compounds  can  be  tested  rapidly,  in  a  cost-­
efficient  manner,  and  molecules  previously  unknown  to  have  any  relevance  to  the  tissue  
or  growth  pattern  of   interest  may  unexpectedly  produce  a  desired  response.  Using  this  
HTMS  device,  our  goal  is  to  identify  novel  molecules  and  pathways  that  not  only  improve  
the  functional  properties  of  engineered  cartilage,  but  also  intervene  to  enhance  cartilage  
repair  in  clinically  relevant  joint  pathology.    
  
Reprinted  from  Journal  of  Biomechanics,  Volume  47,  Issue  9,  Mohanraj  B,  Hou  C,  Meloni  
GR,   Cosgrove   BD,   Dodge  GR,  Mauck   RL.   A   High   Throughput   Mechanical   Screening  
Device   for   Cartilage   Tissue   Engineering,   Pages   2130-­2136,   Copyright   2014,   with  













Chapter  5.  A  High  Throughput  Model  of  Post-­Traumatic  Osteoarthritis  using  
Engineered  Cartilage  Tissue  Analogs	  
	  
5.1  Introduction    
The  primary  function  of  articular  cartilage  is  as  a  load-­bearing  structure  that  supports  and  
distributes  the  high  stresses  generated  during  normal  physiological  activities  (Ateshian  et  
al.  2005).  While  cartilage  generally  functions  well  over  a  lifetime  of  use,  acute  instances  
of   supra-­physiologic   loading   (e.g.  an  accident  or  other   traumatic  event),   often   result   in  
tissue  damage  that  initiates  degenerative  processes  within  the  joint.  Indeed,  a  subset  of  
osteoarthritis  (OA),  termed  post-­traumatic  osteoarthritis  (PTOA)  represents  the  significant  
fraction  of  patients  who  develop  OA  secondary  to  joint  trauma.  Based  on  the  incidence  of  
knee,  hip,  and  ankle  OA  for  patients  with  a  history  of  joint  injuries  (Brown  et  al.  2006),  it  is  
estimated   that   up   to   ~6  million   individuals   are   burdened   with   PTOA   in   the   US   alone.  
Cartilage   pathology   and   PTOA   incidence   generally   correlate   with   the   intensity   of   the  
original  injury.  Patients  with  ligamentous  or  meniscal  injuries  are  10-­fold  more  likely,  and  
those  with   articular   fractures   are   20-­fold  more   likely   to   develop   knee  OA  compared   to  
individuals  without  previous  joint  injuries  (Roos  et  al.  1998;;  Gillquist  et  al.  1999).  Despite  
a  growing  understanding  of  the  mechanical  thresholds  that  instigate  PTOA,  the  molecular  
pathogenesis  and  mechanisms  of  disease  progression  are  not  yet  well  understood.    
  
To  that  end,  a  number  of  in  vitro,  ex  vivo,  and  in  vivo  models  of  cartilage  injury  have  been  
developed  to  explore  the  temporal  patterns  of  anabolic  and  catabolic  events  that  culminate  
in  cartilage  degeneration.     These  models  serve  as  useful  platforms   in  which   to  explore  
variables   that   regulate   the   extent   of   damage,   including   the   impact   energy,   peak  
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stress/strain,  and  stress/strain  rate.  Common  markers  of  load  induced  injury  include  tissue  
swelling  and  fibrillation  (Kurz  et  al.  2001),  cell  death  at  or  near  the  injury  site  (Quinn  et  al.  
2001;;   Natoli   et   al.   2008),   and   increased   expression   of   proteases   and   inflammatory  
cytokines  (Lee  et  al.  2005;;  Natoli  et  al.  2008).  Biologic  mediators  of  PTOA  act  collectively  
to   decrease   chondrocyte  matrix   biosynthesis(Kurz   et   al.   2001)   and   instigate   a   loss   of  
proteoglycans  and  other  matrix  elements  (Kurz  et  al.  2001;;  Quinn  et  al.  2001;;  Patwari  et  
al.   2003;;  DiMicco  et  al.   2004).     Together,   these  molecular  and  compositional   changes  
culminate  in  a  loss  of  tissue  mechanical  integrity  (Kurz  et  al.  2001;;  Natoli  et  al.  2008).      
  
The  timeline  of  activation  of  these  degenerative  processes  (and  the  controlling  signaling  
mechanisms)  is  particularly  important,  as  the  different  stages  of  response  post-­injury  may  
represent   opportunities   for   therapeutic   intervention   (Anderson   et   al.   2011).   Indeed,  
previous  studies  have  focused  on  small  molecules   targeting   the  early  events,   including  
mechanisms  that  lead  to  cell  death,  release  of  inflammatory  mediators,  and  proteoglycan  
loss.  Examples  of  such  compounds  include  pan-­caspase  inhibitors  (D'Lima  et  al.  2001;;  
Martin  2009)  to  decrease  cell  death,  amphiphilic  surfactants  (Phillips  et  al.  2004;;  Natoli  et  
al.  2008;;  Bajaj  2010)  to  repair  disrupted  cell  membranes,  oxidative  free  radical  scavengers  
(Martin   2009)   to   limit   early   inflammatory   processes,   as   well   as   growth   factors  
(Chubinskaya   et   al.   2007;;   Hurtig   et   al.   2009)   and   glucocorticoids   (Lu   et   al.   2011)   to  
increase  anabolic  response  post-­injury.  In  the  above  studies,  these  factors  have  shown  
varied  success  in  reducing  cell  death  and  matrix  degradation  in  in  vitro  and  in  vivo  models  
of   PTOA,   indicating   that   these   early   pathologic   changes   are   appropriate   targets   for  




To  date,  the  selection  of  agents  that  might  abrogate  PTOA  initiation  has  been  based  on  
their  roles  in  canonical  pathways  involved  in  cell  physiology  and/or  OA  progression.  Since  
the  mechanisms  of  PTOA  have  not  yet  been  fully  elucidated,  there  may  be  other  agents  
not  previously  known  to  play  a  role  in  PTOA  that  could  have  chondro-­protective  effects.  In  
recent  work,  Sampson  et  al.  showed  that  parathyroid  hormone  (clinically  used  to  improve  
bone  mass)  administered   to  mice  after  meniscus  destabilization  surgery  was  chondro-­
protective  (or  regenerative)  in  that  it  limited  hypertrophic  changes  after  onset  of  instability  
(Sampson  et  al.  2011).  Wang  et  al.  also  showed  that  the  inflammatory  complement  system  
regulated  cartilage  degradation  in  mouse  models  of  joint  instability  (Wang  Q  et  al.  2011).  
These  studies  illustrate  the  significant  role  that  such  non-­canonical  pathways  may  play  in  
mediating   the  degenerative   response   in  situations  of  chronic  overload;;   the  acute   injury  
response  may  similarly  initiate  heretofore  unexplored  signaling  pathways.    
  
High  throughput  (HT)  screening  enables  the  rapid  evaluation  of  small  molecule  libraries  
for  the  discovery  of  novel  compounds  relevant  to  tissue  development  and  healing  without  
prior  knowledge  of  the  mechanism  of  action.  Recently,  Johnson  et  al.  developed  an  image-­
based   high   throughput   screening   system   to   identify   molecules   that   promoted  
chondrogenic  differentiation  of  MSCs  (Johnson  et  al.  2012).  From  the  1000s  of  molecules  
screened  in  that  study,  several  “hits”  were  identified,  with  the  small  molecule  kartogenin  
emerging  as  the  most  promising.  Follow-­up  secondary  in  vitro  assays  (e.g.  RT-­PCR)  and  
tertiary  in  vivo  investigations  (rodent  joint  instability  models)  illustrated  that  kartogenin  also  
had   a   chondro-­protective   effect   and   acted   by   disrupting   the   binding   of   a   specific  
transcription   factor   subunit   to   an   actin   associated   protein.   Given   the   non-­intuitive  
mechanism  of  action,  this  study  highlights  the  need  for  unbiased  screening  tools  to  guide  




To  enable  such  screens  in  the  context  of  PTOA,  we  developed  a  high  throughput  in  vitro  
mechanical  injury  platform  that  is  compatible  with  drug  screening.  While  in  vitro  models  of  
injury  using  explants  have  been  valuable  in  elucidating  regional  changes  in  cell  viability  
and  matrix   loss,   explants   are   not   ideal   for   high   throughput   screening   due   to   the   large  
number  of  samples  required  and  variation  in  the  cellular  and  molecular  stratifications  found  
throughout   the   joint.  Cartilage  tissue  engineering,  which  aims  to  mimic   the  biochemical  
and  mechanical  properties  of  native  cartilage  for  joint  repair,  can  generate  cartilage-­like  
analogs  with  which  to  study  the  pathogenesis  of  PTOA.  Engineered  cartilage  can  also  be  
fabricated   in   a   uniform   manner   and   in   large   quantity,   and   as   such   are   ideal   for   high  
throughput  screening  applications.    In  particular,  we  have  studied  a  scaffold-­less  method  
to   generate   cartilage   tissue  analogs   (CTAs)   that   closely  mimic   native   cartilage  both   in  
terms   of   extracellular  matrix   composition   and   biomechanical   properties   (Estrada   et   al.  
2001;;  Novotny  et  al.  2006;;  Mohanraj  et  al.  2013).        
  
Here,  we  adapted  our  high  throughput  mechanical  testing  system  (Mohanraj  et  al.  2014)  
to  apply   compressive   injury   to  CTAs   in  a   rapid  and   reproducible  manner.  The  primary  
goals   of   this   study   were   to   determine   the   strain   and   rate   dependent   response   of  
engineered   cartilage   to   compressive   injury,   to   evaluate   the   acute   progression   of  
degeneration,   and   to   validate   this   response   with   respect   to   native   articular   cartilage  
explants   treated   similarly.      Our   findings   validate   the   use   of   engineered   cartilage   as   a  
surrogate  for  studying  mechanisms  of  PTOA  pathogenesis  and  introduce  a  new  screening  
tool  with  which   to   identify   novel   compounds   that   can   attenuate   degeneration   following  





5.2.1.  Fabrication  of  Cartilage  Tissue  Analogs    
Engineered   cartilage   tissue   analogs   (CTAs)   were   produced   as   described   previously  
(Novotny  et  al.  2006;;  Mohanraj  et  al.  2013).    Briefly,  articular  cartilage  was  harvested  from  
juvenile  bovine  knees  (2-­6  months  old,  Research  87,  MA),   finely  minced,  and  digested  
overnight  (12-­16  hours)  in  DMEM  containing  collagenase  Type  II  (298U/mL  Worthington,  
NJ).   Tissue   digests   were   filtered   (70µm   pore   mesh),   washed   with   PBS   containing  
200U/mL  penicillin,  200μg/mL  streptomycin,  5μg/mL  Fungizone  (PSF,  Life  Technologies,  
NY),  and  centrifuged  at  1750  rpm  for  15  minutes  at  12oC  (3X)  until  collected  into  a  single  
suspension.  Chondrocytes  were  resuspended  at  5x106  cells/mL  in  complete  medium  (high  
glucose   DMEM   containing   10%   FBS,   100U/mL   penicillin,   100μg/mL   streptomycin,  
2.5μg/mL  Fungizone,  1%  MEM  Vitamin  Solution  (Gibco),  25mM  HEPES  buffer,  50μg/mL  
ascorbic   acid   (Mohanraj   et   al.   2013)).      This   cell   suspension   was   plated   into   ultra-­low  
adhesion   (polyHEMA   coated)   96   well   plates   (Corning,   NY)   at   1x106   cells/well,   where  
chondrocytes  coalesced  within  24-­48  hours  to  form  a  CTA  (Mohanraj  et  al.  2013).  CTAs  
were  cultured  for  a  minimum  of  14-­16  weeks  in  complete  medium  prior  to  injury.      
	  
5.2.2.  Injurious  Compression  of  CTAs  and  Native  Tissue  Explants      
To  determine  the  level  of   injury  necessary  to  induce  pathological  changes  in  CTAs  that  
mimic  changes  in  cartilage  explants,  four  different  injurious  compression  protocols  were  
applied   in   a   single-­sample  manner   based   on   previously   established   injury   parameters  
(Kurz  et  al.  2001;;  Quinn  et  al.  2001;;  Lee  et  al.  2005).  CTAs  were  subjected  to  either  50  or  
75%  strain  at  one  of  two  strain  rates,  10%  strain/sec  or  50%  strain/sec,  followed  by  a  hold  
period   for   a   total   ramp-­hold   compression   time   of   10   seconds.   Constructs   were   then  
cultured  for  5  days  after  injury,  and  both  CTAs  and  media  were  harvested  at  12,  24,  and  
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120   hours   post-­injury   for   evaluation   of   biochemical   content   and   presence   of   soluble  
catabolic  markers  as  described  below.  Based  on  the  outcomes  of  single-­sample   injury,  
high  throughput  injury  was  applied  to  constructs  at  75%  strain  at  50%  strain/sec.  For  this,  
a  custom  high  throughput  mechanical  screening  device  (Mohanraj  et  al.  2014)  was  used.  
The  device  consisted  of  an  aluminum  housing  with   linear  bearings  to  guide  the  vertical  
displacement  of  a  loading  platen  which  included  a  force-­sensitive  resistor  (FSR)  array  for  
real-­time  monitoring   of   compressive   forces   during   injury.   In   the   current   version   of   the  
device,  48  samples  are  housed  in  a  standard  48-­well  plate  and  are  compressed  via  PTFE  
indenters,  with  load  recorded  continuously  during  injury  using  a  NI-­DAQ  board  (National  
Instruments,  USB-­2665)  and  a  custom  Labview  program  (National  Instruments,  V8.6)  with  
post-­processing  in  MATLAB  (Mathworks,  R2012a).    Injurious  strain  and  strain  rate  were  
calculated   based   on   the   average   height   of   constructs.      After   injury,   constructs   were  
cultured  for  up  to  5  days  with  sample  harvest  at  24,  48,  and  120  hours  post-­injury.  As  a  
positive  control,  constructs  were  treated  with  IL-­1β  (10ng/mL)  for  5  days  (Cook  et  al.  2001;;  
Wehling   et   al.   2009;;   Ousema   et   al.   2012).   To   validate   the   injury   response   in   CTAs,  
cartilage   explants   were   injured   in   a   similar   manner.      Full-­thickness   articular   cartilage  
(chondral   only)   explants   (4mm  diameter)  were   harvested   from   the   trochlear   groove   of  
juvenile   bovine   knees   and   trimmed   to   3-­4mm   thickness,   keeping   the   superficial   layer  
intact.  Cartilage  cylinders  were  subjected   to  75%  strain  at  50%  strain/s  using  a  single-­
sample   injury   protocol   matching   the   high   throughput   injury   of   the   CTAs.      Cartilage  
cylinders  were  cultured  for  5  days  and  evaluated  as  above  in  order  to  make  comparisons  




5.2.3.  Treatment  with  Putative  Therapeutic  PTOA  Compounds      
In  a  subset  of  studies,  and  immediately  following  injury  at  75%  strain  applied  at  50%/sec  
with  the  high  throughput  device,  engineered  cartilage  was  treated  with  one  of  the  three  
following   agents:   (1)   N-­Acetyl-­Cysteine   (NAC,   2mm,   Sigma,   MO)   a   reactive   oxygen  
species  scavenger,  (2)  Z-­VAD-­FMK  (ZVF,  100µM,  Promega,  WI)  a  pan-­caspase  inhibitor,  
or  (3)  Polaxamer  188  (P188,  8mg/mL,  Corning,  NY),  an  amphiphilic  polymer  capable  of  
inserting  into  the  cell  membrane.    Each  compound  was  included  in  the  culture  medium  for  
the  initial  48  hours  post-­injury  at  levels  previously  reported  to  have  beneficial  effects  in  the  
context  of  cartilage  injury  (D'Lima  et  al.  2001;;  Phillips  et  al.  2004;;  Natoli  et  al.  2008;;  Martin  
2009).  Harvest  time  points  and  outcome  measures  were  the  same  as  described  above.    
  
5.2.4.  Biochemical  and  Molecular  Evaluation  of  Injury  Response  
Following   injury,   construct   wet   weight   and   dry   weight   (following   lyophilization)   were  
determined.    Samples  were  then  papain  digested  and  glycosaminoglycan  (GAG)  content  
determined  using  the  dimethylmethylene  blue  (DMMB)  assay,  with  chondroitin-­6-­sulfate  
as  a  standard,  as  previously  described   (Farndale  et  al.   1986).  DNA  per   construct  was  
measured   using   the   PicoGreen   assay   (Life   Technologies,   NY).   Matrix   content   was  
measured  per  construct  or  normalized  to  DNA,  and  the  swelling  ratio  was  calculated  as  
the  ratio  of  wet  to  dry  weight  at  the  time  of  harvest.  Medium  was  assayed  at  all  harvest  
time   points   for   GAG   release   and   lactate   dehydrogenase   activity   (LDH;;   CytoTox-­ONE  
Homogeneous   Membrane   Integrity   Assay,   Promega,   WI),   which   is   released   upon  
disruption  of  the  cell  membrane  and  is  a  measure  of  cell  damage.    
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5.2.5.  Histological  Analysis  of  Injury  Response  
For  viability  analysis,  constructs  were  stained  using  the  Live/Dead  staining  kit  (Live/Dead  
Viability/Cytotoxicity  Kit,  Life  Technologies.  NY)  and  imaged  on  a  Nikon  Eclipse  TE2000-­
U   (excitation   wavelengths:   Live-­   420-­495nm   and   Dead-­   532-­587nm)   using   2X   or   10X  
objectives.   Additional   samples   were   fixed   in   4%   paraformaldehyde   (Affymetrix,   CA),  
dehydrated,   embedded   in   paraffin,   and   sectioned   to   8µm   thickness.      Sections   were  
stained  for  proteoglycan  distribution  with  Alcian  Blue  (Rowley  Biochemical  Institute,  MA)  
as  previously  described  (Erickson  et  al.  2009).    
  
5.2.6.  Statistical  Analysis  
Effect  of  strain  and  strain-­rate  for  single  sample  injury,  differential  effects  of  injury  or  IL-­1β  
as  a  function  of  time,  and  comparisons  to  chondral  explants  were  assessed  by  two-­way  
ANOVA  with  Bonferroni’s  post-­hoc  test  (p<0.05).  PTOA  compound  effects  were  compared  
to  injury  alone  using  a  single  sample  t-­test  (p<0.05).  All  statistical  analysis  was  conducted  
using  the  SYSTAT13  software  (v.13.00.05,  San  Jose,  CA).  
  
5.3.  Results  
5.3.1.  Effect  of  Strain  Magnitude  and  Strain  Rate  on  CTA  Injury  Response    
CTAs  were  injured  in  a  single  sample  manner,  with  compression  to  50  or  75%  strain  at  10  
or  50%  strain/sec.  Representative  stress  versus  time  profiles  of  injured  CTAs  showed  that  
both  strain  and  strain-­rate  significantly   increased  peak  stress  (with  values  reaching  1-­2  
MPa)   (Figure   5-­1).      Interestingly,   compression   of   CTAs   up   to   75%   strain   resulted   in  
multiple  peaks,  likely  indicative  of  construct  fracture  and  re-­compression  during  loading.  
Construct   failure  at  high  strains  was  confirmed  by  histological  analysis.     At  50%  strain,  
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there  was  some  internal  fissuring  of  the  construct  and  focal  areas  of  GAG  loss  (Figure  5-­
2G).  At  the  higher  75%  strain  level,  there  was  obvious  surface  fibrillation,  loss  of  construct  
shape,  and  widespread  GAG  depletion  (Figure  5-­2H).  In  comparison,  control  constructs  
maintained   uniform   GAG   distribution   throughout   the   construct   (Figure   5-­2F).      Rapid  
application  of  50%  strain  resulted  in  cell  death  throughout  the  intact  construct  thickness,  
while  75%  strain  primarily  resulted  in  cell  death  in  areas  adjacent  to  fissures  (Figure  5-­2,  
C-­E).  GAG  within  the  construct  and  released  to  the  medium  was  measured  0-­12,  0-­24,  
and  24-­120  hours  post-­injury.  75%  strain  applied  at  either  strain  rate  reduced  GAG/DNA  
in  constructs  for  all  time  points  post-­injury  (Figure  5-­2A).    Furthermore,  injury  at  both  50  
and   75%   strain   significantly   increased  GAG   released   to   the  medium   compared   to   un-­
injured  controls.  Application  of  75%  strain  resulted  in  an  ~2-­fold  greater  increase  in  GAG  
release  compared  to  50%  strain  applied  at  the  same  rate  (Figure  5-­2B).  In  these  outcome  






Figure  5-­1.  Injurious  compression  protocol.  (A,B)  Engineering  strain  and  stress  profiles  
of  CTAs  for  the  four  injury  protocols  tested:  50%  or  75%  strain  applied  at  either  10  or  50%  
strain/sec   for   a   total   compression   time   (ramp   and   hold)   of   10   sec.   Profiles   are  
representative  of  constructs   injured   in  that  group  (N=24/group,  all  CTAs  fabricated  with  
pooled   chondrocytes   of   a   single   animal).   (C)   Strain   and   strain-­rate   both   significantly  






Figure  5-­2.  Effect  of  strain  and  strain   rate  on  matrix   retention  and   loss   following  
injury.   (A)  GAG  content  normalized  to  DNA  content  within  CTAs  (N=3/group,  all  CTAs  
fabricated  with  pooled  chondrocytes  of  a  single  animal)  showed  consistent  loss  of  matrix  
following  injury  applied  to  75%  strain  at  10  and  50%  strain/sec.  (B)  GAG  released  to  the  
medium   (N=3/group,   all  CTAs   fabricated  with   pooled   chondrocytes  of   a   single   animal)  
mirrored   that   of   the   construct,   but  with   significant   loss   observed   in   a   strain-­dependent  
manner   at   both   50   and   75%   strain,   regardless   of   the   strain-­rate   during   injury.   (C-­E)  
Live/Dead   staining   (green:   viable;;   red:   non-­viable)   24   hours   post-­injury   for   the   highest  
strain  rate   illustrated  that  50%  strain  resulted   in  focal  regions  of  cell  death  with   internal  
fissuring  while   control   constructs   contained  viable   cells   throughout.   75%  strain   caused  
more   extensive   cell   death   superficially   and   adjacent   to   large   and   full-­depth   fissures  
(N=2/group).  (D-­F)  Alcian  blue  staining  for  proteoglycans  showed  control  constructs  with  
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well   distributed  matrix,   that   50%   strain   caused   internal   fissuring   with   local  matrix   loss  
(black   arrows),   and   that   75%   strain   caused   wide-­spread   matrix   damage   with   fainter  
staining  for  proteoglycans  throughout  the  construct  (N=2/group).  *p  vs.  control  and  #p  vs.  
50%  strain  for  a  respective  time  point;;  p<0.001  for  *  and  #  symbols  alone.  
	  
5.3.2.  High  Throughput  Injury  of  Engineered  Cartilage    
Based  upon   the  outcomes  of  single  sample   injury  of  CTAs,  75%  strain  applied  at  50%  
strain/sec  was  chosen  for   the  high  throughput  application  of  compressive   injury.      Injury  
was   carried   out   using   the   custom   high   throughput  mechanical   injury   device,   shown   in  
Figure  5-­3A.  While  CTAs  had  slight  variations  in  height  due  to  their  free  form  assembly  
and  growth  during  pre-­culture,  an  applied  target  strain  of  75%  resulted  in  applied  strains  
ranging  from  59%  to  99%  in  individual  CTAs,  with  a  mean  strain  of  78+/-­10%  for  a  full  48-­
well  plate  of  constructs  (Figure  5-­3B).  Simultaneous  compression  resulted  in  peak  loads  
in  CTAs  comparable  to  single-­sample  compression;;  a  3D  graphical  representation  of  the  
real  time  peak  voltages  (peak  load)  is  provided  in  Figure  5-­3C,  showing  similarity  across  
constructs.  GAG  released  from  high  throughput  constructs  was  2  to  3-­fold  higher  than  un-­
injured  controls  for  all  time  points  (Figure  5-­4A),  a  response  similar  to  that  evoked  by  the  
single  sample  injury.    Interestingly,  while  IL-­1  treatment  initially  caused  GAG  release  at  a  
similar   magnitude   as   mechanical   injury,   by   120   hours   of   continuous   treatment,   GAG  
release  was  ~9-­fold  higher   than  un-­injured  controls  and  4  to  5-­fold  greater   than   injured  
samples.    Evaluation  of  LDH  in  the  medium  indicated  that  injury  resulted  in  dramatic  loss  
in  viability  over  the  short  term  (Figure  5-­4B).    Conversely,  IL-­1  treatment  did  not  disrupt  
membrane  integrity  and  so  resulted  in  little  LDH  release  relative  to  baseline  levels.  Tissue  
swelling  was  calculated  as  a  measure  of  degeneration,  as  swelling  is  observed  clinically  
in  early  stages  of  osteoarthritis.  While   injured  constructs  swelled  significantly  within  24  
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hours,  control  constructs  did  not  change  (Figure  5-­4C).   In  contrast,   treatment  with  IL-­1  




Figure  5-­3.  HTMS  device  for  applying  compressive  injuries  to  CTAs.  (A)  The  HTMS  
injury  device  consisted  of  an  aluminum   frame  with   linear  bearings   to  guide   the  vertical  
motion  of  the  sensor  loading  platen.  The  sensor  adhered  to  the  underside  of  the  loading  
platen  comes  into  contact  with  a  well  plate  assembly  consisting  of  PTFE  indenters  aligned  
with  a  standard  48  well  plate  containing  engineered  constructs.  Average  sample  height  
was  measured  prior  to  testing,  with  a  target  injurious  compression  of  75%  strain  at  50%  
strain/sec  applied  to  constructs.  (B)  Example  distribution  of  sample  heights  and  applied  
strains   for   each   construct   (N=48/plate).      Average   strain   was   78+/-­10%   strain   for   the  
population.  (C)  Peak  voltage  recordings  in  each  well  showed  the  uniformity  of  peak  load  







Figure  5-­4.  Release  of  ECM  and  cellular  enzymes  and  alterations  in  CTA  properties  
following   high   throughput   mechanical   injury.   (A)   Injury   of   engineered   cartilage  
significantly   increased  GAG   release   to   the  medium   in   a  manner   similar   to   that   of   IL-­1  
treatment  alone  for  the  first  48  hours;;  after  48  hours,  IL-­1  causes  a  4  to  5-­fold  higher  level  
of  GAG  release  from  the  construct  compared  to  injury  alone  (N=8  media  collections  per  
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sample  combined   into  4  aliquots,  Sol-­GAG   is  an  average  value  per  aliquot/group).   (B)  
LDH  release  (a  measure  of  cell  viability)  indicated  that  injury  caused  a  large  increase  in  
chondrocyte  membrane  disruption  in  the  first  24  hours  after  injury,  while  IL-­1  resulted  in  
little  membrane  damage  with  continuous  exposure  for  5  days  (N=8  media  collections  per  
sample  combined   into  4  aliquots/group,  LDH   is  an  average  value  per  aliquot).   (C)  The  
swelling  ratio  (calculated  as  the  ratio  of  wet  to  dry  weight)  indicated  that  that  injury  caused  
gross  tissue  damage  and  swelling  within  24  hours  post-­injury.  In  contrast,  IL-­1  treatment  
resulted  in  increased  swelling  only  after  120  hours  of  treatment  (N=4  samples/group;;  all  
CTAs  fabricated  with  pooled  chondrocytes  of  a  single  animal).  *p  vs.  control  and  #p  vs.  IL-­
1  for  a  respective  time  point;;  p<0.001  for  *  and  #  symbols  alone.  
  
5.3.3.  Validation  of  Engineered  Cartilage  as  an  Analog  for  Injury  of  Native  Tissue    
To   validate   the   injury   response   of   CTAs,   explants   were   subjected   to   the   same   injury  
protocol  and  outcomes.  A  representative  peak  stress  profile  for  a  cartilage  explant  shows  
multiple  peaks,  similar  to  that  observed  with  the  engineered  cartilage,  with  the  first  peak  
concurrent  with  gross  tissue  failure,  followed  by  a  second  or  third  peak  due  to  the  further  
compression  of  the  fragments  (Figure  5-­5A,  inset).    The  first  peak  in  stress  occurred  at  
~16  MPa  for  cartilage  explants,  similar  to  previously  reported  values  for  explants  subject  
to  injurious  compression  at  high  strains  or  strain-­rates(Torzilli  et  al.  1999;;  Kurz  et  al.  2001).  
GAG  release  from  explants  and  CTAs  24  hours  post-­injury  showed  similar  loss  in  matrix  
content  per  construct  (Figure  5-­5A).  Similarly,  LDH  release  showed  comparable  findings,  
with   injured   CTAs   and   explants   both   showing   evidence   of   cell   membrane   damage  
compared  to  un-­injured  controls,  though  LDH  release  from  explants  was  ~2-­fold  greater  






Figure  5-­5.  Comparison  of  native  and  engineered  cartilage  injury  response.    Bovine  
cartilage  explants  were  compressed  to  75%  strain  at  50%/s.  (A-­inset)  Representative  peak  
stress  profile  of  explants  during  injurious  compression  showing  a  first  peak  concurrent  with  
gross  tissue  failure,  followed  by  a  second  peak  resulting  from  further  compression  of  the  
fragments.  Average  first  peak  stress  was  16.8+/-­4.3  MPa  (N=12,  all  explants  harvested  
from  a  single  animal).  Soluble  factors  released  to  the  medium  in  the  first  24  hours  showed  
that   (A)   GAG   release   was   comparable   between   injured   explants   and   CTAs   and   was  
significantly  greater  than  un-­injured  samples  (N=4  for  explants,  and  N=8  media  collections  
per   sample   combined   into   4   aliquots/group).   (B)   In   contrast,   LDH   release   was  
approximately   2-­fold   greater   in   explants   compared   to   CTAs   following   injury.   (N=4   for  
explants,  and  N=8  media  collections  per  sample  combined  into  4  aliquots/group).  p<0.001  
for  *  vs  control  within  tissue  type  and  #  vs  CTAs.  
  
5.3.4.  Response  of  Engineered  Cartilage  to  Putative  PTOA  Therapeutic  
Compounds    
As  a  secondary  validation  of  this  high  throughput  injury  system,  we  subsequently  screened  
several   putative   therapeutic   PTOA   compounds.   In   the   initial   24   hours,   ZVF   treatment  
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significantly  reduced  LDH  release  by  20%  compared  to  injury  alone;;  however,  NAC  and  
P188  did  not  alter  membrane  disruption  (Figure  5-­6A).  By  120  hours  post-­injury,  however,  
both  NAC  and  P188  decreased  GAG  loss  (by  18  and  20%  respectively)  compared  to  injury  
alone,   although   neither   agent   restored   GAG   content   to   control   levels   (Figure   5-­6B).  
Despite  increasing  initial  cell  viability  after  injury,  ZVF  treatment  did  not  alter  GAG  content  




Figure  5-­6.  Effect  of  putative  PTOA  therapeutics  on  matrix  content  and  cell  death  
after   injury.   (A)   LDH   release   24   hours   post-­injury   was   reduced   by   ~30%   with   ZVF  
80	  
	  
treatment   while   NAC   and   P188   had   no   effect   compared   to   injury   alone   (N=8   media  
collections  per  sample  combined  into  4  aliquots/group).  (B)  GAG  content  in  the  construct  
120  hours  post-­injury  showed  that  NAC  and  P188  treatment  resulted  in  retention  of  ~20%  
more  GAG  compared   to   injury  alone   (N=4/group).  Dashed   red   line  demarcates   results  
from   two   separate   experiments   (CTAs   for   each   experiment   fabricated   with   pooled  
chondrocytes  of  a  single  animal)  evaluating  the  effects  of  NAC,  ZVF,  and  P188.  
  
5.4.  Discussion  
Traumatic   joint   injury   initiates   a   cascade   of   catabolic   and   anabolic   processes,   the  
imbalance  of  which  often  results  in  further  cartilage  degeneration.  However,  the  pathways  
that  underlie  these  irreversible  changes  remain  poorly  understood.  As  such,   in  order  to  
conduct   an   efficient   and   unbiased   evaluation   of   molecules   that   may   modulate   PTOA  
biologic   processes,   high   throughput   screening   would   be   a   valuable   tool   to   evaluate  
compound   libraries   after   injury.   In   this   study,  we   utilized   engineered   cartilage   analogs  
(CTAs)   in   conjunction   with   a   high   throughput   mechanical   injury   device   to   develop   a  
platform   for   studying   PTOA   pathology   and   to   enable   the   discovery   of   potential  
therapeutics.    
  
Primary  markers  of  cartilage  damage  following  traumatic  injury  include  matrix  disruptions,  
GAG  loss  from  the  matrix,  and  cell  death.    Using  CTAs  as  an  in  vitro  cartilage  surrogate  
for   studying   PTOA,   our   objective   was   to   define   the   thresholds   for   inducing   such   a  
response,  to  determine  the  uniformity  of  response  using  a  high  throughput  device,  and  to  
benchmark  the  response  against  that  of  native  cartilage.  To  define  thresholds  for  injury,  
single  sample  compression  was  applied  to  constructs  at  strains  (50%  and  75%)  and  strain  
rates  (10%  and  50%  strain/sec)  previously  explored  (Kurz  et  al.  2001;;  Quinn  et  al.  2001;;  
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Lee  et  al.  2005).  In  explants,  while  strains  larger  than  50%  cause  permanent  deformation  
and  surface  fibrillation  (stresses  >15MPa),  strains  greater  than  80%  (stresses  >20MPa)  
cause  deep  fibrillation  and  complete  destruction  of  matrix  integrity  (Torzilli  et  al.  1999).  In  
CTAs   cultured   for   up   to   16   weeks,   whose   properties   approach   that   of   native   tissue  
(Mohanraj  et  al.  2013),  application  of  75%  strain  resulted  in  widespread  fissuring,  with  a  
2-­fold   increase   in  release  of  GAG  to   the  medium  compared  to  50%  strain.  The  greater  
release  of  GAG  observed  at  this  higher  strain  may  be  due  to  the  increased  surface  area  
for  diffusion.  DiMicco  et  al.  observed  with  injury  of  osteochondral  explants  an  initially  high  
rate  of  GAG  release  not  blocked  by  MMP  or  biosynthesis   inhibitors,   indicating   that   this  
early   release   (≤4   days   post-­injury)   likely   consisted   of   diffusion   of   larger   proteoglycan  
molecules  out  of  the  tissue  rather  than  enzymatically-­cleaved  fragments,  as  is  observed  
at  later  time  points  (DiMicco  et  al.  2004).    
  
In  our  study,  for  both  levels  of  injury,  extensive  cell  death  was  observed  adjacent  to  surface  
fissures  and   internal  cavities.      In  cartilage  explant  studies,   the  extent  and  depth  of  cell  
death  has  been  reported  to  be  both  strain  and  strain-­rate  dependent  (Quinn  et  al.  2001;;  
Morel   et   al.   2004;;   Green   et   al.   2006;;   Natoli   et   al.   2008).   In   addition,   similar   to   our  
observations,   extensive   loss   of   cell   viability   occurs   along   fissure   lines/regions   both   in  
whole  joint  (Tochigi  et  al.  2011)  and  osteochondral  explant  (Quinn  et  al.  2001;;  Stolberg-­
Stolberg  et  al.  2013)  models  with  cell  viability   increasing  with  distance   from  the   fissure  
line.   However,   with   time,   cell   death   expands   to   these   non-­fissure   regions,   which  may  
suggest  two  mechanisms  by  which  cell  viability  decreases  with  injury.  Under  high  loading  
rates,  cells  may  not  be  able  to  “recruit”  sufficient  membrane  components  in  order  to  deform  
under  compression,  and  in  areas  of  cartilage  fissuring,  cells  experience  high  strains  and  
these  cells  rupture  (Moo  et  al.  2013).  The  expansion  of  the  region  of  cell  death  to  non-­
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fissure   regions   with   time   may   be   the   result   of   diffusible,   soluble   factors   that   induce  
apoptosis   and   contribute   to   the   propagation   of   the   injury   response   (Levin   et   al.   2001;;  
Tochigi  et  al.  2011;;  Stolberg-­Stolberg  et  al.  2013).  
  
Upon  determining  that  75%  strain  at  50%  strain/sec  induced  a  degenerative  response  in  
CTAs,  we  next  used  our  high  throughput  device  to  apply  consistent  compressive  injury  to  
up  to  48  samples  simultaneously.  While  there  were  small  variations  in  applied  strain  due  
to  differences  in  construct  height,  the  response  was  sufficiently  uniform  so  as  to  provoke  
a  ~2-­3  fold  increase  in  GAG  release  compared  to  un-­injured  controls,  comparable  to  the  
single  sample  response.    Monitoring  LDH  release  as  a  quantitative  measure  of  cell  death  
similarly   confirmed   that   cell  membrane   damage   is   a   repeatable   effect   of   compressive  
injury  in  this  engineered  model  of  PTOA.    
  
We   subsequently   validated   the   CTA   response   against   that   of   native   cartilage.   Peak  
stresses  during  compressive  injury  of  native  tissue  were  ~20-­fold  higher  than  CTAs.  This  
difference  could  explain  the  2-­fold  greater  increase  in  LDH  release  as  compared  to  CTAs  
in   the   first   24   hours.   Indeed,   strain   rate   and   peak   stress   dependent   increases   in   LDH  
release  have  been  observed  in  cartilage  explants  (Bush  et  al.  2005;;  Nishimuta  et  al.  2012).    
Additional   factors   which   may   also   influence   the   extent   of   cell   death   include   matrix  
composition   and   organization   (Tan   et   al.   2010).   In   our   study,   GAG   release   was  
comparable  between  explants  and  CTAs,  with  a  4-­fold   increase   in  GAG  release   to   the  
medium   compared   to   un-­injured   controls   within   the   first   24   hours.   Previous   work   has  
similarly  reported  an  ~2-­fold  increase  in  GAG  release  in  the  first  24  hours  from  explants  
subjected   to   injury  at   fracture   levels   (e.g.  50%  strain  at  100%  strain/sec   (Patwari  et  al.  
2003;;  DiMicco  et  al.   2004)  or  high  strain   rates  of  50%  or  70%  strain/sec   (Quinn  et  al.  
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2001)).    Given  that  the  CTA  can  be  injured  at  any  point  in  its  maturation,  from  the  cell-­rich,  
matrix-­poor  more   fetal-­like  state,   through   to   the  mature,  matrix-­rich,  cell  poor  adult-­like  
state  (Mohanraj  et  al.  2013),  a  range  of  studies  may  be  performed  to  determine  how  injury  
and  tissue  maturation  state  interact.  
  
Using   our   CTAs,   we   observed   a   consistent   and  marked   effect   of   load-­induced   injury;;  
however,   in   PTOA,   degeneration   is   also   potentiated   by   the   presence   of   inflammatory  
cytokines,  such  as  IL-­1β,  which  may  differentially  govern  the  chondrocyte  response  in  our  
in   vitro   system.  While  mechanical   injury   caused   extensive   cell  membrane   damage   as  
measured  by  LDH  release,   IL-­1  had  a  minimal  effect.   In  contrast,  while   IL-­1  and   injury  
initially  increased  GAG  release  to  similar  levels,  by  120  hours  of  exposure  to  IL-­1,  GAG  
release  was  3-­fold  higher  than  injury  alone.  IL-­1  is  known  to  cause  matrix  degradation  via  
increased  NF-­κB  activation,  expression  of  proteases  (e.g.  MMP  and  ADAMTS),  and  other  
pro-­inflammatory  molecules   (e.g.  NO  and  COX-­2)   (Lianxu  et  al.  2006;;  Montaseri  et  al.  
2011).  Such  temporal  patterns  of  matrix  disruption  may  also  explain  why   injury  caused  
rapid  construct  swelling   (mechanical  disruption  of   the  nascent  collagen  network),  while  
this  swelling  response  took  longer  with  IL-­1  mediated  degradation  (sustained  enzymatic  
cleavage).  These  observations  are  consistent  with  reports  of  injury-­induced  increases  in  
water  content  of  explants   in  a  strain  dependent  manner  (Torzilli  et  al.  1999;;  Kurz  et  al.  
2001),  as  well  as  of  chondrocyte-­seeded  agarose  hydrogels  following  a  crush  injury  (Tan  
et  al.  2010).    
  
Finally   to   determine   whether   this   CTA   model   is   useful   for   screening   new   PTOA  
therapeutics   in   a   high   throughput   manner,   bioactive   molecules   previously   reported   to  
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reduce  cell  death  and  proteoglycan  loss  post-­injury  were  evaluated.  Application  of  these  
compounds   to  CTAs  resulted   in  early  protection  against   loss  of  viability   (ZVF)  and   late  
protection  against  matrix   loss   (P188  and  NAC)  after   injury.  ZVF  has  been  observed   to  
increase   cell   viability   by   15-­20%  with   48   hours   of   treatment   following   compression   of  
explants   (30%  strain  at   0.6s-­1   (D'Lima  et  al.   2001)  or   impact  at   7J/cm2   (Martin  2009)).  
Although  NAC   has   likewise   been   shown   to   increase   viability   by   ~30%   following   injury  
(Martin  2009),  here  we  found  no  effect  on  reducing  membrane  damage.    However,  NAC  
was  effective  at  reducing  GAG  loss,  consistent  with  observations  of  a  ~20%  reduction  in  
GAG   loss   from   chondral   explants   following   injury   (7J/cm2   (Martin   2009)).      While   our  
findings  also  showed   that  P188   improved  GAG  retention,   literature   findings  have  been  
variable,  with  some  studies  noting  a  ~20%  increase  in  cell  viability  (Phillips  et  al.  2004)  
with  minimal  changes  in  GAG  loss  (Natoli  et  al.  2008).    One  possible  explanation  is  that  
P188   insertion   into   the  membrane  may   prevent   the   expulsion   of   intracellular   contents  
which  in  turn  may  preserve  local  ion  concentration  gradients  (Yasuda  et  al.  2005)  to  allow  
living  cells  to  function  normally.  It  is  important  to  note  that  although  these  compounds  did  
have  acute  effects  on  matrix  retention  and  cell  viability,  none  were  able  to  return  constructs  
to  control  levels,  highlighting  the  importance  of  continuing  therapeutic  discovery.  
  
5.5.  Conclusion  
Taken  together,  these  studies  illustrate  that  injurious  compression  of  CTAs  replicates  key  
markers  of  the  injury  response  in  native  cartilage  explants,  validating  this  approach  as  a  
model   system   for   studying   the  processes   that  govern  cartilage  degeneration   in  PTOA.    
While   our   current   model   focuses   on   mimicking   articular   fracture,   this   system   can   be  
adapted  for  applying  insults  that  do  not  produce  structural  damage  to  mimic  subtle  injury  
scenarios  and  also  for  cyclic  overloading  injuries.  In  addition,  our  testing  platform,  along  
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with  the  ability  to  form  large  numbers  of  these  cartilage  analogs  in  a  micro-­scale  format,  
sets   the  stage   for  high   throughput  screening  of   large  chemical   libraries   to  more  rapidly  
identify  therapeutics  to  attenuate  progressive  degenerative  joint  changes  after  injury.  
  
Reprinted  from  Osteoarthritis  and  Cartilage,  Volume  22,  Issue  9,  Mohanraj  B,  Meloni  GR,  
Mauck  RL,  Dodge  GR.  A  High  Throughput  Model  of  Post-­Traumatic  Osteoarthritis  using  





















Chapter  6.  Small  Molecule  Library  Screening  for  Modulators  of  Post-­Traumatic  
Osteoarthritis	  
	  
6.1  Introduction    
High   throughput  screening   (HTS)  aims   to  use  preclinical  models   to  predict   the  efficacy  
and  safety  of  drug  candidates  in  vivo.  In  this  early  stage  of  drug  development,  it  is  critical  
to   identify   therapeutic   candidates   that  meet   (or   fail   to  meet)   the   necessary   targets   for  
altered  cell  function  or  response  and  to  prioritize  those  that  are  most  promising.  The  use  
of  appropriate  preclinical  models  can  reduce  the  number  of  drug  failures  that  occur  during  
clinical  trials.  Indeed,  drug  development  attrition  rates  between  1964-­2000  resulted  in  a  
success  rate  of  less  than  11%  in  bringing  drugs  to  market  in  the  US  and  Europe  (Prentis  
et   al.   1988;;   Kola   et   al.   2004;;   Astashkina   et   al.   2012).   Conventionally,   the   ability   of  
candidates  to  modulate  a  specific  biologic   target   is  assessed  using  an   in  vitro,  2D  cell-­
based  assay  and  lead  candidates  from  these  initial  screens  are  directly  assessed  in  vivo  
using  a  relevant  animal  model  (Breslin  et  al.  2013).  However,  2D-­monolayer  cultures  may  
not   recapitulate   important  aspects  of   the   tissue  microenvironment,   including  native  cell  
morphology,  cell-­cell  and  cell-­ECM   interactions,  and  biophysical  cues  derived   from   the  
surrounding  3D  matrix.  These  environmental  factors  also  differentially  regulate  a  number  
of   cell   behaviors   as   compared   to   2D   culture   (e.g.   adhesion   (Cukierman   et   al.   2001),  
proliferation   (Baker   et   al.   2015),   and   differentiation   (Cosgrove   et   al.   2016)).   These  
differences   highlight   the   gap   that   exists   between   2D   monolayer   cultures   and   animal  
models  for  understanding  the  cellular  response  to  therapeutics  in  vivo.  Therefore,  given  
the  time  required  for  and  expense  of  bringing  a  new  drug  to  market  (DiMasi  et  al.  2016),  
the  adaptation  of  3D  in  vitro  cultures  for  screening  applications  presents  an  opportunity  to  
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improve  predictive  efficacy  of  preclinical  models.  In  this  Chapter,  we  develop  a  system  for  
use  in  musculoskeletal  research,  with  a  particular  focus  on  post-­traumatic  osteoarthritis.    
  
The  primary  focus  of  tissue  engineering  is  to  repair  degenerated  tissues  through  the  use  
of  constructs  that  mimic  the  structure,  function,  and  cellular  behaviors  of  its  healthy,  native  
tissue  counterpart.  Recently,  however,  engineered  tissues  have  gained  traction  as  3D  in  
vitro  model   systems   to   investigate  mechanisms  and  microenvironments  of   disease,  as  
well  as  screen  therapeutic  compounds  (Griffith  et  al.  2006;;  Gibbons  et  al.  2013;;  Kimlin  et  
al.   2013).  While   these   systems  may   not   capture   the   full   complexity   of   the   physiologic  
environment,  key  features  of  the  tissue  environment  can  be  recapitulated  in  vitro  to  mimic  
hallmarks   of   the   in   vivo  environment   that  may   impact   drug   response   (Rai   et   al.   2008;;  
Hongisto  et  al.  2013).  In  addition,  engineered  tissues  are  fabricated  as  tightly  controlled  
environments,  enabling  systematic  and  quantitative  investigation  of  cellular  responses  to  
drug  exposure  in  a  reproducible  context.  Screening  thousands  of  compounds  in  preclinical  
animal  models  is  neither  economically  feasible  nor  ethically  responsible  (Astashkina  et  al.  
2012).  Therefore,  scale-­up  of  3D   in  vitro  models   to  HTS  compatible  platforms  meets  a  
critical  need  in  the  drug  discovery  process.  A  number  of  screening  platforms  for  various  
tissue  types  are  currently  in  development  (Griffith  et  al.  2006;;  Gibbons  et  al.  2013;;  Kimlin  
et  al.  2013),  including  engineered  skeletal  (Vandenburgh  et  al.  2008)  and  heart  (Hansen  
et  al.  2010;;  Boudou  et  al.  2012;;  Mathur  et  al.  2015)  muscle  models  to  measure  the  effect  
of  therapeutics  on  contractile  activity,  as  well  as  organoid-­derived  3D  cultures  of  kidney  
proximal  tubules  to  screen  drugs  for  nephrotoxicity  (Astashkina  et  al.  2012).  Our  focus  in  
this   context,   is   the   design   of   preclinical   models   for   musculoskeletal   conditions;;   more  
specifically,   joint   and   cartilage   pathologies   for   which   the   disease   modifying   therapies  




To  date,  several  tissue  engineering  strategies  have  successfully  matched  functional  and  
phenotypic  characteristics  of  native  cartilage  using  various  cell  sources,  biomaterials,  and  
environmental  cues  (Elisseeff  et  al.  2001;;  Wang  et  al.  2005;;  Novotny  et  al.  2006;;  Moutos  
et  al.  2007;;  Ofek  et  al.  2008;;  Erickson  et  al.  2009;;  Johnstone  et  al.  2013;;  Sharma  et  al.  
2013).  While  efforts  to  translate  these  native-­like  implants  is  ongoing  (Gotterbarm  et  al.  
2006;;  Holland  et  al.  2007;;  Mrugala  et  al.  2008;;  Wang  et  al.  2010;;  Kim  et  al.  2015;;  Fisher  
et   al.   2016),   there   also   exists   the   potential   to   use   engineered   cartilage   for   screening  
purposes  to   identify   factors   that  can  treat  osteoarthritis   (OA).  OA   is  considered  to  be  a  
disease   that   affects   the   entire   joint,   but   the   primary   features   include   cartilage   erosion,  
proteoglycan   depletion  within   the   tissue,   and   chondrocyte   apoptosis   leading   to   loss   of  
load-­bearing   function   (Little   et   al.   2013).   A   subset   of   OA,   termed   post-­traumatic  
osteoarthritis  (PTOA),  is  defined  by  the  initial  occurrence  of  a  traumatic  injury  to  the  soft  
tissues   within   the   joint   (e.g.   meniscus   or   ligament   tear)   that   initiates   progressive  
degenerative   changes   within   cartilage.   Towards   the   discovery   of   disease-­modifying  
osteoarthritis  drugs  (DMOADs),  genetically  engineered  mice  have  been  used  in  preclinical  
models  of  PTOA  (surgically-­induced  joint  instability)  to  identify  potential  targets.  Targets  
that  have  been  validated  across  independent  studies  include  ADAMTS5  (Glasson  et  al.  
2005;;  Botter  et  al.  2009;;  Malfait  et  al.  2010),  MMP13  (Little  et  al.  2009;;  Wang  et  al.  2013),  
and  FGF2  (Chia  et  al.  2009).  Although  animal  preclinical  models  provide  strong  support  
to  further  pharmaceutical  investigations,  in  vitro  drug  screening  platforms  are  needed  to  
identify  lead  candidates  that  effectively  modulate  these  targets.  
  
To  address  this  need  for  a  3D  in  vitro  model  of  PTOA,  our  group  recently  developed  a  high  
throughput  model  of  mechanical  injury  using  engineered  cartilage.  A  48-­well  mechanical  
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testing  system  (Mohanraj  et  al.  2014)  was  adapted  to  apply  compressive  injury  to  cartilage  
tissue  analogs  (CTAs)  (Mohanraj  et  al.  2014).  Acute  hallmarks  of  the  injury  response  (cell  
death  and  matrix   loss)  were  observed   in  vitro,  mimicking  the  effects  of   injury  applied  to  
native  cartilage  tissue  explants  in  vitro,  as  well  as  in  destabilization  models  in  vivo.  A  pilot  
screen  of   putative   therapeutic   compounds   for   early   intervention   in  PTOA  also   showed  
similar   efficacy   in   engineered   cartilage   compared   to   published   results   (Mohanraj   et   al.  
2014).    Here,  we  build  upon  this  platform  to  conduct  unbiased  screens  of  small  molecule  
libraries  to  identify  novel  candidates  that  have  the  capacity  to  modulate  the  acute  injury  
response.  HTS-­compatible  assays,  measuring  cell  viability  and  matrix  remodeling  post-­
injury,  were  used  to  determine  the  effect  size  of  screened  compounds  and  to  identify  ‘hits’  
for  further  analysis  in  secondary  screens.    
  
6.2.  Methods    
6.2.1.  Cartilage  Tissue  Analog  Fabrication  for  Screening  Studies    
Cartilage  tissue  analogs  (CTAs)  were  fabricated  as  described  previously  (Novotny  et  al.  
2006;;   Mohanraj   et   al.   2014)   using   primary   chondrocytes   seeded   at   high   density   in  
suspension  culture  to  form  aggregated  masses  (1  million  cells  per  CTA  in  96-­well,  poly(2-­
hydroxyethyl  methacrylate)-­coated  plates).  CTAs  for  screening  experiments  were  cultured  
for   at   least   14   weeks   to   achieve   functional   maturity.   For   the   initial   library   screen   and  
secondary  evaluation  of   individual  small  molecules,  chondrocytes  were  harvested   from  
the  knees  of  a  single  juvenile  bovine  donor  (2-­6  months  old,  Research  87,  MA).  For  the  
second  library  screen,  CTAs  were  formed  by  pooling  chondrocytes  in  equal  number  from  
bovine  knees  from  different  animals  (N=7  knees  from  separate  bovine  donors).  An  aliquot  
of   chondrocytes   from   each   animal  was   also   reserved   to   form   donor-­specific   CTAs   for  
validation  of  the  behavior  of  pooled  CTAs  in  a  pre-­screening  study.  All  CTAs  were  cultured  
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in  complete  medium  as  described  previously   (Mohanraj  et  al.  2014)   for   the  duration  of  
construct  growth  and  injury-­screening  experiments.  
  
6.2.2.  High  Throughput  Mechanical  Injury  for  Compound  Library  Screening        
A   high   throughput   mechanical   injury   (HiTMI)   system   (Chapter   5)   was   used   to   apply  
compressive  strains   (50-­75%  strain  at  50%  strain/s)  previously  observed   to   induce  key  
hallmarks  of  the  acute  injury  response  in  engineered  cartilage  (Mohanraj  et  al.  2014).  Prior  
to  injury,  the  height  of  all  CTAs  was  measured  and  CTAs  were  placed  in  a  standard  48-­
well  plate  (Cat.  No.  351178,  BD  Falcon,  NJ).  Injury  strain  and  strain  rate  were  calculated  
based  on  the  average  height  of  constructs  in  the  well  plate.  The  HiTMI  device  (as  shown  
in  Figure  5-­3)  consisted  of  an  aluminum  housing  with  linear  bearings  to  guide  the  vertical  
displacement   of   a   loading   platen   controlled   by   an   Instron   5948.   PTFE   indenters  were  
placed  on  CTAs  in  each  well,  the  loading  platen  was  brought  to  the  average  CTA  height,  
and  the  displacement  protocol  applied.  Immediately  following  injury,  CTAs  were  treated  
with   library   compounds   (all   compounds:   10µM,  N=1/compound;;   treatment   applied   <15  
minutes   post-­injury).   The   commercial   libraries   chosen   for   these   experiments   targeted  
pathways  relevant  to  the  acute  hallmarks  of  injury,  cell  death  and  matrix  remodeling.  The  
first   library,   containing   29   compounds,   included   small  molecules   relevant   to   apoptosis  
signaling   pathways   (e.g.   capsases,   TNF-­α;    Apoptosis   Compound   Library,   L3300,  
SelleckChem,   TX).   The   second   library,   containing   89   compounds,   targeted   pathways  
relevant  to  chondrocyte  signaling  and  cartilage  development  (e.g.  TGF-­β,  JAK;;  Stem  Cell  
Signaling  Library,  L2100,  SelleckChem,  TX).  A  number  of  controls  were  also  included  to  
aid  ‘hit’  identification  and  to  define  the  range  of  the  assay  measures.  Injured  and  un-­injured  
CTAs  cultured  in  complete  medium  alone,  served  as  the  baseline  injury  and  naïve  control,  
91	  
	  
respectively   (N=2/plate).   Injured  CTAs  were   also   treated  with   factors   to   induce   known  
responses:  TNF-­α to   induce  GAG  loss  (10ng/mL),  TGF-­β3   to   increase  GAG  production  
(10ng/mL),  Triton-­X  to  lyse  all  cells  for  maximal  LDH  release  (0.18%  w/v),  and  DMSO  as  
a  delivery  vehicle  control  (0.1%  v/v,  matched  to  compound  dilution)  (N=1/plate).  After  48  
hours,  medium  and  CTAs  were  collected  and  stored  at  -­80°C  until  further  analysis.  The  
wet  weight  of  each  construct  was  measured  at  the  time  of  harvest  to  normalize  outcome  
measures  (represented  as  %WW)  to  make  comparisons  across  samples.  
  
6.2.3.  Screening  Assays  and  ‘Hit’  Identification    
CTAs  for  biochemical  analysis  were  digested  in  proteinase  K  (1:200  in  10mM  Tris-­HCl)  
overnight.  Glycosaminoglycan  (GAG)  content   in  the  tissue  and  released  to  the  medium  
was  determined  using  the  dimethylmethylene  blue  (DMMB)  assay  as  previously  described  
(Farndale).  Lactate  dehydrogenase  (LDH)  was  measured  as  an   indication  of  cell  death  
(CytoTox-­ONE  Homogeneous  Membrane  Integrity  Assay,  Promega,  WI);;  LDH  is  released  
into   the  medium   following  cell  membrane  disruption  or  damage.  To   identify   ‘hits’  using  
data   from   these   assays,   dual   flash-­light   plots   were   constructed   to   show   the   strictly  
standardized  mean  difference  (SSMD,  statistically-­favored  measure)  vs.  log2  fold  change  
(biologically-­favored  measure)  (Zhang  et  al.  2007;;  Zhang  2011)   for  each  assay.  SSMD  
indicates  the  magnitude  of  difference  between  two  conditions  and  accounts  for  the  non-­
normality,   variability,   skewness,   and   outliers   within   a   population,   compared   to   other  
statistical  methods  These  features  are  common  in  high  throughput  screening  data  where  
‘hits’  are  few,  and  the  majority  of  compounds  produce  negative  results  (i.e.  are  similar  to  
baseline).  Assay  values  were  log  transformed,  and  the  SSMD  score  was  calculated  as  the  
ratio  of  two  components:  (1)  the  difference  between  the  measured  value  for  a  compound  
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and  the  median  of  the  negative  reference  (un-­treated,  injured  control)  and  (2)  the  median  
absolute  deviation,  adjusted  for  sample  size  (SSMD  based  on  UMVUE,  (Zhang  2011)).  
Gating  criteria  were  applied,  wherein  compounds  with  an  -­1  ≤  SSMD  ≥  1  and  -­1.5  ≤  Fold  
Change  ≥  1.5,  were   identified  as   ‘hits’   (i.e.  positive  or  negative   regulators  of   the   injury  
response).   SSMD   scores   for   ‘hits’   were   also   cross-­referenced   against   an   additional  
outcome  measure  (GAG  release  vs.  LDH  release)  to  determine  if  compounds  were  able  
to   modulate   multiple   hallmarks   of   the   injury   response.   ‘High-­performing’   hits   were  
subsequently  evaluated  in  secondary  screens  in  the  HiTMI  device  using  multiple  ‘donor-­
specific’  CTAs  (N=3-­4  bovine  donors,  aged  6  months  to  1  year)  and  biological  replicates  
(N=3  CTAs  per  small  molecule  treatment).    
  
6.2.4.  Validation  of  Pooled  CTA  Response  in  an  Inflammatory  Environment        
To   determine   if   the   response   of   pooled  CTAs  was   comparable   to   that   of   the   average  
response  of  donor-­specific  CTAs,  constructs  were  subjected  to  inflammatory  challenge.  
IL-­1β   is   a   pro-­inflammatory   cytokine   found   in   the   synovial   fluid   of   osteoarthritic   joints  
(McNulty   et   al.   2013)   and   is   known   to   induce   catabolic   processes   that   cause   matrix  
degradation  and  inhibit  chondrocyte  biosynthesis  in  engineered  cartilage  (Goldring  2000;;  
Ousema   et   al.   2012).   CTAs  were   pre-­cultured   for   four   weeks   prior   to   exposure   to   IL-­
1β (10ng/mL)   for   5   days.   Medium   collected   during   this   period   was   analyzed   for   GAG  
(DMMB  assay)  and  nitrite   (Griess  assay,  Promega,  WI)   release.  Nitrite   is  a  breakdown  
product   of   nitric   oxide   and   promotes   cartilage   degradation   by   inhibiting   aggrecan  
synthesis,   activating  MMPs,   and   increasing   chondrocyte   susceptibility   to   apoptosis   by  
other  oxidants  (Scher  et  al.  2007).  The  MTT  assay  was  also  used  as  a  measure  of  cell  




6.2.5.  Statistical  Analysis    
Single   sample   t-­tests   (p<0.05)   were   used   for   analysis   of   pre-­screening   experiments  
comparing  the  effect  of  IL-­1β to  control  for  each  donor-­specific  or  pooled  CTA.  One-­way  
ANOVA  with  Tukey’s  post-­hoc  test  (p<0.05)  was  used  in  secondary  screens  to  determine  
differences  between  naïve  control,   injury  alone,  and  treated   injury  groups.  All  statistical  
analysis   was   conducted   using   Graphpad   Prism   (v.5,   CA)   and   SYSTAT13   software  
(v.13.00.05,  CA).    
  
6.3.  Results  
6.3.1.  Identification  of  ‘Hits’  in  a  Screen  Targeting  Apoptosis-­Related  Pathways    
Cell  death   immediately  and  acutely   following  compressive   injury  has  been  observed   in  
both  cartilage  explant  (Quinn  et  al.  2001;;  Morel  et  al.  2004;;  Green  et  al.  2006;;  Martin  2009;;  
Rosenzweig  et  al.  2012)  and  engineered  cartilage  models  (Tan  et  al.  2010;;  Mohanraj  et  
al.  2014).  While  the  parameters  of  mechanical  loading  may  affect  the  location,  depth,  and  
expansion   of   the   non-­viable   area,   both   necrosis   and   apoptosis   are   thought   to   be  
contributing  mechanisms  to  the  widespread  loss  of  viability.  Therefore,  the  objective  of  the  
first  screen  in  the  HiTMI  platform  was  to  evaluate  a  curated  library  of  small  molecules  (29  
compounds)  that  modulate  signaling  pathways  related  to  apoptosis.  A  total  of  9  ‘hits’  were  
identified  that  modulated  the  injury  response  across  the  three  primary  outcome  measures.  
Compounds   that   modulated   cell   damage,   and   indirectly   cell   viability   post-­injury,   were  
assessed  by  LDH  release.  Three  molecules  that  attenuated  LDH  release  were  identified:  
Pomalidomide  (an  inhibitor  of  LPS-­induced  TNF-­α  release),  Z-­VAD-­FMK  (a  pan-­caspase  
inhibitor),  and  Necrostatin-­1  (an  inhibitor  of  TNF-­α  induced  necroptosis)  (Figure  6-­1A).  To  
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determine  if  compounds  within  this  library  also  had  off-­target  effects  on  remodeling  as  a  
secondary  effect,  GAG  release  and  retention  were  also  measured.  Two  compounds  that  
attenuated  GAG  release  were  identified:  ABT-­199  (a  Bcl-­2  inhibitor)  and  JNJ-­26854165  
(a  HDM2  ubiquitin  ligase  antagonist)  (Figure  6-­1B).  In  addition,  one  negative  regulator  of  
injury  was  identified:  BV-­6  (a  cIAP  and  XIAP  inhibitor)  that  increased  GAG  release,  similar  
to   exogenous   TNF-­α   treatment.   A   separate   group   of   molecules   was   also   found   that  
increased  GAG  content  within  the  tissue;;  these  included  Apoptosis  Activator  2  (induces  
caspase  3  activation),  GDC-­0152  (an  IAP  antagonist),  and  TW-­37  (a  non-­peptide  inhibitor  







Figure  6-­1.  ‘Hits’  identified  during  screening  of  small  molecules  related  to  apoptosis  
signaling   pathways.   Black   circles   represent   ‘hits’   that   meet   gating   thresholds   as  
compared  to  all  other  molecules  (grey  circles);;  controls  are  color-­coded  as  described  in  
the  legend.  (A)  LDH  release  as  an  indirect  measure  of  cell  viability  identified  3  ‘hits’  that  
attenuated  cell  death:  ZVF,  Pomalidomide,  and  Necrostatin  1.  (B)  GAG  release  identified  
two  positive  (JNJ-­26854165  and  ABT-­199,  and  one  negative  (BV-­6)  regulator  of  the  injury  
response.  (C)  GAG  content  in  CTAs  identified  3  ‘hits’  that  improved  retention  post-­injury:  




6.3.2.  Scale-­Up  of  the  HiTMI  Platform  for  Small  Molecule  Screens        
To   scale-­up   the   throughput   of   screens   using   the   HiTMI   platform,   CTAs   needed   to   be  
fabricated  in  large  quantity  so  as  to  match  the  size  of  large,  small  molecule  libraries.  To  
achieve  this,  chondrocytes  were  pooled  from  multiple  bovine  knees  to  form  single  batches  
of   CTAs.   Donor-­specific   batches   of   CTAs   were   also   fabricated   in   parallel   to   enable  
comparisons   of   ‘pooled’   versus   ‘donor-­specific’   CTA   responses   to   an   inflammatory  
challenge,  as  a  pre-­screening  test.  We  hypothesized  that  ‘pooled’  CTAs  would  exhibit  the  
average  response  of   ‘donor-­specific’  CTAs   following  exposure   to   IL-­1β   (10ng/mL)   for  5  
days.  As  shown  in  Figure  6-­2,  in  two  separate  studies,  while  nitrite  and  GAG  release  was  
variable  across  ‘donor-­specific’  CTAs,  the  ‘pooled’  response  was  similar  to  the  calculated  
average.  MTT,  a  measure  of  metabolic  activity,  also  showed  a  similar  pattern  (Figure  6-­
2C).   These   results   indicate   that   a   single   ‘donor’   population   of   chondrocytes   did   not  
dominate  the  overall  response  and  supported  the  use  of  a  ‘pooled’  CTA  fabrication  method  






Figure  6-­2.  Pre-­screening  comparison  of  ‘pooled’  vs.  ‘donor-­specific’  CTA  response  
to  an  inflammatory  challenge.  (A)  GAG  and  (B)  Nitrite  released  to  the  medium  following  
exposure  to  IL-­1β  for  5  days  show  that  the  pooled  CTA  response  is  similar  to  the  average  
(green  dashed  line)  resposne  of  individual  CTAs.  (C)  MTT  measurement  of  cell  metabolic  
activity   falls   within   the   range   of   the   donors   tested.      Individual   bovine   ‘donors’   are  
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represented  in  the  figures  as  ‘B’  followed  by  a  number  (^p<0.05,  +p<0.01,  *p<0.001  vs.  
control).  
  
In  the  second  screen,  a  larger  library  of  small  molecules  was  chosen  that  broadly  targeted  
signaling  pathways  related  to  chondrocyte  signaling  and  cartilage  development.  A  total  of  
89  unknown  compounds  were  screened,  along  with  controls  on  each  48-­well  plate  (un-­
injured,  injured  un-­treated,  TNF-­α,  TGF-­β,  DMSO,  and  Triton-­X).  A  total  of  28  ‘hits’  were  
identified   from  LDH  and/or  GAG   release  outcome  measures;;  16   ‘hits’   exacerbated   the  
injury  response,  while  an  additional  12  ‘hits’  attenuated  cell  damage  or  matrix  loss  (Figure  
6-­3).   Those   that   reduced   LDH   release   affected   signaling   related   to   JAK   (Filgotinib,  
Tofacitinib   Citrate,   and   WHI-­P154),   GSK-­3   (1-­Azakenpaullone),   histamine   receptor  
(Hesperetin),   and   Hedgehog/Smoothened   (BMS-­833923)   signaling.   Tofacitinib   citrate  
(CP-­690550,  pan-­JAK  inhibitor)  and  BMS-­833923  (smoothened  antagonist)  reduced  LDH  
release  to  naïve,  un-­injured  control  levels.  The  6  ‘hits’  that  reduced  GAG  release  included  
a  number  JAK  pathway  inhibitors  (Filgotinib,  Tofacitinib  Citrate,  Oclacitinib,  and  Pacritinib).  
LY2157299,  a  TGFβ  receptor  I  inhibitor,  and  Wnt  agonist  1,  a  cell  permeable  Wnt  signaling  






Figure   6-­3.   ‘Hits’   identified   during   screening   of   small   molecules   related   to  
chondrocyte  signaling  and  cartilage  development  pathways.  A  total  of  28  ‘hits’  were  
identified  in  this  screen  of  89  compounds.  16  ‘hits’  exacerbated  the  injury  response,  while  
12   ‘hits’   attenuated  markers   of   injury   in   terms   of   both   (A)   LDH   and   (B)   GAG   release  
outcome  measures.   (C)  No  compounds  were   identified   that  modulated  GAG   retention.  
Several   positive   regulators   of   the   injury   response   affected   JAK,   as   well   as   TGF-­β,  




6.3.3.  ‘Hits’  that  Affect  Multiple  Injury  Hallmarks  and  Secondary  Screens  
‘Hits’  derived  from  these  two  small  molecule  library  screens  were  identified  based  on  the  
effect   size   of   a   single   outcome   measure;;   however,   these   compounds   likely   regulate  
multiple   cellular   activities.   To   probe   this,   the   SSMD   score   for   GAG   release   and   LDH  
release   (those   measures   which   contained   the   greatest   number   of   ‘hits’)   were   plotted  
together  (Figure  6-­4).  Only  a  few  compounds  exacerbated  the  injury  response,  including  
TW-­37  and  GDC-­0152,  which  increased  GAG  retention  in  the  first  screen,  but  at  the  same  
time   increased  GAG  and  LDH   release.  Although  Pacritinib  and  Wnt  agonist  1   reduced  
GAG   release,   these   compounds   also   decreased   chondrocyte   viability.   Overall,   most  
compounds  either  attenuated  a  single  or  both  markers  of  injury.  Pomalidomide  and  ZVF  
reduced  only  LDH  release,  indicating  that  their  protective  response  was  to  maintain  cell  
viability.  Compounds  that  significantly  reduced  both  cell  damage  and  matrix  loss  included  
Necrostatin-­1,  Filgotinib,  and  WHI-­p154.  Finally,   the   two   ‘hits’   that   reduced  LDH   to  un-­
injured,  control  levels  (BMS-­833923,  Tofacitinib  Citrate)  also  showed  a  marked  reduction  
in  GAG  release.  These  7  compounds  were  subsequently  chosen  for  secondary   in  vitro  





Figure   6-­4.   Candidate   small   molecules   that   modulate   multiple   hallmarks   of   the  
injury  response.  SSMD  scores  for  GAG  release  and  LDH  release  were  plotted  together  
to  assess  syngergistic  effects  post-­injury.  While  a  few  compounds  exacerbated  injury  in  
at   least   one   outcome  measure,   the  majority   of   positive   ‘hits’   attenuated   either   one   or  
multiple  measures  of  the  injury  response.  In  particular,  ZVF  and  Pomalidomide  particularly  
affected  cell  viability,  while  several  JAK  inhibitors  (WHI-­P154,  Fligotinib,  and  Tofacitinib  
Citrate)  and  a  Smoothened  antagonist  (BMS-­833923)  had  the  added  effect  of  attenuating  




‘Donor-­specific’  CTAs  (a  total  of  four  bovine  donors)  were  used  to  independently  evaluate  
the  selected  ‘high  performing  hits’.  As  shown  in  Figure  6-­5,  compounds  had  variable  effect  
sizes  in  attenuating  the  injury  response  across  donors,  and  some  donors  appeared  to  be  
more  responsive  than  others  to  treatment  (Figure  6-­6).   In  terms  of  GAG  release,  WHI-­
P154   consistently   had   an   effect   across   donors,   wherein   the   level   of   matrix   loss   was  
between  that  of  un-­injured  and  injured  CTAs  (not  significantly  different  from  either).  ZVF,  
Filgotinib,  and  BMS-­833923  also  similarly  affected  GAG  release,  but  only   for  Donors  3  
and  4.  Measurement  of  LDH  release  showed  greater  variability,  with  only  two  out  of  the  
four  donors  responding  to  treatment  (Figure  6-­6).  In  particular,  ZVF,  Filgotinib,  and  BMS-­
833923   showed   reduced   levels   of   LDH   release,   approaching   that   of   un-­injured   CTAs  










Figure  6-­5.  Secondary  screening  of  the  7  ‘high-­performing  hits’  was  performed  in  
several  sets  of  ‘donor-­specific’  CTAs.  (A)  Donor  1  and  (B)  Donor  2  showed  attenuation  
of  GAG   release   in   response   to  WHI-­P154   (not   statistically   different   from   un-­injured   or  
injured  groups).  No  changes  were  seen  with  any  treatment  for  LDH  release.    (C)  Donor  3  
showed  a  similar  effect  in  terms  of  GAG  and  LDH  release  for  ZVF,  Filgotinib,  and  BMS-­
833923.   WHI-­P154   modulated   only   GAG   release   and   the   remaining   compounds  
approached  statistical  significance  compared  to  un-­injured  CTAs.     (D)  Donor  4  showed  
attenuated  GAG   release   for   all   compounds,   while   LDH   release   was  most   affected   by  
Pomalidomide,   ZVF,   Filgotinib,   BMS-­833923,   and  WHI-­P154.   (*p<0.05   vs.   un-­injured,  
^p<0.05  vs.  injury,  NSp>0.05  vs.  un-­injured  and  injury).  
  
	  
Figure  6-­6.  Variability  of  ‘donor-­specific’  CTA  response  to  ‘high  performing  hits’  in  
a   secondary   screen.   The   average   response   of   biological   replicates   for   each   donor  
(represented  by  a  single  point),   in  response  to  each  compound  is  shown  normalized  to  
injury  alone  for  GAG  and  LDH  release.  Donors  3  and  4  were  the  most  responsive,  with  
the  greatest  number  of  compounds  attenuating  the  injury  response,  while  WHI-­P154  was  





Micro-­engineered   tissues   have   the   potential   to   improve   the   predictive   capability   of  
preclinical  screens  as  compared  to  2D  cellular  assays.  While   the  entirety  of   the   in  vivo  
milieu  is  difficult  to  recapitulate  in  vitro,  3D  tissues  can  be  used  to  assess  how  candidate  
drugs  affect  specific  cellular  behaviors  already  established  to  closely  approximate  the  in  
vivo   response.   Furthermore,   development   of   novel   HTS   assays   and   scale-­up   of  
biofabrication   methods   will   support   drug   screening   and   discovery   applications   for  
engineered  constructs.    We  previously  described  an  in  vitro  model  of  compressive  injury  
that  induces  the  acute  hallmarks  of  the  injury  response  (cell  death  and  proteoglycan  loss)  
in  engineered  cartilage  similar   to  native   tissue   (Mohanraj  et  al.  2014).   In   this  work,  we  
show  the  utility  of  our  high  throughput  injury  platform  for  conducting  unbiased  screens  of  
small  molecule  libraries  to  identify  ‘hits’  that  modulate  the  injury  response.  Although  the  
selected  libraries  were  chosen  for  their  relevance  to  signaling  pathways  associated  with  
cartilage  injury,  the  compounds  were  curated  independently  (SelleckChem).  Of  the  118  
compounds  screened,  20   ‘hits’  were   identified   that  attenuated   the   injury   response   in  at  
least  one  outcome  measure.  Within  this  group,  7  ‘high-­performing  hits’  were  identified  that  
strongly  modulated  either  cell  death  alone,  or  matrix  loss  and  cell  death  together.  One  of  
the   two   ‘hits’   that  specifically   improved  viability  was  Z-­VAD-­FMK  (ZVF),  a  pan-­caspase  
inhibitor.  This  finding  confirmed  the  protective  effect  of  ZVF  that  has  been  observed  in  an  
in  vivo  ACL  transection  model  of  PTOA  (D'Lima  et  al.  2006),  as  well  as   in  vitro  explant  
(D'Lima  et  al.  2001;;  Martin  2009)  and  engineered  cartilage  (Mohanraj  et  al.  2014)  models.  
Although  the  remaining  6  ‘high-­performing  hits’  have  not  yet  been  explored  in  the  context  
of  early  intervention  for  PTOA,  the  pathways  targeted  by  these  compounds  are  relevant  
to  human  disease  and  injury.  Several  JAK  inhibitors  were  identified,  including  Tofacitinib  
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Citrate  which   inhibits   cytokine  mediated   degradation   (Jatiani   et   al.   2010)   and   is   being  
investigated  as  a  potential  treatment  for  rheumatoid  arthritis  (Milici  et  al.  2008),  and  WHI-­
P154  which  has  been  shown  to  reduce  NO  production  in  IFN-­γ-­stimulated  macrophages  
(Sareila  et  al.  2006)  and  leptin-­treated  human  OA  cartilage  (Vuolteenaho  et  al.  2009).    
  
Secondary  screens  using  multiple  ‘donor-­specific’  CTAs  showed  variable  results  across  
donors;;  however,  ZVF,  WHI-­P154,  and  BMS-­833923  trended  towards  attenuating  GAG  
release  and  maintaining  cell  viability.  Previous  work  has  shown  ‘hits’  in  primary  screens  
may  have  different  effect  sizes  in  secondary  screens  (Brey  et  al.  2011).  It  is  also  important  
to  note  that  variability  is  inherently  a  part  of  the  biological  response  in  many  systems.  An  
investigation   of   donor   to   donor   variability   in   cell   sources   commonly   used   for   tissue  
engineering  (chondrocytes  and  mesenchymal  stem  cells)  showed  heterogeneity  not  only  
between   donors,   but   also   within   clones   themselves   (Cote   et   al.   2016).   Moreover,   the  
impact  of  drugs  across  patients  is  known  to  have  widely  varying  efficacies  (Bathon  et  al.  
2000;;  Wolbink   et   al.   2006).   These   findings   highlight   the   importance   of   understanding  
donor-­based   differences   to   potential   therapeutics   within   pre-­clinical   disease   models.  
Future  experiments  will  focus  on  dosage,  timing,  and  additional  donors  to  tease  out  the  
effectiveness  of  these  small  molecules  across  a  potential  ‘patient’  population.  
  
While   we   have   demonstrated   that   engineered   cartilage   can   be   used   to   create   a  
reproducible   model   of   the   acute   changes   in   load-­induced   injury,   long-­term   cartilage  
degeneration  in  PTOA  is  potentiated  by  the  presence  of  inflammation.  Pro-­inflammatory  
cytokines  found  in  the  synovial  fluid  of  osteoarthritic  joints  (e.g.  IL-­1β,  TNF-­α, IL-­6,  REF)  
stimulate  catabolic  processes  (e.g.  production  of  MMPs,  inhibition  of  matrix  biosynthesis)  
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that   lead   to   progressive   cartilage   degradation   (Goldring   2000).   To   screen   for   drug  
candidates  that  can  reduce  catabolic  activity  in  this  context,  a  number  of  studies  have  built  
engineered   cartilage  models   of   OA   using   inflammatory  microenvironments.   Rai   et.   al.  
described  key   temporal  differences   in   the  production  of  catabolic  mediators   (nitrite  and  
PGE2)  by  chondrocytes   in  2D  monolayer  vs  3D  culture   (Rai  et  al.  2008).  Willard  et.  al.  
developed  a  scalable  platform  (96-­well)   for  engineering  cartilage  with  a  defined  genetic  
background   using   iPSCs   and   demonstrated   the   effectiveness   of   known  OA   candidate  
drugs   against   an   IL-­1α   challenge   (Willard   et   al.   2014).   Finally,   towards  mimicking   the  
complexity   of   inflammation   in   vivo,   Sun   et.   al.   showed   that   3D   constructs   treated  with  
macrophage-­conditioned   medium   (as   compared   to   exogenous   addition   of   cytokines)  
exhibited  many  of   the  early  hallmarks  of  OA   in  vivo,   including  chondrocyte  hypertrophy  
and  apoptosis  (Sun  et  al.  2011).  Taken  together,  our  work  and  others’  highlights  the  ability  
of  engineered  cartilage  to  mimic  key  aspects  of  disease  progression.  As  multiple  stages  
of  OA  progression  become  incorporated  into  a  single  model  system,  the  predictive  power  
of  a  3D   in  vitro  preclinical  model  is  likely  to  improve,  leading  to  efficient  identification  of  
lead  drug  candidates.      
  
Using  the  current  iteration  of  our  high  throughput  mechanical  injury  system,  a  total  of  118  
compounds  were  screened  and  a  number  of  promising  ‘hits’  were  identified.  However,  the  
strength  of  a  high  throughput  system  lies  in  size  of  the  library  (i.e.  number  of  molecules)  
that   can   be   rapidly   screened   using   amenable   outcome  measures.  As   such,   this   study  
serves  as  a  proof-­of-­concept   for  adapting  our   system   to  screen   larger,   small  molecule  
libraries,  including  those  that  not  specifically  curated  towards  ‘known’  pathways.  In  support  
of  this  scale-­up,  assays  for  tissue  engineering  are  being  adapted  for  robotic  liquid  handling  
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systems.  Automated  cell  seeding  (Ibold  et  al.  2007),  as  well  as  biochemical  measurements  
(Huang  et  al.  2008)  and  cellular  activity  assays  (Brey  et  al.  2011)  have  been  performed  
by  robotic  platforms  in  recent  years.  In  particular,  the  discovery  of  the  chondroprotective  
molecule  Kartogenin  (from  22,000  drug-­like  molecules,  (Johnson  et  al.  2012))  serves  as  




This   study   demonstrated   the   ability   of   our   high   throughput  mechanical   injury  model   to  
screen  small  molecule  libraries  to  identify  drugs  that  attenuate  the  injury  response  through  
un-­explored   or   non-­canonical   pathways.   Future   secondary   screens   will   focus   on  
constructing   dose   response   curves,   determining   the   duration   of   efficacy,   and   optimal  
timing  of  drug  administration  post-­injury.  From  the  results  of  these  studies,  should  a  lead  
candidate  show  a  consistent  effect   in   improving  cartilage  outcomes  post-­injury,   tertiary  
screens  will  be  conducted  to  evaluate  drug  safety  and  efficacy  in  an  in  vivo  model  of  PTOA  
to  determine  the  potential  for  clinical  translation.  The  work  presented  here  is  a  first  step  in  
the  process  of  advancing  an   in  vitro  micro-­engineered  model  of  PTOA  as  a  pre-­clinical  









Chapter  7.  Chondrocytes  and  Mesenchymal  Stem  Cell  Derived  Engineered  Cartilage  
Exhibits  Differential  Sensitivity  to  Pro-­Inflammatory  Cytokines    
	  
7.1  Introduction    
Osteoarthritis  (OA)  is  a  progressive,  degenerative  joint  disease  characterized  by  articular  
cartilage  fibrillation  and  erosion  leading  to   loss  of   load-­bearing  function  (Goldring  2000;;  
Little   et   al.   2013).   Tissue   engineering   aims   to   restore   function   via   the   combination   of  
biomaterials,  cells,  and  exogenous  cues  (e.g.  growth  factors,  mechanical  stimulation),  in  
order  to  fabricate  cartilage  analogs  in  vitro  for  their  eventual  in  vivo  application.  Decades  
of  work  have  culminated   in  the  ability   to  engineer  cartilage  tissue  that  recapitulates  the  
native  phenotype  and  structure-­function  properties  (Elisseeff  et  al.  2001;;  Wang  et  al.  2005;;  
Moutos  et  al.  2007;;  Erickson  et  al.  2009;;  Sharma  et  al.  2013).  Despite  this  achievement,  
these  tissues  were  realized  under  ‘optimal’  growth  conditions,  which  are  not  representative  
of   the   implantation  milieu.   Indeed,   inflammatory  mediators   in   the  OA   joint  environment  
(Goldring  2000)  will  challenge  the  survival  and  growth  of  these  constructs  when  they  are  
implanted  in  vivo.  Interleukin-­1  (IL-­1α  and  IL-­1β)  and  tumor  necrosis  factor-­alpha  (TNF-­α)  
are   the   primary   cytokines   that   induce  matrix   catabolism   and   are   detected   at   elevated  
levels  in  cartilage,  synovial  fluid,  and  synovium  of  OA  joints  (Wood  et  al.  1983;;  Towle  et  
al.  1997;;  Lotz  2001;;  McNulty  et  al.  2013).  While  TNF-­α  is  considered  an  early  marker  of  
OA,   IL-­1β   is  present  at  both  early  and   late  stages  of  degeneration   (Goldring  1999).   In  
human  OA  cartilage,  both  cytokines  co-­localize  with  the  expression  and  activity  of  matrix  
metalloproteinases  (MMPs),  which  mediate  degradation  of  the  collagen  network  (Tetlow  




To  investigate  the  mechanisms  by  which  IL-­1β  and  TNF-­α  induce  cartilage  degradation,  
a   number   of   in   vitro   explant   and   engineered   cartilage   models   have   been   developed.  
Treatment  of  newborn  and  adult  bovine  explants  with  IL-­1β  and  TNF-­α  result  in  a  dose-­
dependent   increase   in   proteoglycan   release,   nitric   oxide   and  MMP  synthesis,   and   cell  
death,  as  well  as  a  decrease  in  collagen  content  and  tissue  mechanical  properties  (Patwari  
et   al.   2003;;  Wilson  et   al.   2007;;  Palmer  et   al.   2009;;  Torzilli   et   al.   2010).   In  engineered  
cartilage  fabricated  using  articular  chondrocytes,  sensitivity  to  cytokine-­mediate  changes  
has   been   evaluated   as   a   function   of   construct   maturity   and   in   a   biomaterial   system.  
Constructs  allowed  to  mature  prior  to  IL-­1β  (or  IL-­1α)  exposure  were  less  susceptible  to  
matrix  degradation  and  showed  attenuated  loss  of  mechanical  properties  as  compared  to  
those  exposed  at  earlier  time  points  (Cook  et  al.  2001;;  Lima  et  al.  2008;;  Francioli  et  al.  
2011).  Kwon  et  al.  showed  that  biomaterial  selection  can  influence  chondrocyte  response  
to   inflammation,  where  silk-­based  scaffolds  were  chondro-­protective  compared   to  PLA-­
based   systems   (Kwon   et   al.   2013).   In   addition,   it   has   been   noted   that   the   ability   of  
chondrocytes  to  robustly  produce  matrix  and  integrate  with  native  cartilage  is  limited  in  an  
inflammatory  environment  (Djouad  et  al.  2009).    
  
While  chondrocytes  can   inherently  synthesize  cartilage  matrix  components,  autologous  
cells  are  of  limited  supply  for  regenerative  medicine  applications,  particularly  in  patients  
with  advanced  OA.  Mesencymal  stem  cells  (MSCs)  are  an  alternative  cell  source  that  may  
be  appropriate   for   cartilage   repair.  Bone  marrow-­derived  MSCs  can  differentiate  along  
chondrogenic,   osteogenic,   and   adipogenic   lineages,   when   cultured   in   the   appropriate  
scaffold   environment   and  with   defined   chemical   stimuli   (Pittenger   1999).   A   number   of  
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studies   have   described  MSC   chondrogenesis   in   the   presence   of   TGF-­β   to   induce   the  
production  of  proteoglycans  and  collagen  type  II  and  the  gradual  development  of  near-­
native  functional  properties  (Huang  et  al.  2010;;  Moutos  et  al.  2010;;  Erickson  et  al.  2012;;  
Kim  et  al.  2012;;  Bian  et  al.  2013).  In  addition,  MSCs  may  also  exhibit  immunomodulatory  
behaviors  (da  Silva  Meirelles  et  al.  2009;;  Bunnell  et  al.  2010).  Despite  the  potential  of  this  
cell   source,   MSCs   have   been   shown   to   produce   less   functional   matrix   compared   to  
chondrocytes   (Mauck   et   al.   2006;;   Farrell   et   al.   2012),      to   have   a   distinct   molecule  
phenotype  even  after  differentiation  (Huang  2010),  and  to  be  more  susceptible  to  nutrient  
deprivation-­induced  cell  death  (Farrell  et  al.  2015).  Based  on  these  finidngs,  it  is  likely  that  
MSC-­based  engienered  cartilage  will  show  a  distinct  response  to  cytokine  challenge.  Data  
supports  that  MSC-­based  engineered  cartilage,  similar  to  chondrocyte-­based  constructs,  
is  affected  by   the  presence  of   inflammatory  cytokines.   IL-­1β  and  TNF-­α   inhibited  MSC  
chondrogenesis  in  pellet  and  3D  constructs  by  down-­regulating  SOX9,  COMP,  collagen  
type  II,  and  aggrecan  expression,  despite  the  continued  presence  of  chondrogenic  gorwth  
factors  (Majumdar  et  al.  2001;;  Wehling  et  al.  2009).  These  results  suggest  that  MSCs  are  
sensitive  to  cytokines  during  and  after  chondrogenesis.    
  
To   determine   how   cell   source   impacts   the   response   of   engineered   cartilage   to  
inflammatory   stimuli,   this   study   directly   compared   the   effect   of   IL-­1β   and   TNF-­α   on  
chondrocyte-­  and  MSC-­based  constructs.  Cellular-­  and  tissue-­level    response  to  cytokine  
exposure  was  evaluated  by  measuring  release  of  catabolic  mediators  (nitric  oxide,  MMP  
activity)  and  changes  in  matrix  composition  and  mechanical  properties.  Findings  from  this  
study   may   have   impllications   of   the   clinical   use   of   chondrocyte-­   or   MSC-­derived  





7.2.1.  Engineered  Cartilage  Fabrication  and  Culture  with  Inflammatory  Cytokines    
Articular   cartilage   was   harvested   from   the   trochlear   groove   and   femoral   condyles   of  
juvenile   bovine   knees   (aged   2   to   6   months;;   Research   87,   MA).   Chondrocytes   were  
isolated   as   previously   described   (Mohanraj   et   al.   2014;;  Mohanraj   et   al.   2014).   Briefly,  
cartilage   was   minced,   digested   in   collagenase   for   18   to   24   hours   at   37oC   (type   2  
collagenase,   298  U/mg,  Worthington  Biochemical  Corp,  NJ).   The   cell   suspension  was  
filtered  through  a  70µm  cell  strainer  and  washed  (2%  penicillin/  streptomycin/  fungizone  
(PSF)   in  phosphate  buffered  saline,  1750   rpm   for  15  minutes)   to  collect  chondrocytes.  
Mesenchymal  stem  cells  (MSCs)  were  isolated  from  bone  marrow  harvested  from  the  tibia  
and  femur  of  juvenile  bovine  knees  and  expanded  in  monolayer  (P2  or  P3)  (Mauck  et  al.  
2006).   Each   cell   type   was   suspended   in   chemically   defined  medium   (CM-­,   40  million  
cells/mL)  and  combined  with  4%  w/v  agarose  (Type  VII,  in  PBS)  in  equal  volumes  to  form  
a   cell-­agarose   solution   at   a   final   cell   concentration   of   20   million   cells/mL   in   2%   w/v  
agarose.  The  cell  slurry  was  cast  between  glass  plates,  gelled  at  room  temperature  for  10  
minutes,  and  biopsy  punched  to  form  uniform  cylindrical  constructs  (Ø:  4mm,  H:  2.25mm).  
Constructs   were   pre-­cultured   for   21   days   in   chemically   defined   medium   containing  
10ng/mL  TGF-­β  (CM+,  DMEM,  1%  PSF,  1%  ITS+  premix,  40  µg/mL  L-­proline,  50  µg/mL  
ascorbic  acid,  0.1  µM  dexamethasone,  0.5%  v/v  bovine  serum  albumin,  and  100µg/mL  
sodium  pyruvate  (Johnstone  et  al.  1998)).  Following  this  pre-­culture  period,  chondrocyte-­  
and   MSC-­seeded   constructs   were   transferred   to   CM-­   (medium   lacking   TGF-­β)   and  
exposed  to  either  IL-­1β  or  TNF-­α  for  6  days.  To  evaluate  dose-­response,  cytokines  were  
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added   to   the  medium  at   increasing   concentrations   (1,   5,   and   10   ng/mL).  Medium  and  
cytokines  were  refreshed  on  day  3,  with  medium  harvested  on  days  3  and  6.      
	  
7.2.2.  Assays  to  Measure  Engineered  Cartilage  Response  to  Inflammatory  
Cytokines    
Engineered  cartilage  mechanical  properties  were  evaluated  by  unconfined  compression  
testing   (N=4  per   condition)   after   6  days  of   cytokine  exposure,   as  previously   described  
(Mauck  et  al.  2006).  Constructs  were  subjected   to  a  2  gram  creep   load,   followed  by  a  
stress  relaxation  protocol  (10%  compressive  strain  applied  at  0.05  strain/s  held  for  1000s)  
and  dynamic  loading  (1%  strain,  1Hz,  10  cycles)  to  measure  the  equilibrium  and  dynamic  
modulus   (Huang   et   al.   2009).   For   biochemical   assays,   constructs   were   subsequently  
lyophilized   and   papain   digested   overnight.   Glycosaminoglycan   (GAG)   content   was  
measured  using  the  dimethylmethylene  blue  (DMMB)  assay  (Farndale  et  al.  1986)  and  
collagen   content   via   the   OHP   assay   (Stegemann   et   al.   1967).   GAG   and   OHP   were  
normalized  by  construct  wet  weight.  Medium  (N=2  per  condition,  for  5  constructs  cultured  
together)  was  analyzed  for  the  GAG  release,  as  well  as  established  catabolic  mediators,  
nitric  oxide  (NO,  Griess  assay,  Promega  (Henrotin  2003))  and  MMP  activity  after  APMA  
activation   (Generic   MMP   520   Fluorescence   kit,   Anaspec).   At   the   terminal   time   point,  
constructs   were   also   fixed   (4%   paraformaldehyde),   ethanol   dehydrated,   and   paraffin  
embedded  (N=1  per  condition).  Constructs  were  sectioned  across  the  cross-­sectional  face  
(8µm   sections)   and   stained   with   Alcian   Blue   to   qualitatively   assess   changes   in  




7.2.3.  Statistical  Analysis        
The   dose-­dependent   effects   of   IL-­1β   and   TNF-­α   on  mechanical   properties   and  matrix  
content  were  analyzed  using  a  one-­way  ANOVA  with  Tukey’s  post-­hoc  test  (p<0.05)  for  
each  cell  type.  GAG  release,  and  NO  and  MMP  production  were  evaluated  using  a  two-­
way  ANOVA  with  Tukey’s  post-­hoc  test  (p<0.05)  for  chondrocytes  and  MSCs  individually,  
with   time   in   culture   (day   3   or   day   6)   and   dose   serving   as   independent   variables.  
Differences   in   the  magnitude   of   change   between   chondrocyte   and  MSC   response,   for  
each   cytokine   concentration,   was   also   assessed   using   a   two-­way   ANOVA   with  
Bonferroni’s   post-­hoc   test   (p<0.05).   Equilibrium  modulus   data  was   also   fit   to   a   single-­
phase   exponential   decay   curve,   to   test   the   hypothesis   that   chondrocyte   and   MSC  
responses   could   be   fit   with   the   same   parameters.   Rejection   of   this   hypothesis   would  
indicate  differences  in  the  rate  of  decay  in  mechanical  properties  as  a  function  of  cytokine  
concentration  between  the  two  cell  types.  Results  shown  here  are  representative  of  two  
(chondrocytes)  or  three  (MSCs)  independent  experiments.    
  
7.3.  Results  
7.3.1.  Effect  of  Cytokines  on  Mechanical  Properties  and  Matrix  Composition        
Exposure  to  either  IL-­1β  or  TNF-­α  significantly  reduced  mechanical  properties  in  a  dose-­
dependent  manner   in  chondrocyte-­  and  MSC-­derived  constructs.  Although  exposure   to  
IL-­1β  or  TNF-­α  at  1ng/mL  induced  a  moderate  decrease  in  equilibrium  (Figure  7-­1,  A-­B)  
and  dynamic  (Figure  7-­1,  C-­D)  moduli,  a  greater  reduction  in  properties  was  observed  at  
both  5  and  10ng/mL  (no  differences  were  found  between  these  two  groups).  MSCs  were  
more  sensitive  than  chondrocytes  to  cytokine  exposure  at  a  given  dose  (e.g.  EY,  5ng/mL,  
IL-­1β:   -­79%  CH,   -­97%  MSCs,  TNF-­α:   -­   71%  CH,   -­99%  MSCs  vs.   control),  with  nearly  
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complete   loss  of  mechanical   integrity  at   the  highest  concentrations  of   IL-­1β  and  TNF-­α  
assayed.  A  single-­phase  exponential  decay  curve  fit  to  equilibrium  modulus  data  showed,  
for  both  cytokines,  a  significant  increase  in  the  decay  rate  constant  (K)  for  MSCs  compared  
to   chondrocytes   (Figure   7-­1,   E-­F).   ‘Half-­life’   was   also   calculated,   or   the   cytokine  
concentration  at  which  a  50%  reduction  in  mechanical  properties  would  be  expected.  For  
both  IL-­1β  and  TNF-­α,  chondrocytes  required  higher  concentrations  in  order  to  elicit  the  
same   response   in  MSC-­derived   engineered   cartilage   (IL-­1β,   CH:   0.58   vs  MSCs:   0.33  






Figure   7-­1.  Mechanical   properties  of  MSC-­derived   engineered   cartilage   are  more  
sensitive   to   cytokine   challenge   compared   to   chondrocyte-­derived   constructs.  
Construct  equilibrium  (EY)  and  dynamic  (G*)  modulus  show  a  dose-­dependent  effect  for  
(A-­C)  IL-­1β  and  (B-­D)  TNF-­α.  Cytokine  challenge  of  MSC-­derived  cartilage  shows  a  near  
complete   loss   of   mechanical   integrity   at   the   highest   cytokine   concentrations   (5   and  
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10ng/mL).  (E-­F)  Fit  of  an  exponential  decay  curve  indicated  an  accelerated  rate  of  decline  
in   mechanical   properties   (K)   for   MSC-­   compared   to   chondrocyte-­derived   constructs.  
p<0.05   for   *  vs.  control,   +   vs.  1ng/mL  and  control,  S   vs.  MSC-­derived  constructs  at   the  
same  cytokine  concentration.    
	  
GAG  content  in  chondrocyte-­  and  MSC-­derived  constructs  was  consistent  with  the  dose-­
dependent  effect  of  cytokines  on  mechanical  properties  (Figure  7-­2,  A-­B).  That  is,  MSC-­
derived  constructs  showed  a  greater  magnitude  of  GAG  loss  compared  to  chondrocytes  
across  all  IL-­1β  or  TNF-­α  concentrations  (e.g.  GAG%WW,  5ng/mL,  IL-­1β:  -­47%  CH,  -­64%  
MSCs,   TNF-­α:   -­   37%  CH,   -­74%  MSCs   vs.   control).   In   contrast,   collagen   content   was  
relatively   stable   with   cytokine   challenge   (Figure   7-­2,   C-­D).   Chondrocyte-­derived  
constructs  exposed  to  either  IL-­1β  or  TNF-­α  consistently  showed  a  modest  decrease  in  
collagen  content  at  concentrations  of  5  and  10ng/mL.  No  significant  differences  in  collagen  
content  were  observed  in  MSC-­derived  constructs  in  response  to  either  cytokine.  Alcian  
Blue   staining   for   proteoglycans   reflected   changes   in   GAG   content   and   mechanical  
properties.   In   chondrocyte-­derived   constructs,   less   intense  extracellular  matrix   staining  
was  seen  following  exposure  to  IL-­1β  and  TNF-­α  as  compared  to  the  control  group  (Figure  
7-­3,  A-­D,  I-­L).  In  all  cases,  pericellular  matrix  staining  was  present  around  chondrocytes  
regardless  of   the   treatment  condition.  MSC-­derived  constructs,   in  comparison,  showed  
reduced  extracellular  and  pericellular  matrix  staining  intensity  with  the  greatest  decrease  




Figure  7-­2.  Matrix  loss  from  engineered  constructs  reflects  changes  in  mechanical  
properties  with  IL-­1β  or  TNF-­α   treatment.      (A-­B)  GAG  content  was  reduced  in  MSC-­
derived  constructs  to  a  greater  extent  than  chondrocyte-­derived  constructs,  and  in  a  dose-­
dependent   manner.   Conversely,   collagen   content   (C-­D)   was   largely   unaffected   by  
cytokine   exposure.   Chondrocyte-­derived   constructs   showed   a   moderate   decrease   in  
response   to   IL-­1β  or  TNF-­α  exposure;;  no  significant  differences  were   found   for  MSCs.  
p<0.05   for   *  vs.  control,   +   vs.  1ng/mL  and  control,  S   vs.  MSC-­derived  constructs  at   the  




Figure  7-­3.  Alcian  Blue  staining  for  proteoglycans  in  engineered  cartilage  treated  
with   IL-­1β   or   TNF-­α.   (A-­D,   I-­L)   In   chondrocyte-­derived   constructs,   a   reduction   in  
extracellular   matrix   staining   intensity   was   observed.   (E-­H,   M-­P)   In   comparison,   MSC-­
derived  constructs  showed  progressive  loss  of  extracellular  matrix  and  pericellular  matrix  
staining  in  a  dose-­dependent  manner  with  cytokine  treatment.    
	  
7.3.2.  Cytokine-­mediated  Release  of  GAG,  NO  and  MMPs    
Catabolic  mediators  transiently  increased  in  response  to  cytokine  challenge,  as  measured  
by   nitric   oxide   release   to   and   MMP   activity   in   the   medium.   Nitric   oxide   production  
(measured   as   nitrite,   a   byproduct   of   NO   breakdown)   was   dose-­dependent   and   was  
consistently  greater  on  day  3  compared  to  day  6,  and  for  chondrocyte-­  compared  to  MSC-­
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derived  constructs  at  higher  concentrations  (Figure  7-­4,  A-­B).  In  comparison,  the  pattern  
of  MMP  activity  was  both  cytokine-­specific  and  cell   type-­dependent.  Although  absolute  
MMP  activity  between  chondrocyte-­  and  MSC-­derived  constructs  was  similar,  the  activity  
levels   relative   to   un-­treated   controls   showed   differences   with   IL-­1β   treatment.  
Chondrocyte-­derived  constructs  showed  an  increase  in  relative  activity  compared  to  MSC-­
derived  cartilage  on  both  day  3  at  10ng/mL  (CH:  27.6x  CH,  MSCs:  3.5x  vs.  control)  and  
day   6   (CH:   26.2x,  MSCs:   6x   vs.   control)   at   the   highest   concentrations   (Figure   7-­4C).  
However,  only  MSC-­derived  constructs  were  sensitive  to  IL-­1β  at  the  lowest  concentration  
(1ng/mL)   on   day   6   and   showed   an   increase   in   overall   activity   compared   to   day   3.   A  
markedly   different   response   was   observed   in   constructs   following   exposure   to   TNF-­α  
(Figure  7-­4D).  Although  minimal  MMP  activity  was  detected  on  day  3,   the  response  of  
chondrocyte-­derived   constructs   was   higher   than   that   of   MSCs.   However,   by   day   6,  
activated  MMP  levels  were  significantly  increased  for  MSC-­derived  constructs  compared  
to  control  and  chondrocytes  for  all  TNF-­α  concentrations  (e.g.  10ng/mL,  CH:  0.6x,  MSCs:  
6.4x  vs.  control).  To  determine  how  these  catabolic  mediators  effect  matrix  degradation,  
GAG  release  to  the  medium  was  also  measured  (Figure  7-­4,  E-­F).  In  response  to  either  
cytokine,  GAG  release  from  chondrocyte-­derived  constructs  was  lower  on  day  3  compared  
to  day  6  at  concentrations  of  5  and  10ng/mL.  No  differences  were  observed  between  time  
points   for  MSC-­derived  constructs,  with  GAG   release  maintained  at   this  elevated   level  
throughout   the   culture   period.   For   IL-­1β,   matrix   release   was   also   higher   for   MSC-­  
compared  to  chondrocyte-­derived  constructs  on  day  3  (e.g.  10ng/mL,  CH:  1.9x,  MSCs:  
3.3x  vs.  control),  but  by  day  6  the  chondrocyte  response  was  equivalent  (e.g.  10ng/mL,  
CH:  5.5x,  MSCs:  4x  vs.  control)  (Figure  7-­4E).    Following  exposure  to  TNF-­α,  a  similar  
response  difference  between  cell  types  was  observed  on  day  3  (e.g.  10ng/mL,  CH:  1.9x,  
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MSCs:   4.2x   vs.   control).   However,   by   day   6   GAG   release   from   chondrocyte-­derived  
constructs  matched  that  of  MSCs  (e.g.  10ng/mL,  CH:  4x,  MSCs:  5x  vs.  control;;  Figure  7-­





Figure  7-­4.  Differential   release  of  catabolic  mediators  by  chondrocyte-­  and  MSC-­
derived  engineered  cartilage   in   response   to  cytokine  challenge.   (A-­B)  Nitric  oxide  
production  (nitrite)  was  higher  for  chondrocyte-­derived  constructs  compared  to  MSCs,  and  
on  day  3  compared  to  day  6,  for  both  cytokines  and  across  all  doses.  (C-­D)  In  response  
to   IL-­1β,   MMP   activity   increased   from   day   3   to   day   6,   in   a   dose-­dependent   manner.  
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Although   absolute   measurement   of   activated   MMPs   was   higher   for   MSC-­derived  
constructs,  the  relative  increase  compared  to  control  was  larger  for  chondrocytes  due  to  
a  lower  baseline  response.  In  contrast,  TNF-­α  induced  low  levels  of  MMP  activity  on  day  
3   for   both   chondrocytes  and  MSCs;;   however,   by  day  6  MMP  activity   for  MSC-­derived  
constructs  increased  to  match  that  observed  for  IL-­1β.  (E-­F)  GAG  release  to  the  media  
was  consistently  lower  for  chondrocyte-­derived  constructs  than  MSCs  on  day  3  for  both  
cytokines.  However,  by  day  6,  minimal  differences  in  matrix  loss  were  observed  between  
both  cell  types.    
  
7.4.  Discussion    
The   inflammatory  environment  of  an  osteoarthritic   joint  presents  a  significant  challenge  
for  the  success  of  tissue  engineered  cartilage  strategies.  Here,  we  show  that  inflammatory  
cytokines,  including  IL-­1β  and  TNF-­α,  induce  degenerative  changes  in  structure-­function  
properties  through  the  action  of  catabolic  mediators  (e.g.  NO,  MMPs,  ADAMTS).  These  
factors,  in  combination  with  cytokine-­mediated  inhibition  of  matrix  biosynthesis,  would  be  
expected  to  prevent  cell-­based  constructs  from  effectively  restoring  load-­bearing  capacity.  
Two   of   the   primary   cell   sources   utilized   for   cartilage   tissue   engineering   are   native  
chondrocytes   and   mesenchymal   stem   cells.   Although   both   cell   types   have   been  
successfully  used  to  engineer  cartilage   in  vitro  (Elisseeff  et  al.  2001;;  Wang  et  al.  2005;;  
Moutos   et   al.   2007;;   Erickson   et   al.   2009;;   Sharma   et   al.   2013),   challenges   remain   in  
repairing  cartilage  within  the  in  vivo  joint  environment  (Gotterbarm  et  al.  2006;;  Holland  et  
al.  2007;;  Mrugala  et  al.  2008;;  Wang  et  al.  2010;;  Kim  et  al.  2015;;  Fisher  et  al.  2016).  To  
determine  whether  inflammation-­induced  degeneration  is  dependent  on  cell  source  in  this  
context,  we  directly  compared  the  response  of  chondrocyte-­  and  MSC-­derived  constructs  
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to   IL-­1β  and  TNF-­α   in  an   in  vitro  model  system.  While  both  cell   types  showed  a  dose-­
dependent   reduction   in   mechanical   properties,   MSC-­derived   constructs   were   more  
sensitive  to  inflammatory  challenge,  with  complete  loss  of  structural  integrity  measured  at  
high  cytokine  concentrations.  Consistent  with  these  observations,  construct  GAG  content  
and  histological  staining  intensity  were  markedly  reduced;;  however,  collagen  content  was  
only   moderately   affected   by   cytokine   exposure.   Although   collagen   contributes   to   the  
equilibrium  and  dynamic  mechanical  properties  (Charlebois  et  al.  2004;;  Park  et  al.  2008),  
the  loss  of  GAG  may  play  a  larger  role  in  engineered  cartilage  due  to  the  immaturity  of  the  
collagen  network  (<1%WW  vs.  15-­20%WW  in  native  tissue  (Mow  et  al.  2005)).  Our  results  
complement  previous  studies  describing  matrix  depletion  in  response  to  IL-­1β  and  TNF-­α  
in  engineered  tissues  using  chondrocytes  (Cook  et  al.  2001;;  Lima  et  al.  2008;;  Francioli  et  
al.  2011;;  Sun  et  al.  2011)  and  MSCs  (Wehling  et  al.  2009;;  Ousema  et  al.  2012),  as  well  
as  iPSCs  (Willard  et  al.  2014).  Similarites  across  cell  types  include  ‘maturation-­dependent’  
effects  of  cytokines  that  have  previously  been  characterized  for  chondrocytes  constructs  
(Cook  et  al.  2001;;  Lima  et  al.  2008;;  Francioli  et  al.  2011),  and  more  recently  for  MSCs.  
Ousema  et  al.  showed  that  IL-­a  significantly  impaired  MSC  chondrogenesis  in  woven  PCL  
scaffolds  when  present  in  the  media  from  the  onset  of  culture  (with  TGF-­β3)  as  compared  
to  constructs  pre-­cultured  for  2  weeks  prior  to  cytokine  treatment  (Ousema  et  al.  2012).  
This  inhibition  of  chondrogenic  (and  osteogenic)  differentiation  of  MSCs  (29,  30,  47)  may  
be   due   to   inhibition   of   Sox-­9   transcriptional   activity,   which   is   critical   for   collagen   and  
aggrecan  synthesis  (Murakami  et  al.  2000).    
  
To   determine   if   cell   source   affects   the   production   of   catabolic   factors,   nitric   oxide   and  
MMPs  were  measured  in  culture  medium  during  exposure  of  constructs  to  IL-­1β  and  TNF-­
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α.   NO   promotes   cartilage   degradation   through   inhibition   of   aggrecan   and   collagen  
synthesis,  activation  of  MMPs,  and  increased  susceptibility  to  other  oxidants  which  cause  
apoptosis   (Scher   et   al.   2007).   Activated  MMPs   further   contribute   to   destruction   of   the  
collagen   network   (Tetlow   et   al.   2001;;   Piecha   et   al.   2009),   and   together   with   NO  may  
mediate  the  loss  of  construct  functional  properties  and  biochemical  composition  seen  in  
this  work.  Higher  NO  concentrations  were  consistently  found  in  the  media  of  chondrocyte-­
derived  constructs  cultured  with  either  IL-­1β  or  TNF-­α,  as  compared  to  MSCs  at  both  time  
points  (days  3  and  6).   In  comparison,  MMP  activity  showed  a  differential  response  that  
depended  on  both   the  cytokine  and  cell   type.  Although   the  absolute  measurements  of  
MMP  activity  were  higher  for  MSC-­derived  constructs  than  chondrocytes  following  IL-­1β  
treatment,  the  baseline  level  of  activity  in  naïve  constructs  was  also  higher.  As  a  result,  
the   relative   increase   in  MMP  activity   (vs.   control)  was   greater   for   chondrocyte-­derived  
constructs   than  MSCs,   though   these   findings  suggest   that  MSC-­derived  constructs  are  
actively  degrading  formed  matrix  at  a  higher  rate  in  naïve  (control)  constructs.    Despite  
the   overall   increase   in   the   activity   of   catabolic   mediators   for   chondrocyte-­derived  
constructs,  GAG  released  to  the  media  was  initially  higher  for  MSC-­derived  constructs  on  
day  3.    
  
The   exacerbated   matrix   loss   from   MSC-­derived   constructs   supported   the   observed  
changes  in  mechanical  and  biochemical  properties,  and  suggests  that  MSCs  may  exhibit  
greater  sensitivity  to  IL-­1β  than  chondrocytes.  These  results  contrast  with  the  response  to  
TNF-­α   treatment,   where   only   MSC-­derived   constructs   showed   a   marked   increase   in  
activated   MMPs   on   day   6   of   culture.   Although   NO   production   was   elevated   for  
chondrocytes  throughout,  and  MMP  activity  was  only  elevated  at  the  later  time  point  for  
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MSCs,   GAG   released   to   the   media   was   still   higher   for   MSC-­derived   constructs   than  
chondrocytes  on  day  3.  Similar  to  the  effect  of  IL-­1β,  MSCs  seem  to  be  more  sensitive  to  
TNF-­α  than  chondrocytes  in  engineered  cartilage.  Notably,  the  temporal  patterns  of  NO  
and  MMP  production  were  different  for  each  cytokine  and  cell  type,  highlighting  the  need  
for  additional  studies  to  investigate  the  regulation  of  relevant  pro-­inflammatory  signaling  
pathways.  The  NF-­kB  pathway  is  one  of  particular  interest,  since  IL-­1β  and  TNF-­α  induce  
catabolic  activity  through  associated  signaling  cascades  (Hess  et  al.  2009;;  Wehling  et  al.  
2009).  This  pathway  is  a  primary  target  for  therapeutic  intervention  in  OA  and  studies  have  
focused  on   the  development  of   in   vitro,  engineered  cartilage  models   to   investigate   the  
effect   of   NF-­kB   inhibition   (e.g.      small   molecules   (SC-­514   (Willard   et   al.   2014))   and  
dominant  negative  epxression  of  IkB  (Wehling  et  al.  2009)).  Recent  work  by  Brunger  et  al.  
also  demonstrated  that  genome  engineering  (CRISPR/Cas9)  can  be  used  to  create  stem  
cells   that   produce   antagonists   in   response   to   IL-­1   and   TNF-­α   treatment   in   an   auto-­
regulated  manner   to  protect  against  cartilage  degradation   (Brunger  et  al.  2017).   In   this  
context,  the  choice  of  cell  source  for  cartilage  tissue  engineering  may  not  only  influence  
the   likelihood  of   repair   in   vivo,   but  also   the   response   to  candidate   therapeutics   for   the  
treatment  of  OA.    
  
7.5.  Conclusion    
Overall,   this   study   demonstrated   that   cell   source   (native   chondrocytes   vs.   MSCs)  
influences   the   response   of   engineered   cartilage   to   pro-­inflammatory   cytokines.   MSC-­
derived   constructs  were  more   responsive   than   chondrocytes   to   IL-­1β   and  TNF-­α,  with  
greater  loss  of  matrix  and  functional  properties  at  lower  doses  of  cytokine  challenge.  While  
elevated   levels   of   NO   and   MMPs   were   generally   observed   for   chondrocyte-­derived  
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constructs,   exacerbated  construct   degeneration  was  observed   for  MSCs,   indicating  an  
increased  sensitivity  of  MSCs  to  catabolic  mediators.  Although  MSCs  and  chondrocytes  
both   have   the   capacity   to   produce   matrix   in   engineered   constructs,   fundamental  
differences   exist   between   the   two   cell   types   that   impact   their   potential   regenerative  
capacity  upon  implantation  in  vivo.  Our  findings  illustrate  these  differences  in  the  context  
of  a  cytokine  challenge,  and  further  support  the  notion  that  choice  of  cell  source  in  tissue  
engineering   approaches   may   influence   the   likelihood   of   successful   repair   within   the  





















Chapter  8.  Mechanically-­Activated  Microcapsules  for  ‘On-­Demand’  Drug  Delivery  
in  Dynamically  Loaded  Musculoskeletal  Tissues    
	  
8.1  Introduction    
Controlled  drug  delivery  has  several  advantages  over  systemic  delivery  of  therapeutics,  
including   localized   delivery   to   specific   locations,   maintenance   of   drug   concentrations  
within  the  therapeutic  range,  and  preservation  of  activity  for  long-­term  administration  (Kost  
et  al.  2012).  More  specifically,  microcapsule  systems  encompass  a  subset  of  controlled  
drug  delivery  approaches   that  are  characterized  by  size  (diameter  of  1-­1000µm)  and  a  
core-­shell  morphology.  The  active   agent   encapsulated  within   a   solid   shell   is   protected  
against  degradation  and  other  environmental  factors,  and  release  can  be  controlled  as  a  
function  of   time  or   stimulus   in  order   to  program   the   release  profile   to  match  a  desired  
profile   (Singh  et  al.  2010;;  Datta  et  al.  2014).  The  use  of  a  stimuli-­responsive  approach  
enables  self-­regulation,  wherein  physiological  feedback  actively  controls  release  kinetics  
(Siegel  2014).  These  internal  triggers  include  temperature  (Windbergs  et  al.  2013)  and  pH  
(Abbaspourrad  et  al.  2013;;  Yang  et  al.  2014),  as  well  as  enzyme-­substrate  (Qi  et  al.  2009)  
reactions.  When  activated,  such  physicochemical  mechanisms  initiate  capsule  dissolution  
or  disruption,  resulting   in  the  release  of   the  encapsulated  drug.  The  sensitivity  of   these  
triggers   can   be   tuned   for   a   particular   physiologic   or   pathophysiologic   state   in   order   to  
initiate  and  maintain  therapeutic  release  as  is  necessary.    
  
To  date  however,  few  systems  have  taken  advantage  of  the  mechanical  environment  to  
initiate  release.  Recently,  Korin  et.  al.  designed  microscale  aggregates  of  nanoparticles  
which  disaggregate  under   the  abnormally  high  shear  stresses  found   in  narrowed  blood  
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vessels   to   deliver   tissue   plasminogen   activator   to   dissolve   clots   (Korin   et   al.   2012).  
Alternatively,   mechanical   stimuli   have   been   combined   with   passive   degradation  
mechanisms   for   drug   release   from  microdepots  within   stretchable   substrates   (Di   et   al.  
2015)  or  with   thermal  mechanisms   for   liquidization  of   a   solid   core   to  enable  pressure-­
induced   release   in   the   GI   tract   (Wilde   et   al.   2014).   Building   upon   the   premise   of  
mechanically   regulated   systems,  we  sought   to  design  microcapsules  with   ‘on-­demand’  
release  that  could  operate  in  the  dynamic  mechanical  context  of  musculoskeletal  tissues  
in  order  to  stimulate  tissue  repair  and  regeneration.    
  
Musculoskeletal  tissues  within  the  human  body  experience  mechanical  stimulation  across  
multiple   force  magnitudes  and   length  scales,   from  mechanotransduction  at   the  cellular  
level  (Engler  et  al.  2006)  to  the  large  and  dynamic  loads  seen  in  articulating  joints.  These  
forces  not  only  maintain  tissue  integrity  (through  modulation  of  cellular  activity),  but  can  
also,   at   supraphysiologic   levels,   initiate   degenerative   processes   that   require   surgical  
intervention   to   restore   load-­bearing   function   (Kijowski   et   al.   2014;;   Carter   et   al.   2015).  
Healing  capacity   is  minimal   in  articular  cartilage,  which   functions   to  bear  and  distribute  
loads  in  joints.  Lesions  in  the  articular  surface  can  cause  pain  and  disability,  and  may  even  
initiate   further   degenerative   processes   (Lee   et   al.   2000).   These  mechanical   demands,  
combined  with   the   inflammatory  milieu   (Sward   et   al.   2012;;  McNulty   et   al.   2013)   of   an  
injured  or  osteoarthritic  joint,  present  a  challenging  environment,  and  so  repair  of  cartilage  
defects  remains  a  clinical  challenge.  To  date,  tissue  engineering  strategies  for  cartilage  
repair  have  used  a  wide  variety  of  cell  sources  (Chung  et  al.  2009;;  Erickson  et  al.  2009;;  
Diekman  et  al.  2012;;  Craft  et  al.  2013),  scaffold  materials  (Wang  et  al.  2005;;  Erickson  et  
al.  2009;;  Moutos  et  al.  2010;;  Sharma  et  al.  2013),  and  growth  factors  (Johnstone  et  al.  
1998;;  Elisseeff  et  al.  2001;;  Wang  et  al.  2009;;  Kim  et  al.  2012)  to  successfully  grow  tissues  
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in  vitro  that  mimic  the  matrix  composition  and  mechanical  properties  of  native  cartilage.  
However,   challenges   remain   in   successfully   repairing   cartilage   defects   in   vivo.   In  
particular,  growth   factors,  which  are  critical   for  engineered  cartilage  maturation   in  vitro,  
require   local   and   controlled   delivery   in   vivo   in   order   to   avoid   the   undesirable   effects  
associated   with   supraphysiologic   and   systemic   delivery   (e.g.   synovial   fibrosis,  
endochondral  ossification  (van  Beuningen  et  al.  2000;;  Bakker  et  al.  2001)).    
  
Advances  in  biomaterials  design  for  cartilage  repair  have  allowed  for  greater  control  over  
biofactor  release  in  vivo  in  terms  of  spatial,  temporal,  and  multi-­factor  delivery  (Gotterbarm  
et  al.  2006;;  Holland  et  al.  2007;;  Mrugala  et  al.  2008;;  Fan  et  al.  2010;;  Wang  et  al.  2010;;  
Kim  et  al.  2015;;  Lam  et  al.  2015;;  Fisher  et  al.  2016).  While  these  delivery  systems  have  
improved  defect  fill,  matrix  deposition,  and  mechanical  properties  compared  to  biofactor-­
free   formulations,   achieving   native-­like   cartilage   properties   remains   elusive.  Moreover,  
approaches  delivering  multiple  factors  (e.g.  TGF-­β  and  IGF-­1)  have  often  failed  to  elicit  
optimal  in  vivo  responses,  despite  evidence  of  staged  delivery  in  in  vitro  (Elisseeff  et  al.  
2001;;  Anseth  et  al.  2002;;  Holland  et  al.  2007).  These  limitations  may  in  part  be  due  to  the  
nature  of   release   in   these  systems,  where  biofactors  emerge   from   implanted  materials  
based  on  passive-­release  mechanisms.  Stimuli-­responsive  approaches,  wherein  release  
is  based  on  features  of   the  repair  environment,  may  be  required  to  enable  more  active  
and  precise  control  over  the  timing  and  long-­term  maintenance  of  delivery  to  improve  in  
vivo  outcomes.    
  
To  address  this  need,  we  developed  mechanically-­activated  microcapsules  (MAMCs)  as  
a  stimuli-­responsive  drug  delivery  system  in  which  the  mechanical  loading  environment  is  
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harnessed  to  elicit  a  therapeutic  response.  This  bioengineering  approach  is   inspired  by  
self-­healing  polymer  systems  used  in  material  science  applications,  where  microcapsules  
embedded   in   a   polymer  matrix   rupture   upon   physical   damage   releasing   a   catalyst   for  
polymerization  and  repair  of  the  surrounding  material  (White  et  al.  2001).  We  generated  
uniform  populations  of  biocompatible  and  biodegradable  microcapsules  (Lee  et  al.  2012;;  
Tu  et  al.  2012)  using  a  custom  microfluidic  device,  and  established  the  tunability  of  their  
mechano-­activation   based   on   the   physical   attributes   of   the   microcapsule   and   its  
composition.  From  this  parameter  space,  we  selected  a  cohort  of  MAMCs  and  evaluated  
their   response   in  3D  matrices   that  mimicked  regenerating  cartilage  tissue,  and  showed  
that   the   physical   properties   of   the   microenvironment   modulated   MAMC   mechano-­
activation  under  dynamic  loading.  Finally,  we  demonstrated  the  feasibility  of  encapsulating  
biologically  active  compounds  within  MAMCs,  and  showed   that  mechanically  mediated  
release  of  TGF-­β3,  a  growth  factor   important   in   the  maturation  of  engineered  cartilage,  
could  promote   tissue   formation.  These  data  establish  a  novel  means  by  which   to   tune  




8.2.1.  Polymer  Microcapsule  Fabrication  
Microcapsules  were   fabricated  using  a  glass  capillary  microfluidic  device  as  previously  
described   (Lee   et   al.   2012;;   Tu   et   al.   2012)   to   form   a   monodisperse   Water/Oil/Water  
(W/O/W)  double  emulsion  from  three  fluid  phases  (Figure  8-­1  A,B).  The  inner  aqueous  
phase   was   maintained   at   pH   7.4   and,   for   all   experiments,   included   a   fluorescent  
compound  to  visualize  microcapsule  integrity.  The  middle  oil  phase  consisted  of  poly(D,L-­
lactide-­co-­glycolid)   acid   (PLGA)   dissolved   in   chloroform   or   dichloromethane   with   the  
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addition  of  Nile  Red  (100µg/mL,  Sigma,  N3013)  to  fluorescently  visualize  the  shell  wall.  
PLGA  of  various  molar  ratios  of  lactic:glycolic  acid  were  evaluated:  ester-­terminated  PLGA  
50:50  (MW  38,000-­54000,  ester-­terminated,  Sigma  739944),  PLGA  75:25  (0.55-­0.75  dL/g,  
MW   76,000-­119,900,   ester-­terminated,   Lactel   B6007-­1),   PLGA   85:15   (0.55-­0.75   dL/g,  
MW   76,000-­119,900,   ester-­terminated,   Lactel   B6006-­1).   The   outer   aqueous   phase  
contained  2%  wt  poly(vinyl  alcohol)  (PVA).  All  double  emulsions  were  collected  in  0.1-­1%  
w/v   bovine   serum   albumin   (BSA,   Sigma   A7906)   in   phosphate   buffered   saline   (PBS,  
P4417),  with  the  pH  tuned  to  the  PLGA  composition  (PLGA  50:50  ≥  pH  7,  PLGA  85:15  
and  75:25  >  pH12)  to  maintain  stability  during  microcapsule  condensation  (Figure  8-­1C).  
Shell   thickness   and   outer   diameter   of   the  microcapsules  was   tuned   by   controlling   the  
sheath  flow  rates  (inner  and  middle  flow  rates,  Q)  and  PLGA  concentration  (%  w/v)  in  the  
middle  phase.  Average  estimated  shell  thickness  was  derived  from  conservation  of  mass  
as  previously  described   (Tu  et  al.   2012)  where   the   inner  and  outer   radii   of   the  double  
emulsion  was   quantified   from   images   taken   during   fabrication   using   an   upright   optical  
microscope.  The  average  outer  diameter  of  fully  condensed  microcapsules  was  measured  
from  the  maximum  intensity  projection  of  a  confocal  z-­stack  image  (Nikon  A1R+  confocal  
microscope,   20X   magnification,   NIS   Elements   AR   software).   Shell   thickness   to   outer  
diameter  (t/D)  ratio  was  calculated  as  a  metric  to  assess  effect  of  microcapsule  geometry  
on   mechano-­activation.      MAMC   concentration   (as   defined   by   the   number   of  
microcapsules/µL,  n=3-­4  aliquots  per  fabrication  batch)  was  also  measured  by  confocal  
microscopy  within  the  first  three  days  (‘Day  0’)  following  microcapsule  condensation  prior  





Figure  8-­1.  Fabrication  of  mechanically-­activated  microcapsules  in  a  glass  capillary  
microfluidic   device.   (A)   Schematic   and   (B)   image   of   water/oil/water   (W/O/W)   double  
emulsion  generation.  (C)  Schematic  showing  the  time  evolution  of  microcapsules.    
  
8.2.2.  2D  Mechano-­Activation    
A  single  layer  of  microcapsules  (~500  MAMCs)  was  seeded  between  two  glass  coverslips  
and  uniaxially  compressed  at  a  controlled  strain  rate  (𝜀=0.5/s)  to  defined  loads  (0.1  to  5N)  
(based  on  parallel  plate  compression   testing  methods  previously  described   (Fery  et  al.  
2007)).   Unloaded   (0N)   microcapsules   seeded   between   coverslips   served   as   negative  
controls.   Microcapsules   in   these   experiments   contained   a   model   drug,   fluorescein  
isothiocyanate-­dextran  (0.01  to  0.05%  w/v,  FITC-­dextran,  2MDa,  Sigma  FD2000S)  with  
1%  w/v  BSA  in  PBS.  Following  compression,  microcapsules  were  collected  into  PBS  for  
overnight   incubation   at   37C,   5%   CO2   to   allow   for   complete   release   of   encapsulated  
contents.      Microcapsules   were   imaged   on   a   confocal   microscope   (4X   magnification,  
microcapsule   mid-­plane)   before   and   after   load   application.   Images   were   analyzed   to  
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quantify   the   number   of   intact  microcapsules   based   on   a   threshold   of   >50%  of   ‘Day   0’  
fluorescence  signal  intensity  (FITC  signal),  as  well  as  the  total  number  of  microcapsules  
(Nile  Red  signal).  The  fraction  of  empty  microcapsules  (%  empty)  was  then  calculated  at  
each   load   level.  Representative  confocal  z-­stack   images  (20X  magnification)  were  also  
obtained   for   volume   reconstructions.   In   select   experiments,   scanning   electron  
micrographs   (SEM,   FEI   Quanta   600   ESEM)   were   obtained   to   visualize   the   failure  
morphology   of   microcapsules.   Mechano-­activation   was   assessed   on   Day   1   for  
microcapsule   geometry   experiments   and   at  weekly   time   points   for   up   to   10  weeks   for  
polymer  degradation  experiments,  where  microcapsules  were  incubated  at  37oC  and  5%  
CO2.    
  
8.2.3.  3D  Mechano-­Activation    
Microcapsules  were  embedded  in  poly(ethylene  glycol)  diacrylate  (PEGDA,  MW  508  kDa)  
and  cast  between  two  glass  plates  to  create  a  uniform  hydrogel  sheet.  The  polymer  matrix  
was  cross-­linked  using  a  free-­radical  initiation  method  as  previously  described  (Temenoff  
et   al.   2002;;   Saxena   et   al.   2016)   using   ammonium   persulfate   (APS,   1mg/mL,   BioRad  
1610700)   and tetramethylethylenediamine   (TEMED,   0.4%   v/v,   BioRad   1610801).   A  
methacrylated   dye   (9-­anthracenylmethyl  methacrylate,   Sigma   578207,   0.1mg/mL)  was  
also  included  in  some  cases  to  visualize  the  hydrogel  matrix  in  which  the  microcapsules  
were   embedded.   Cylindrical   constructs   (∅:   4mm,   H:   2.25mm)   were   cored   via   biopsy  
punch  from  the  hydrogel  sheet.  Unconfined  compression  testing  of  blank  hydrogels  across  
a   range  of  PEGDA  concentrations   (5-­20%  w/v)  was  used   to  determine   the  equilibrium  
modulus  of  the  encapsulating  matrix.  For  static-­loading  experiments,  microcapsule-­laden  
hydrogel   constructs   (0.1%   v/v)   were   evaluated   using   a   custom   confocal-­mounted  
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compression   device   (Farrell   et   al.   2012).   MAMC   deformation   was   tracked   over   20%  
compressive  strain  applied  to  the  hydrogel  surface,  with  strain  steps  of  5%  followed  by  
compression   until   hydrogel   failure.   At   each   strain   step,   confocal   z-­stack   images   were  
collected   (10X  magnification,  depth:  300  µm),  processed   to  acquire  maximum   intensity  
projections   of   the  microcapsule   shell,   and   thresholded   to   determine   the   bounding   box  
lengths   (x-­   and   y-­axis)   for   each   identified   microcapsule   object   in   the   binary   image.  
Microcapsules   in  contact  with  one  another  or  void  of   internal   fluorescent  contents  were  
excluded  from  analysis.  Deformation  was  quantified  according  to  the  MAMC  strain  in  the  
direction   of   loading   (E11,   x-­direction)   and   perpendicular   to   (E22,   y-­direction)   loading.    
MAMC  strain  was  computed  as  the  difference  in  bounding  box  length  between  each  strain  
step  and  the  initial,  un-­loaded  (ε=0)  state,    normalized  to  the  initial,  un-­loaded  state.  For  
dynamic   loading   experiments,   constructs   were   cyclically   loaded   in   unconfined  
compression   (Instron   Electropuls)   under   physiologic   conditions   (PBS,   37oC).   Free-­
swelling  constructs  maintained  under   the  same  conditions  served  as  negative  controls.  
Constructs  were  compressed  to  a  2%  tare  strain,  followed  by  20%  cyclic  strain  applied  at  
5Hz  for  up  to  1.5  hours  (shorter  time  intervals  were  used  for  temporal  experiments).  After  
loading,  all   constructs  were   incubated  at  37C  overnight  and   imaged   the   following  day.  
Maximum  projection  images  of  confocal  z-­stacks  of  constructs  collected  prior  to  dynamic  
loading  (10X,  depth:  300µm)  were  compared  to  post-­dynamic  loading  images  of  the  same  
microcapsule  population   in  order   to  compute  the  number  of  ruptured  microcapsules  (%  




8.2.4.  Biofactor  Activity      
Microcapsules  were  fabricated  containing  activated  Transforming  Growth  Factor-­β3  (TGF-­
β3,  R&D  243-­B3/CF,  10µg/mL)  with  BSA  (1mg/mL)  and  AlexaFluor  488-­BSA  (100µg/mL,  
Life  Technologies,  A13100)  in  PBS.  Microcapsules  containing  only  AlexaFluor  488-­BSA  
(protein  control)  or   the  TGF-­β3  activation  solution   (vehicle  control,  1mg/mL  BSA,  4mM  
HCl)  served  as  negative  controls.  All  solutions  were  filtered  for  sterility  prior  to  fabrication  
for  use  in  cell  culture  experiments.  TGF-­β3  activity  was  assessed  in  the  supernatant  of  
ruptured  and  intact  microcapsules  via  ELISA  (R&D  Systems,  DY243).  Microcapsules  were  
ruptured   using   a   TissueLyser   LT   system   (Qiagen)   in   PBS.   Both   intact   and   ruptured  
microcapsules  were  diluted  with  an  additional  volume  of  PBS  and  centrifuged  to  separate  
the  shell  pellet   from   the  supernatant.   In  a  separate  set  of  studies,  microcapsules  were  
stored  at  4oC,  with  activity  regularly  assessed  over  three  weeks  to  determine  the  shelf  life  
of   the   growth   factor.   Functional   activity   of   TGF-­β3   released   from   microcapsules   was  
measured   using   an   engineered   cartilage  model   previously   established   in   the   literature  
(Mauck  et  al.  2006).  Briefly,  mesenchymal  stem  cells  were  isolated  from  femoral  and  tibial  
bone  marrow  from  juvenile  bovine  knees  (Research  87,  Bolyston,  MA),  cultured  in  basal  
medium   during   passaging   (high   glucose   DMEM,   10%   FBS,   1%  
penicillin/streptomycin/fungizone).  MSCs  (passage  2,  20  million  cells/mL)  were  embedded  
in   agarose   (2%  w/v,   Type   VII,   Sigma)   to   generate   cylindrical   constructs   (∅:   4mm,   H:  
2.25mm).   Microcapsules   were   ruptured   as   described   above   and   diluted   in   chemically  
defined  medium  (CM).    For  this,  the  number  of  microcapsules  was  tuned  such  that  100%  
release  would  equate  to  a  media  concentration  of  10ng/mL  of  TGF-­β3  (Johnstone  et  al.  
1998).  Supernatant  from  intact  TGF-­β3  microcapsules,  as  well  as  from  ruptured  and  intact  
‘vehicle’  and  ‘protein’  microcapsules  served  as  delivery  controls.  CM  with  or  without  the  
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addition   of   exogenous   TGF-­β3   (10ng/mL)   served   as   positive   and   negative   aqueous  
controls,   respectively.   Cell-­seeded   constructs   were   cultured   under   the   above   media  
conditions   for   a   period   of   7   days.   All   media   was   prepared   at   the   time   of   construct  
fabrication,   with   a   separate   aliquot   frozen   at   -­20oC   for   a   media   change   on   Day   4.  
Chondrogenesis  was   assessed   by   sulfated   glycosaminoglycan   (GAG)   content   (DMMB  
assay  (Farndale  et  al.  1986))  and  matrix  deposition  by  histological  evaluation  (Alcian  Blue,  
Nikon  Eclipse  Ni).  
  
8.2.5.  Statistical  Analysis      
To  determine  mechano-­sensitivity   in  2D  environments,   linear  regression  was  applied  to  
‘%  empty’   vs.   load  plots  and   the  slopes  compared  between  microcapsule  batches   (t/D  
ratios).  For  all  following  analysis,  Bonferroni’s  post-­hoc  test  was  used  to  make  pairwise  
comparisons.   In   experiments   evaluating   the   effect   of   polymer   degradation   kinetics   on  
mechano-­activation,  one-­way  ANOVA  was  used  to  compare  ‘%  empty’  values  across  time  
points  at  0.5N  load.  For  static  compression  of  3D  hydrogels,  two-­way  ANOVA  was  used  
to  compare  microcapsule  E11  strain  between  50  and  500  kPa  hydrogels  at  each  strain  
step.  In  dynamic  loading  experiments,  one-­way  ANOVA  was  used  to  compare  ‘dynamic  
%   empty’   values   across   all   hydrogel  matrix   stiffness   values   and   free-­swelling   controls  
hydrogels.   For   TGF-­β   ELISA   and  GAG  measurements,   two-­way  ANOVA  was   used   to  
compare  intact  vs.  released  conditions  within  a  MAMC  subset,  and  to  determine  dosage  
differences  in  TGF-­MAMCs.  One-­way  ANOVA  was  also  used  to  compare  all  BSA,  vehicle,  
TGF  intact,  and  TGF  released  groups  to  CM-­  for  GAG  quantification.  Finally,  TGF  activity  
monitored  over  time  was  analyzed  using  a  one-­way  ANOVA  to  compare  activity  at  each  




8.3.  Results    
8.3.1.  Microcapsule  Physical  Properties  Determine  Mechano-­activation  Thresholds  
To  determine  how  physical  properties  determine  the  thresholds  for  mechanical  activation  
of  MAMCs,  two  fabrication  parameters  were  tuned  to  control  shell  thickness  and  the  outer  
diameter   of   the  microcapsule:   (1)   PLGA   concentration   and   (2)   fluid   phase   flow   rates.  
Decreasing  the  PLGA  concentration  in  the  middle  phase  reduced  the  thickness  of  the  shell  
wall  while  maintaining  the  same  outer  diameter  (Figure  8-­2  A,B,  1.8  and  2.7%  w/v).  The  
combined  effect  of  a  lower  polymer  concentration  (0.9%  w/v)  and  reduced  flow  rates  of  
the   inner  and  middle  phases   resulted   in  a   thinner  shell  wall  as  well  as  a  smaller  outer  
diameter  (Figure  8-­2  A,B,  0.9%  w/v).  Thus,  the  resulting  thickness  to  diameter  (t/D)  was  
not   different   between   the   two   lower   PLGA   concentration   MAMCs   (0.9   and   1.8%   w/v,  
t/D~0.006).  Conversely,  the  highest  PLGA  concentration  MAMCs  had  a  higher  t/D  ratio  
(t/D=0.0096,  2.7%  w/v).  To  determine  how   the  mechano-­activation  was  determined  by  
these  physical  properties  (shell  thickness,  outer  diameter,  and  t/D  ratio),  a  single  layer  of  
MAMCs   was   subjected   to   uniaxial   compression.   Mechano-­activation   on   Day   1   was  
depended  on  the  t/D  ratio,  with  MAMCs  having  a  lower  t/D  ratio  (t/D~0.006)  showing  high  
sensitivity  to   increasing  load,  despite  differences  in  outer  diameter  (Figure  8-­2  C,D).   In  
contrast,  a  higher   t/D  ratio  (t/D=0.0096)  rendered  MAMCs  insensitive  to   load  within  the  





Figure   8-­2.   MAMC   physical   attributes   regulate   mechano-­activation.   (A)   Polymer  
concentration  and  fluid  flow  rates  control  MAMC  shell  thickness  (t)  and  diameter  (D)  (N=7-­
8  double  emulsion  images/batch  for  shell  thickness  calculations).  (B)  Confocal  mid-­slices  
of  MAMCs  with  different  t/D  ratios  containing  dextran  (green)  with  labeled  shells  (red).  (C-­
D)  MAMCs  rupture  with  increasing  load,  releasing  fluorescent  dextran  from  the  aqueous  
core,   dependent   on   the   t/D   ratio   (+p<0.01   comparison   of   slopes,   N=3  
replicates/load/level/MAMC  batch,  mean  ±  SD).  White  bar  =  100μm.    
  
One  consideration   in   the  mechano-­activation  attributes  of   these  MAMCs   relates   to   the  
choice  of  polymer.    Since  PLGA  is  biodegradable,  the  rate  of  polymer  degradation  is  likely  
to   influence   shell   structural   integrity   and   therefore,  mechanoactivation  as   a   function   of  
time.   To   measure   this,   mechanical   activation   was   assessed   as   a   function   of   time   for  
MAMCs  stored  in  physiologic  conditions  (37°C,  PBS),  with  comparisons  made  between  a  
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fast-­degrading  MAMC  (PLGA  50:50)  and  a  slower  degrading  MAMC  formulation  (PLGA  
85:15).   Differences   in   the   degradation   profile   of   each   PLGA   type   was   confirmed   by  
tracking  the  empty  fraction  of  MAMCs  over  time  under  no  load  conditions  (Figure  8-­3).  
MAMCs  that  rapidly  degraded  (PLGA  50:50)  showed  a  marked  increase  in  sensitivity  to  
applied   load  at  Day  7  compared   to  Day  1   (Figure  8-­4  B,C).  The   failure  morphology  of  
these  MAMCs  was  confirmed  by  3D  volume  reconstructions  of  confocal  z-­stacks  and  SEM  
(Figure   8-­4A),   which   showed   a   midline   rupture   in   the   shell   wall   and   loss   of   internal  
fluorescent  contents.  By  Day  14,  degradation  of  the  shell  of  PLGA  50:50  MAMCs  resulted  
in   80%   of   the   microcapsule   population   observed   to   be   empty   under   zero   load.   Upon  
application  of   increasing   loads,  microcapsule  shells   fractured   into  fragments  with  100%  
rupture   observed.   In   comparison,   for   the   slower   degrading   MAMC   population   (PLGA  
85:15),  the  mechanical  release  profile  remained  stable  over  the  first  3  weeks,  and  showed  
a  slightly  suppressed  mechano-­activation  response  at  4,  6,  and  10  weeks  of  incubation  
(Figure  8-­4  D,E).  
  
	  
Figure  8-­3.  Comparison  of  PLGA  50:50  and  85:15  MAMC  degradation  profiles  under  
physiologic  conditions.  PLGA  50:50  MAMCs  show  an  accelerated  degradation  rate  (as  
determined   by   empty   microcapsules   under   zero   load)   as   compared   to   PLGA   85:15  
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MAMCs  with  incubation  at  37oC  in  PBS  over  10  weeks  (N=3  replicates/time  point,  mean  
±  SD).    
  
	  
Figure  8-­4.  Polymer  degradation   regulates  MAMC  mechano-­activation  profile.   (A)  
Reconstruction   of   the   volume   (confocal)   and   morphology   (SEM)   shows   the   rupture  
mechanism   in  3D  as   compared   to   intact  microcapsules  on  day  7   (PLGA  50:50).   (B,C)  
Fast-­degrading  microcapsules  (PLGA  50:50)  show  a  marked  change  in  response  between  
Day  1  (D1)  and  7  (D7),  with  all  microcapsules  degrading  by  Day  14  (D14)  and  undergoing  
complete  rupture.  (D,E)  Slow-­degrading  microcapsules  (PLGA  85:15)  exhibit  a  stable  or  
slightly   suppressed  mechano-­activation   response   compared   to   day   1   over   42   days   of  
incubation  under  physiologic  conditions.  Comparison  at  0.5N  loading  +p<0.01,  *p<0.001,  
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and  #p<0.05  vs  D1  (N=3  replicates/load  level/time  point  with  the  exception  of  PLGA  85:15  
D1  5N,  D42  0.5N,  and  D70  0.25N  where  N=2  replicates/load  level,  mean  ±  SD).    
	  
8.3.2.  Microcapsule  Mechano-­activation  in  3D  is  Determined  by  Matrix  Mechanics  
To  begin   the   translation  of   these  mechano-­activated  microcapsules   for   release   in  a  3D  
setting,   we   next   evaluated   their   release   characteristics   in   engineered   tissues   under  
physiologic   loading   conditions.   We   hypothesized   that   microcapsule   deformation   and  
release  in  these  3D  environments  would  depend  on  the  stiffness  of  the  surrounding  matrix  
and   its   ability   to   transmit   bulk   deformation   to   the   microcapsules.   To   track   MAMC  
deformation   as   a   function   of   matrix   stiffness,   MAMCs   were   embedded   in   PEGDA  
hydrogels   with   equilibrium   moduli   mimicking   the   mechanical   properties   of   maturing  
engineered   cartilage   (Fisher   Biomaterials   2014).   Under   static   compression,   MAMCs  
encapsulated  within  a  soft,  immature  matrix  (EY  =  50  kPa)  deformed  only  minimally  with  
increasing  applied  hydrogel  strain  (0  to  20%  strain,  5%  step  strain  increments,  Figure  8-­
5A).  Conversely,  when  situated  in  a  stiff  representative  of  a  mature  construct  (EY  =  500  
kPa),  MAMC  strain  increased  in  both  the  direction  of  (E11)  and  perpendicular  (E22)  to  that  
of  applied  hydrogel  strain  (Figure  8-­5A),  and  upon  hydrogel  fracture,  MAMCs  remained  
permanently   deformed.   To   further   determine   how   loading   cycles   (in   the   context   of  
changing  matrix  stiffness)  influenced  MAMC  rupture  and  release,  dynamic  compressive  
loading  was  applied  to  MAMC-­seeded  hydrogel  constructs.  The  fraction  of  microcapsules  
ruptured   due   to   dynamic   loading   was   quantified   as   a   function   of   matrix   stiffness   by  
comparing  pre-­  and  post-­loading  confocal  z-­stacks  of  the  same  MAMC  populations.  We  
observed  a  graded  microcapsule  rupture  response  over  a  range  of  hydrogel  equilibrium  
moduli   (~25   to  150  kPa),  with   release  dependent  on   the  stiffness  of   the  encapsulating  
matrix,  with  greater  rupture  in  stiffer  hydrogels  (Figure  8-­5,  B).  Loss  of  internal  fluorescent  
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contents  following  dynamic  loading  in  stiffer  constructs  is  also  visualized  in  representative  
3D  volume  reconstructions  (Figure  8-­5  C,D).  Together,  these  results  highlight  the  role  of  
matrix  mechanical  properties  in  regulating  MAMC  release  in  dynamic  3D  environments.  
  
	  
Figure  8-­5.  MAMC  mechano-­activation  in  3D.    (A)  Schematic  of  microcapsule  stepwise  
compression   in   PEGDA   hydrogels.   Quantification   of   MAMC   strain   (E11   and   E22)   in  
hydrogels  of  two  different  stiffnesses  demonstrates  the  effect  of  encapsulating  hydrogel  
mechanical  properties  on  microcapsule  deformation,  with  representation  images  at  each  
strain  step  shown  (50  kPa  hydrogels:  N=41  microcapsules  and  500  kPa  hydrogels:  N=30  
microcapsules,  *p<0.001  and  +p<0.01  vs.  50  kPa,  mean  ±  SEM).  (B)  Dynamic  loading  of  
hydrogels   shows   a   graded   increase   in   microcapsule   rupture   as   the   stiffness   of   the  
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encapsulating  hydrogel  increases  (2%  tare  strain,  20%  cyclic  strain,  5Hz,  1.5  hours,  FS  =  
free  swelling  response  range,  N=3  to  6  hydrogels  for  dynamic  loading,  N=8  hydrogels  for  
FS  pooled  across  stiffness,  *p<0.001  vs.  FS,  mean  ±  SD).  Representative  confocal  images  
of   MAMCs   (C)   free-­swelling   hydrogel   conditions   or   (D)   dynamically   loaded   hydrogels  
(matrix  stiffness  shown  in  the  top  left  corner)  show  ruptured  microcapsules  mostly  devoid  
of  internal  fluorescent  contents  (Alexa488-­BSA,  green).    
  
8.3.3.  Biofactors  Encapsulated  Within  MAMCs  Retain  Biologic  Activity    
The   clinical   translation   of   MAMCs   depends   on   the   ability   to   encapsulate   within  
microcapsules,   biologically   active   compounds   that   can   modulate   or   accelerate   tissue  
repair  upon  mechanical-­mediated  release.  In  the  context  of  cartilage  tissue  engineering  
for  defect  repair,  TGF-­β3  is  known  to  stimulate  the  production  of  matrix  constituents  (e.g.  
proteogylcans,  type  II  collagen)  that  contribute  to  the  development  of  functional  properties  
(Erickson  et  al.  2012).  To  determine  if  TGF-­β3  remains  active  through  fabrication  and  after  
release  from  MAMCs,  the  supernatant  from  intact  and  ruptured  MAMCs  was  measured  by  
ELISA   (Figure   8-­6A   and   8-­7).   Microcapsules   containing   only   the   carrier   protein  
(fluorescently-­labelled  bovine  serum  albumin,  BSA)  or  the  vehicle  solution  (BSA  and  HCl)  
were   also   tested   as   controls.   No   activity   was   measured   in   control   MAMCs   (intact   or  
ruptured),  and  minimal  TGF-­β3  activity  was  measured  in  the  supernatant  of  intact  TGF-­
β3-­containing   MAMCs   (Figure   8-­6A).   Conversely,   TGF-­β3   was   measured   in   the  
supernatant  of  ruptured  TGF-­β3-­containing  MAMCs  in  a  concentration-­dependent  manner  
based   on   the   number   of   microcapsules   ruptured   (Figure   8-­6A).   To   confirm   that   this  
released  TGF-­β3  from  MAMCs  could  stimulate  a  biologic  response,  MSC  chondrogenesis  
was  assessed  in  agarose  hydrogels  cultured  in  the  supernatant  from  intact  and  ruptured  
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MAMCs  (BSA,  Vehicle,  and  TGF-­β3).  Results  were  compared  to  constructs  cultured  with  
and  without   the   exogenous   addition   of   TGF-­β3   as   positive   (CM+)   and   negative   (CM-­)  
controls,   respectively.  Quantification  of   sulfated  GAGs  produced  within   the  engineered  
construct  showed  that  TGF-­β3  released  from  ruptured  MAMCs  stimulated  matrix  synthesis  
at  the  same  level  as  exogenous  addition  of  TGF-­β3  (CM+,  Figure  8-­6B).  While  minimal  
TGF-­β3  activity  was  measured  in  the  supernatant  of  intact  TGF-­β3-­MAMCs,  the  presence  
of  the  growth  factor  in  the  media  was  sufficient  to  induce  GAG  production  in  constructs,  
but  at  a  lower  concentration  as  compared  to  ruptured  TGF-­β3-­MAMCs.  Control  MAMCs  
(BSA   and   Vehicle)   did   not   stimulate   a   chondrogenic   response,   similar   to   base  media  
lacking   the   growth   factor   (CM-­).   GAG   accumulation   within   engineered   constructs   was  
confirmed   by   histological   analysis   using   Alcian   Blue,   where   expansion   of   pericellular  
staining  and  increased  intensity  of  extracellular  matrix  staining  was  observed  in  CM+  and  





Figure  8-­6.  Biofactors  released  from  MAMCs  retain  biological  activity.   (A)  TGF-­β3  
released  from  MAMCs  measured  by  ELISA  shows  a  concentration-­dependent  response  
as  determined  by  the  number  of  microcapsules  ruptured.  BSA  and  Vehicle  controls  show  
no  activity  (N=3  replicates/group,  *p<0.001  and  +p<0.01  vs.  intact  MAMCs  or  indicated  by  
line  comparison,  mean  ±  SD).  MSCs  seeded  in  agarose  hydrogels  undergo  chondrogenic  
differentiation  in  response  to  released  TGF-­β3  released  from  MAMCs  as  measured  by  (B)  
GAG  accumulation  in  the  construct  (N=4  replicates/group,  *p<0.05,  vs  CM-­  or  indicated  








Figure   8-­7.   Bioactivity   of   TGF-­β3   within   MAMCs   is   sensitive   to   the   storage  
temperature  (4oC  or  37oC   in  PBS).  ELISA  measurements  over  22  days  show  a  more  
rapid   decline   in   TGF-­b3   activity   when  MAMCs   are   stored   at   37oC   (within   4   days),   as  
compared  to  storage  at  4oC  (within  8  days,  N=3  replicates/time  point/storage  temperature;;  
*p<0.001,  +p<0.01,  #p<0.05  vs.  ruptured  or  intact  D0  measurements,  mean  ±  SD).    
  
8.4.  Discussion    
To  advance  repair  in  dynamically  loaded  musculoskeletal  tissues,  we  developed  a  novel  
class  of  mechanically-­activated  microcapsules  (MAMCs)  that  enable  autonomic  healing  
through   the   release   of   growth   promoting   factors   in   response   to   the   mechanical  
environment.  MAMCs  take  advantage  of  this  physiologic  loading  to  initiate  release  when  
microcapsule  failure  thresholds  are  met.  We  demonstrated  that  these  failure  thresholds  
are  governed  by  the  physical  attributes  (t/D  ratio),  polymer  degradation  rate,  and  ratio  of  
MAMC   to  matrix  mechanical   properties.     Additional   factors,   such  as   the  microcapsule-­
matrix  adhesion  properties  (Wu  et  al.  2008)  can  also  be  tuned  to  influence  MAMC  rupture  
behavior.   Interfacial   adhesion   may   likewise   be   modulated   by   changing   physical  
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characteristics  (e.g.  surface  roughness  of  the  shell  wall  (Blaiszik  et  al.  2009))  or  the  nature  
of  the  interaction  (e.g.  electrostatic  interactions  (Raichur  et  al.  2006)).    These  and  other  
modifications   can   be   used   to   generate   a   suite   of  mechano-­responsive  microcapsules,  
whose  release  is  governed  by  physical  inputs.  
  
	  
Figure  8-­8.  MAMC  repair  of  cartilage  defects.  MAMC  physical  properties  can  be  tuned  
for  programmed  and  extended  release  in  maturing  repair   tissue  exposed  to  physiologic  
dynamic  loading.  Biofactors  released  from  microcapsules  allow  for  matrix  deposition  in  the  
repair  tissue,  resulting  in  a  stiffer  environment,  which  can  then  engage  and  initiate  release  
of  additional  MAMC  populations.  
  
This  novel  delivery  system  will  enable  complex  regulation  of  the  healing  environment.    For  
instance,  a  population  of  MAMCs  is  not  limited  to  a  one-­time  release  under  a  single  loading  
event  but  rather,  by  combining  cohorts  of  microcapsules  with  different  rupture  thresholds,  
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a  distribution  of  release  events  can  be  programmed  to  enable  simultaneous  or  sequential  
release  to  initiate  and  maintain  tissue  repair  (Figure  8-­8).  This  would  allow  for  tuning  and  
selection  of  a  particular  drug  release  sequence  in  a  temporal  fashion  to  regulate  the  variety  
of  biological  responses  needed  for  repair.  Growth  factors  can  initiate  a  number  of  anabolic  
signaling   cascades;;   however,   the   delivery   of   other   factors   including   anti-­inflammatory  
compounds,  steroids,  and  small  molecules  (Gorth  2012;;  Kang  et  al.  2014;;  Bajpayee  et  al.  
2016)  may  also  be  enable  progression  of  the  reparative  process.  While  our  initial  studies  
demonstrated  that  TGF-­β3  can  be  encapsulated  and  released  from  MAMCs  to  stimulate  
the  production  of  cartilage  matrix  components,  improving  the  longevity  of  activity  (Figure  
8-­7)  will  be  necessary  for  an  effective  in  vivo  cartilage  repair  strategy.  Loss  of  activity  of  
biologics  encapsulated  within  polymer  systems  are  largely  attributed  to  local  acidification  
due   to   polymer   degradation   products,   protein   aggregation,   and   polymer-­protein  
interactions  due  to  hydrophobic  or  electrostatic  interactions  (Wang  1999;;  van  de  Weert  et  
al.   2000).   Addition   of   excipients   to   the   aqueous   MAMC   core,   including   pH   buffering  
additives,   sugars   (e.g.   sucrose,   trehalose),   polymers   (e.g.  PEG,   cyclodextrins),   or   free  
amino  acids  (e.g.  arginine,  glutamate),  might  improve  long  term  stability  (Wang  1999;;  van  
de  Weert   et   al.   2000;;  Frokjaer   et   al.   2005).   The   inclusion   of   these   types   of   stabilizing  
factors  may  improve  compatibility  of  encapsulation  for  various  payloads  and  help  maintain  
biologic  activity  of  the  drug  over  extended  periods  of  time  in  the  in  vivo  environment.    
	  
8.5.  Conclusion  
As  we  work  towards  clinical  translation  of  the  MAMC  drug  delivery  platform,  it  will  br  critical  
to  expand  our  understanding  of  the  MAMC  property-­function  (release)  relationships  in  the  
context   of   in   vivo   mechanical   loading.   Continued   characterization   of   deformation  
behaviors  and  release  thresholds  for  microcapsules  embedded  in  various  matrices  (over  
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a  range  of  microcapsule  physical  and  matrix  mechanical  properties)  can  be  used  to  inform  
finite  element  (FE)  models  that  will  predict  MAMC  rupture  in  complex  and  time  evolving  
environments.  These  FE  models  will   support   the  prediction  of  MAMC  formulations   that  
can   be   programmed   for   temporal   release   as   a   function   of   tissue   maturation   within   a  
cartilage   defect   site.   Mechanically-­activated   microcapsules   are   a   highly   tunable   drug  
delivery   system,   and   this   work   makes   progress   in   advancing   a   new   strategy   for  
musculoskeletal   tissue   repair   within   the   demanding   mechanical   environments   which  






















Chapter  9.  Summary  and  Future  Directions  
	  
9.1  Summary  
Progressive  joint  degeneration  in  PTOA  is  the  product  of  abnormal  and  traumatic  physical  
events  that  initiate  signaling  cascades  that  irreversibly  affect  the  structure  and  function  of  
articular  cartilage.  While  this  can  eventually  lead  to  severe  pain  and  loss  of  mobility  at  the  
end   stages   of   disease,   this   temporal   disease   progression   also   presents   therapeutic  
windows   for   targeted  early   intervention  using  biological   treatments.   In   this  dissertation,  
high   throughput  and  mechano-­active  platforms  were  developed   to  discover  and  deliver  
new  therapeutics  for  cartilage  repair  and  regeneration.    
  
While  tissue  engineering  approaches  have  conventionally  been  used  to  fabricate  and  grow  
constructs  that  mimic  native  tissue  properties  in  order  to  replace  diseased  counterparts,  
advances  in  this  field  have  also  enabled  the  design  of  in  vitro,  pre-­clinical  disease  models  
to   test   drug   efficacy.   To   build   an   in   vitro   model   of   PTOA   using   engineered   cartilage,  
Chapter   3   focused   on   establishing   cartilage   tissue   analogs   (CTAs)   as   constructs   that  
mature   to   achieve   near-­native   functional   and   biochemical   properties.   The   mechanical  
environment   defines   how   tissue   level   applied   deformations   are   transferred   to   cells   in  
native  cartilage   (Alexopoulos  et  al.  2005),  and   therefore   in   the  context  of   injury,   it  was  
important   to   use   an   engineered   tissue   that   would   have   a   similar   behavior   in   vitro.   By  
tracking  CTA  mechanical  properties  throughout  culture  duration,  a  minimum  pre-­culture  
period  of  14  weeks  was  determined  to  be  the  point  at  which  constructs  were  functionally  





In  parallel  with   this  work,  a  high   throughput  mechanical  device  was  developed   for   two  
applications.  First,  as  a   testing  system  to  rapidly  evaluate   the  compressive  mechanical  
properties  of  engineered  cartilage  (Chapter  4),  and  second,  to  uniformly  apply  mechanical  
injury   to   constructs   to   facilitate   compound   screening   in   an   in   vitro   model   of   PTOA  
(Chapters  5  and  6).      The  device  was  constructed  in  a  48-­well  format  to  standardize  the  
screening  platform  and  was  coupled  to  a  standard  Instron  micromechanical  testing  system  
in  order  to  control  and  apply  step  displacement  to  constructs  via  PTFE  platens   in  each  
well.  A  force-­sensitive  resistor  array  interfaced  with  these  platens  to  measure  the  force-­
response  of  each  sample  individually.  As  a  result,  the  equilibrium  properties  of  48  samples  
could  be  measured  at  once  in  less  than  2  hours;;  in  comparison,  single  sample  testing  of  
48   samples   would   require   16   hours   of   labor.   Proof-­of-­concept   studies   with   acellular  
biomaterials  demonstrated  the  ability  of   the  system  to  measure  elastic  and  viscoelastic  
properties.   Furthermore,   dose-­dependent   differences   in   mechanical   properties   of  
engineered   cartilage   due   to   TNF-­a   treatment   could   be   detected   in   a   high   manner.  
Together,  these  results  supported  the  use  of  this  platform  as  a  high  throughput  mechanical  
screening  tool  as  a  first  pass  for  materials  evaluation.  Complex  or  combinatorial  studies  
that  are  not  possible  using  single-­sample  methods  can  be  carried  out  using  this  device.  
Potential  applications  include  screening  biomaterial  properties  as  a  function  of  chemistry  
and  composition,  evaluating  in  ‘real-­time’  construct  maturation,  and  measuring  the  effect  
of  drug  candidates  on  functional  cartilage  repair  in  vitro.    
  
Validation  of   this  device  as  a  measurement   tool  naturally  supported   its  adaptation   to  a  
high   throughput  mechanical   injury   (HiTMI)   platform   for   an   in   vitro  model   of   PTOA,   as  
described  in  Chapter  5  and  6.  Compression  at  high  strains  (50  to  75%)  and  strain-­rate  
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(50%/s)  induced  an  injury  response  in  mature  CTAs  that  mimicked  the  acute  hallmarks  of  
mechanical  damage  (cell  death  and  proteoglycan  loss)  observed  in  in  vitro  explant  culture  
and  in  vivo  models.  As  a  step  towards  validating  this  platform  for  drug  screening,  putative  
therapeutics  reported  in  the  literature  (ZVF,  NAC,  and  P188)  were  also  tested  and  showed  
similar  levels  of  efficacy  in  CTAs  in  attenuating  either  cell  death  or  matrix  loss.  This  work  
enabled  the  next  step  in  the  process,  which  was  to  conduct  un-­biased  screens  of  small  
molecule   libraries   to   identify   compounds   that   modulate   non-­canonical   or   unknown  
pathways  in  PTOA.  A  total  of  118  compounds  were  screened  that  modulated  apoptotic  
signaling  pathways  or  those  relevant  to  cartilage  development.  Out  of  20  ‘hits’  identified,  
7  strongly  reduced  LDH  release  (a  marker  for  cell  damage  and  death)  alone  or  concurrent  
with  reduced  GAG  loss.  Among  these  was  again  ZVF,  but  also  a  number  of  JAK  inhibitors  
(e.g.  WHI-­P154,  Filgotinib,  Tofacitinib  Citrate)   that  may  modulate  catabolic  activity  and  
have  been  explored  for  the  treatment  of  rheumatoid  arthritis  (Milici  et  al.  2008).  Secondary  
screens   in   ‘donor-­specific’   CTAs   showed   variable   efficacy   across   donors,   however,  
suggesting   that   differences   in   cell   phenotype   (or   patient   characteristics)   may   play   an  
important  role  in  developing  clinically-­translatable  therapeutics.    
  
As  described   in   the  previous  chapters,   the  scope  of   the   in  vitro  model  of  PTOA  was  to  
develop   a   platform   for   therapeutic   screening   in   order   to   target   the   acute   effects   of  
mechanical   overload.   Yet,   long-­term   cartilage   degeneration   is   mediated   by   the  
inflammatory   environment   that   persists   within   the   joint   space.   Towards   strategies   for  
cartilage  repair  for  patients  with  end-­stage  OA,  Chapter  7  focused  on  characterizing  cell  
source-­dependent  sensitivity  to  pro-­inflammatory  cytokines.  Given  that  chondrocytes  and  
MSCs  are  often  considered  for  tissue-­engineered  replacements,  the  goal  of  this  study  was  
to  understand  how  these  two  cell  types  tolerate  and  survive  an  inflammatory  challenge.  
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Compared  to  chondrocytes,  MSC-­derived  constructs   treated  with  either   IL-­1β  or  TNF-­α  
exhibited   a   greater   reduction   in   mechanical   properties   and   matrix   content   in   a   dose-­
dependent   manner.   This   response   was   observed   despite   elevated   levels   of   catabolic  
mediators   (NO   and   MMPs)   for   chondrocyte-­derived   constructs,   indicating   that  
chondrocytes   may   have   an   inherent   resistance   to   inflammation   and   therefore,   an  
advantage  over  MSCs  in  successfully  repairing  cartilage  in  vivo.    
  
Finally,   to   facilitate   the   delivery   of   newly   identified   therapeutics   and   improve   tissue  
engineering  approaches  for  cartilage  repair  across  the  spectrum  of  degeneration  in  PTOA,  
mechanically  activated  microcapsules  (MAMCs)  were  developed  as  described  in  Chapter  
8.  The  rupture  and  release  characteristics  of  MAMCs  were  characterized  in  both  2D  and  
3D  environments.  Under  direct  compression  in  2D,  as  the  microcapsule  shell  thickness-­
to-­diameter  ratio  increased,  the  resistance  to  failure  also  increased.  Given  that  MAMCs  
were  fabricated  using  PLGA,  polymer  degradation  kinetics  also  impacted  the  mechano-­
activation   in   a   predictable   fashion.  While   fast-­degrading  MAMCs   (PLGA  50:50)   rapidly  
showed   a   marked   increase   in   sensitivity   to   applied   loads   (<1   week),   more   slowly-­
degrading  MAMCs  (PLGA  85:15)  maintained  a  stable  mechano-­activation  profile  for  up  to  
10   weeks.   To   further   assess   MAMC   behavior   in   a   3D   context,   microcapsules   were  
embedded  in  hydrogels  analogous  to  engineered  cartilage  with  mechanical  properties  that  
spanned  the  range  of  cartilage  maturity.  For  both  static  step  compression  and  dynamic  
loading,   MAMC   deformation   and   mechano-­activation   increased   with   increasing   matrix  
stiffness.   Together,   these   results   highlighted   the   potential   of  MAMCs   to   be   embedded  
within  biomaterials  and   implanted   in  vivo,  wherein  drug  release  could  be   initiated   in  an  
‘on-­demand’  fashion  as  a  function  of  tissue  maturity  and  loading  conditions  to  stimulate  
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cartilage  repair  over  an  extended  time  frame.   In  order   to  demonstrate  the  ability  of   this  
system   to   encapsulate   and   deliver   active   agents,   TGF-­β3   was   assessed   as   model  
therapeutic.   In  an  engineered  cartilage  model,  TGF-­β3  released   from  ruptured  MAMCs  
induced   chondrogenesis   as  measured   by   increased  GAG   content   and  matrix   staining.  
While   TGF-­β   plays   an   important   role   in   ECM   production,   it   is   only   one   of   a   host   of  
biofactors   that   could   be   encapsulated   within   MAMCs   in   order   to   promote   or   sustain  
cartilage   repair.   These   include   additional   growth   factors   (e.g.   IGF-­1,   BMP-­2),   anti-­
inflammatory  drugs  (e.g.  IL-­1RA,  dexamethasone),  and  small  molecules  (e.g.  Kartogenin)  
that  have  been  experimentally  and  clinically  used  to  treat  OA.    
    
9.2  Future  Directions    
While   considerable   progress  was  made   in   the   completion   of   this   thesis  work,   there   of  
course  exist  additional  studies  and  goals  that  warrant  further  exploration.  Consideration  
of  these  will  be  discussed  in  the  following  sections,  with  a  particular  focus  on  screening  
assays  and  continued  development  of  the  MAMC  system.  
	  
9.2.1.  Secondary  and  Tertiary  Screens  for  Therapeutic  Discovery  in  PTOA  
While  several  candidates  were  identified  in  the  small  molecule  screens  conducted  using  
the  HiTMI  platform,  this  was  only  the  first  step  in  the  process  of  clinical  validation  and  the  
development   of   a   ‘lead’   candidate.   As   described   above,   a   secondary   replicate   screen  
across  bovine  donors  was  conducted   to  determine  which   ‘high  performing  hit’  held   the  
most   promise   in   attenuating   cell   death   and   proteoglycan   loss.   However,   secondary  
screens  also  need  to  be  performed  to  determine  the  dose-­response  curve  (e.g.  IC50)  and  
toxicity   levels   in   injured   and   control   CTAs,   respectively.   The   timing   and   duration   of  
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treatment  also  represents  a  separate  aspect  of  evaluating  compound  efficacy.  While  the  
studies  presented  here   focused  on   the  acute  phase  of   injury,   future  experiments  could  
treat  CTAs  after  a  period  of  delay  post-­injury  (e.g.   immediate  vs.  24  hours,  48  hours,  1  
week)  and  evaluate  the  injury  response  after  extended  periods  of  time  (e.g.  1  to  4  weeks  
post-­injury).   These   experiments   would   determine   the   therapeutic   window   in   which   the  
compound  still  has  a  beneficial  effect  and  indicate  if  compounds  have  long-­term  chondro-­
protective  potential.  Outcome  measures  for  these  secondary  screens  could  also  include  
histology   (e.g.   TUNEL,   Alcian   Blue   to   confirm   LDH   and   GAG   release),   as   well   as  
biochemical  (proteoglycans,  collagen)  and  soluble  assays  (e.g.  MMP  activity)  to  measure  
matrix   accumulation   within   constructs   and   the   presence   of   catabolic   mediators.   An  
additional  consideration  is  the  introduction  of  an  inflammatory  component  into  the  model  
system   after   injury   to   simulate   later   stages   of   PTOA.   While   the   studies   described   in  
Chapter  7  established  the  ability  of  IL-­1β  and  TNF-­α  to  induce  the  production  of  catabolic  
mediators  in  engineered  cartilage,  the  inflamed  joint  microenvironment  is  more  complex  
than   one   or   two   cytokines   alone.   One   possibility   is   to   use   macrophage-­conditioned  
medium  (MCM)  as  previously  described  in  an  engineered  cartilage  model  of  inflammation  
in  OA  (Sun  et  al.  2011).  MCM  as  compared  to  exogenous  addition  of  IL-­1β  and  TNF-­α  (at  
matched  concentrations)  was  able  to  stimulate  chondrocyte  hypertrophy  and  apoptosis,  
two  features  of  early  OA  not  captured  in  simpler  systems.  Since  OA  is  considered  a  ‘whole  
organ’  disease,  including  contributions  from  other  tissues  (e.g.  synovium,  macrophages)  
may  improve  the  accuracy  and  predictive  potential  of  the  in  vitro  model  in  future  screening  
studies.  Lastly,  although  >100  compounds  were  tested  in  the  work  presented  here,  this  
represents  only  the  first  step  in  the  development  of  a  fully  high  throughput  platform.  Scale  
up  to  larger  well  formats  (e.g.  96  well)  and  adaptation  to  robotic  liquid  handling  platforms  
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would  enable  rapid  fabrication  and  culture  of  engineered  cartilage,  as  well  as  the  use  of  
larger   libraries   on   the   order   of   1000’s   of   compounds   (e.g.   NINDS,   Sigma   LOPAC)   to  
conduct  truly  un-­biased  screens  in  this  in  vitro  model  of  PTOA.  
  
In  order   to  understand   if   the   ‘lead’  candidates  found   in  primary  and  secondary  screens  
translate  to  attenuating  pathologic  changes  in  the  complex,  in  vivo  environment,  the  next  
step  would  be   to  conduct   tertiary  screens   in  an  animal  model  of  PTOA.  The  goal   is   to  
mimic  the  progression  of  disease  in  humans,  from  mild  to  moderate  degeneration,  but  on  
a  more  rapid  timeline  than  human  OA  (Christiansen  et  al.  2012;;  Little  et  al.  2013).  Murine  
models,   more   specifically   those   that   induce   OA   via   surgical   injury,   can   consistently  
reproduce   a   diseased   state   and   be   used   to   investigate   the   therapeutic   efficacy   of   a  
candidate  drug  or  molecule  in  an  in  vivo  setting  (Christiansen  et  al.  2012;;  Little  et  al.  2013).  
One  of  the  most  common  models  is  the  destabilized  medial  meniscus  (DMM)  model,  in  
which   the  medial  meniscotibial   ligament   that  anchors   the  medial  meniscus   to   the   tibial  
plateau,  is  transected  (Glasson  et  al.  2007).  Over  a  period  of  8  weeks,  this  disruption  to  
joint   loading   patterns   leads   to   GAG   loss   from   and   surface   fibrillation   of   the   articular  
cartilage  in  the  medial  compartment,  with  lesions  on  the  medial  side  of  the  joint  becoming  
more  severe  (mimicking  mild  to  moderate  OA).  Due  to  the  relatively  slow  progression  of  
disease   (compared   to   more   severe   ACL   transection   models),   therapeutics   can   be  
evaluated  in  this  setting  without  the  injury  response  overwhelming  the  reparative  potential  
of   the   compound.  Previous  work  using   the  DMM  model   validated  potential   therapeutic  
targets  using  genetically  modified  mice,  including  ADAMTS  (Glasson  et  al.  2005),  MMP-­
13   (Little   et   al.   2009),   and   IL-­1β   (Chambers   et   al.   1997).   In   the   context   of   the   ‘lead’  
candidates  identified  using  the  HiTMI  platform,  these  compounds  could  be  injected  into  
158	  
	  
the  joint  space  after  destabilization  induced  by  DMM  surgery  in  a  murine  model.  Similar  
to  the  proposed  in  vitro  experiments,  the  timing  of  administration  (e.g.  immediately,  1  week  
or  2  weeks  post-­injury)  and  duration  of  drug  efficacy  could  be  evaluated  over  a  period  of  
8  weeks  as  joint  degeneration  progresses.  Histological  measures  at  terminal  time  points  
(e.g.  2,  4  and  8  weeks)  would  assess  the  ability  of  the  compound  to  protect  or  attenuate  
cartilage  degeneration  (loss  of  proteoglycans,  fibrillation)  post-­injury.  
  
9.2.2.  Characterizing  MAMC  Release  in  Complex  Loading  Environments  In  Vitro  
and  In  Vivo      
In  the  work  presented  here,  MAMC  rupture  and  release  in  vitro  was  characterized  within  
homogeneous  matrices   and   under   uniform   compressive   dynamic   loading.  However,   in  
vivo,  tissue  maturation  within  constructs  is  likely  to  be  less  homogeneous  and  the  loading  
environment  more  complex.  To  better  predict  deformation  and  rupture  in  inhomogeneous  
matrices,  MAMCs  could  be  embedded  in  tri-­layer  PEGDA  hydrogels  produced  with  depth  
dependent  mechanical  properties  more  similar  to  engineered  and  native  cartilage  (Farrell  
et  al.  2012).  MAMC  release  under  dynamic  loading  would  be  tracked  spatially  and  as  a  
function   of   the   properties   of   each   layer.   Data   from   these   experiments   could   be  
subsequently  used  to  develop  finite  element  models  to  predict  MAMC  stress,  strain,  and  
failure   in   complex   and   time-­evolving   3D   environments   (Figure   9-­1).   To   further  
demonstrate  the  influence  of  tissue  maturation,  hydrogel  constructs  (e.g.  methacrylated  
hyaluronic  acid,  MeHA)  could  be  fabricated  with  encapsulated  cells  (e.g.  MSCs)  and  TGF-­
β3-­MAMCs   together.   Based   on   MAMC   physical   properties   and   mechano-­activation  
profiles  (as  well  as  the  predicted  construct  maturation  profile  (Erickson  et  al.  2012;;  Fisher  
et  al.  2014),  different  sets  of  MAMCs  could  be  embedded  in  constructs  to  program  a  time  
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course  of  release.  The  first  set  could  be  designed  to  completely  rupture  in  an  immature  
matrix  (5   to  50  kPa)   to   jumpstart  chondrogenesis  at   the  onset  of  dynamic   loading.  The  
second  set  could  achieve  partial  to  complete  rupture  as  the  construct  matures  (300  to  600  
kPa).  Finally,  a  third  set  could  be  designed  to  not  rupture,  and  serve  as  an  intact,  positive  
control.  At  various  time  points  during  physiologic  dynamic  loading  (e.g.  10%  strain,  1Hz,  
3  hours  per  day,  5  days  per  week,  8  weeks  (Mauck  et  al.  2000;;  Kelly  et  al.  2006;;  Huang  
et  al.  2010)),  constructs  could  be  harvested   to  evaluate  matrix  deposition  and   function  
properties.  Comparisons   between  TGF-­β3-­MAMC  constructs   and   controls   (e.g.   growth  
factor  free,  free  swelling,  and  exogenous  TGF-­β3)  would  determine  if  MAMCs  could  be  




Figure  9-­1.  Finite  element  (FE)  model  of  a  MAMC-­hydrogel  composite  to  predict  von  
Mises  stress  with  hydrogel  deformation.  FE  analysis  could  be  used  to  predict  stress  in  
and  around  microcapsules,  and  enable  variation  of  geometry,  boundary  conditions,  and  




Should  these  in  vitro  experiments  validate  3D  mechano-­activation,  the  next  step  would  be  
to  demonstrate  that  MAMCs  implanted  in  vivo  remain  structurally  intact  and  sensitive  to  
load.  To  understand  if  MAMC  mechano-­activation  profiles  are  altered  due  to  exposure  to  
the  in  vivo  milieu,  MAMC-­hydrogel  composites  could  be  implanted  subcutaneously  in  a  rat  
model.   After   2,   4   or   8  weeks,   implants   could   be   harvested   and   dynamically   loaded   to  
evaluate  rupture  and  release  as  a  function  of  cycle  number  (i.e.  loading  duration),  similar  
to  the  experiments  described  in  Chapter  8.  In  vivo  constructs  would  then  be  compared  to  
naïve  constructs  (pre-­implantation)  and  those  cultured  in  vitro  for  the  same  length  of  time  
to   determine   the   MAMC   integrity   and   mechanical   stability.   The   appearance   of   the  
surrounding   tissue  would  also  be  documented  and  sampled   for  histological  analysis   to  
determine  if  MAMCs  induce  an  inflammatory  response.  A  separate  subset  of  studies  could  
also  be  conducted  to  determine  how  long  biofactor  activity  can  be  retained   in  vivo.  For  
example,   TGF-­β3-­MAMC   constructs   could   be   harvested   at   specific   time   points,  
homogeneized,  and  evaluated  for  bioactivity  using  an  ELISA  assay.  These  experiments  
would  inform  the  choice  of  of  payload  to  be  encapsulated  within  MAMCs  and  estimate  the  
efficacy  of  a  drug  in  stimulating  functional  repair  long-­term.  
  
Finally,  MAMC  behavior  could  be  characterized  in  an  in  vivo  load  bearing  environment  as  
a  step  towards  clinical  translation.  Previous  work  has  shown  the  clinical  relevance  (Kuster  
et  al.  1997;;  Gomoll  et  al.  2006)  and  utility  of  a  Yucatan  minipig  model  of  focal  cartilage  
defect  repair  for  evaluating  tissue  engineered  approaches  (Belkin  et  al.  2013;;  Fisher  et  al.  
2015;;  Kim  et  al.  2015;;  Pfeifer  et  al.  2015;;  Fisher  et  al.  2016);;  therefore,  this  model  system  
may  be  appropriate  for  measuring  MAMC  mechano-­activation  in  situ.  Prior  to  embarking  
on  a  large  animal  study,  an  ex  vivo  model  of  joint  loading  could  be  used  to  test  final  MAMC  
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formulations  based  on   in  vitro  and  subcutaneous  data.  Defects  could  be  created   in   the  
trochlear   groove   of   an   isolated   patella,   and   filled  with   a  MAMC-­hydrogel   composite   to  
various   heights.   ‘Fully-­filled’   defects   would   contain   a   hydrogel   flush   with   the   cartilage  
surface,   wherease   ‘half-­filled’   defects  would   be   filled   to   only   half   the   depth.  While   the  
majority  of  MAMCs  in  ‘fully-­filled’  defects  would  be  expected  to  rupture,  those  in  ‘half-­filled’  
defects  would  be  minimally  affected  due  to  the  lack  of  load  transfer.  The  femur  and  patella  
could  then  be  potted  and  aligned,  with  the  potential  additoin  of  a  Tekscan  force-­sensor  
between   the   two  surfaces   to  ensure  consistent  distribution  of  contact  pressures  during  
loading  (Figure  9-­2).  Axial,  cyclic  compressive  loading  would  be  applied  (e.g.  1.5x  body  
weight  at  1  Hz  for  1,  6  or  12  hours),  after  which  MAMC  rupture  would  be  quantified  by  
image  analysis.    
  
	  
Figure  9-­2.  Pilot  testing  of  in  situ  pressure  mapping  of  patella  and  trochlear  groove  
contact  during  axial  compressive  loading  in  a  3D  printed  model  constructed  using  
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mini-­pig  MRI  scans.  Higher  cyclic  loads  (in  the  range  of  expected  physiological  forces,  1  
to  1.5x  body  weight)  resulted  in  higher  peak  pressure  readouts  by  the  force  sensor.    
	  
Figure   9-­3.   Schematic   for   in   vivo   characterization   of   MAMC  mechano-­activation  
using   a   bilateral   trochlear   groove   cartilage   defect   model   in   a   mini-­pig.   (Top)  
Exposure  of  the  trochlear  groove  with  one  defect  site  filled.  (Bottom)  Depiction  of  hydrogel  
and  MAMC  groups  to  be  tested  in  the  mini-­pig  model.  Under  each  group,  the  associated  
hypothesis  (H)  is  described  as  minimal  (min.)  or  full  rupture  of  MAMCs  within  the  defect,  
or  for  the  induction  of  chondrogenesis  (chondro.).  
  
If  MAMC  mechano-­activation  is  responsive  in  the  ex  vivo  loading  model,  then  an  in  vivo  
model  could  be  initiated.    Using  a  bilateral  trochlear  groove  full-­thickness  cartilage  defect  
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model  (4  defects  per  knee),  a  total  of  four  hydrogel  groups  could  be  evaluated:  ‘fully-­filled’  
defects  containing  a  PEGDA  hydrogel  (1)  alone,  (2)  with  BSA-­MAMCs  (inactive  protein),  
(3)  with  TGF-­β3-­MAMCs  (e.g.  100ng/defect),  and  (4)  ‘half-­filled’  defect  containing  a  repeat  
of   condition   (2)   (Figure   9-­3).   In   addition,   autologous   porcine   MSCs   (harvested   and  
expanded  prior  to  the  start  of  the  study,  60  million  cells/mL)  would  be  labelled  (fluorescent  
cell  tracker)  and  encapsulated  in  each  hydrogel.  Animals  would  be  euthanized  at  various  
time  points  corresponding  to  physical  activity  level:  2  days  (no  activity,  pigs  are  lying  down,  
minimal  weight  bearing),  at  1  week  (partial  return  to  activity),  and  at  4  weeks  (return  to  
pre-­surgery  activity   levels)   following  surgery  (Qu  et  al.  2016).  Each  of   the   implant  sites  
(surrounding  cartilage  and  bone  included)  could  then  be  harvested  and  analyzed  for  both  
MAMC   rupture   and   release   (via  multi-­photon  microscopy),   as  well   as  TGF-­β3   induced  
chondrogenesis  in  defects  (via  histological  analysis)  to  determine  if  MAMCs  have  clinical  
potential  as  a  drug  delivery  system.    
  
9.3  Conclusion  
Collectively,  these  studies  establish  a  new  micro-­engineered  system  for  drug  screening  to  
identify  novel  compounds  that  could  influence  the  response  of  articular  cartilage  to  injury,  
as  well  as  an  innovative  mechanically  activated  drug  delivery  system  that  could  be  used  
to  guide  tissue  formation  after  injury  has  progressed  to  the  need  for  surgical  intervention.  
While  considerable  effort  and  numerous  studies  are  needed   to   realize   these  platforms,  
this   thesis  work  sets   the  stage   for  such   future  endeavors.   Identification  and  delivery  of  
newly  discovered   therapeutics  has   the  potential   to   transform  current  paradigms   for   the  
treatment  of  post-­traumatic  osteoarthritis  and  expand  the  impact  of  regenerative  medicine  
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